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Abstract
The Panel on Food Additives and Nutrient Sources added to Food (ANS) was asked to deliver a
scientiﬁc opinion on the safety of hydroxyanthracene derivatives and to provide advice on a daily
intake that does not give rise to concerns about harmful effects to health. Hydroxyanthracene
derivatives are a class of chemical substances naturally occurring in different botanical species and
used in food to improve bowel function. The ANS Panel reviewed the available scientiﬁc data on a
possible relationship between hydroxyanthracene derivatives exposure and genotoxic and carcinogenic
effects. On the basis of the data currently available, the Panel noted that emodin, aloe-emodin and the
structurally related substance danthron have shown evidence of in vitro genotoxicity. Aloe extracts
have also been shown to be genotoxic in vitro possibly due to the presence of hydroxyanthracene
derivatives in the extract. Furthermore, aloe-emodin was shown to be genotoxic in vivo and the whole-
leaf aloe extract and the structural analogue danthron were shown to be carcinogenic. Epidemiological
data suggested an increased risk for colorectal cancer associated with the general use of laxatives, several
of which contain hydroxyanthracene derivatives. Considering the possible presence of aloe-emodin and
emodin in extracts, the Panel concluded that hydroxyanthracene derivatives should be considered as
genotoxic and carcinogenic unless there are speciﬁc data to the contrary, such as for rhein, and that
there is a safety concern for extracts containing hydroxyanthracene derivatives although uncertainty
persists. The Panel was unable to provide advice on a daily intake of hydroxyanthracene derivatives
that does not give rise to concerns about harmful effects to health.
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Summary
Following a request from the European Commission, the European Food Safety Authority (EFSA)
was asked to deliver a scientiﬁc opinion on the evaluation of hydroxyanthracene derivatives in
accordance with Article 8 (2) of Regulation (EC) No 1925/2006 on the addition of vitamins and
minerals and of certain other substances to foods. This request was triggered by the concerns raised
by one of the European Union (EU) Member States on the possible harmful effects associated with the
consumption of foods containing hydroxyanthracene derivatives and preparations thereof, for example,
in food supplements.
In particular, EFSA was requested to review the existing scientiﬁc data on the possible link between
the intake of hydroxyanthracene derivatives and harmful effects on health, and to provide advice on a
daily intake of hydroxyanthracene derivatives that does not give rise to concerns about harmful effects
to health, for the general population and for subgroups of the population (including vulnerable groups).
The risk assessment was performed by the EFSA Panel on Food Additives and Nutrient Sources
added to Food (ANS Panel) in accordance with the 2009 EFSA Guidance on safety assessment of
botanicals and botanical preparations intended for use as ingredients in food supplements.
The ANS Panel considered that the speciﬁc issue of concern – the relationship between
hydroxyanthracene derivative exposures and colorectal cancer – should be addressed in this opinion.
Plants containing hydroxyanthracene derivatives are numerous and belong to different botanical
families and genera. The hydroxyanthracene derivatives considered relevant for this risk assessment
were those found in the root and rhizome of Rheum palmatum L. and/or Rheum ofﬁcinale Baillon and/or
their hybrids; leaves or fruits of Cassia senna L. and/or Cassia angustifolia Vahl; bark of Rhamnus
frangula L., bark of Rhamnus purshianus D.C. and in leaves of Aloe barbadensis Miller and/or various
Aloe species, mainly Aloe ferox Miller and its hybrids and further, that are also indicated as present in
the respective EU Pharmacopeia monographs as characteristic active components of these botanicals.
Other structurally related compounds have been assessed by the US National Toxicology Program (NTP)
(anthraquinone, emodin) and have only been included for the purpose of potential read across.
Preparations containing hydroxyanthracene derivatives have been already evaluated by a number of
Committees or international organisations for their potential beneﬁcial effects and/or for their potential
adverse effects as food or as medicinal products.
A public call for data was launched by EFSA to gather information from the relevant food business
operators, on several speciﬁc topics related to food supplements containing hydroxyanthracene
derivatives.
Exposure to hydroxyanthracene derivatives from food supplements has been estimated from the
recommended daily doses of food supplements as provided by the interested parties and range from
2.25 to 24.83 mg/day for sennoside B, from 1.95 to 78.8 mg/day for rhein, from 13 to 26 mg/day for
glucofrangulin A, from 1.2 to 24 mg/day for aloin (barbaloin) and from 17.9 to 51 mg/day for aloin
A+B. However, the Panel noted that exposure to aloe-emodin and emodin is not known due to lack of
data on these substances.
In this opinion, data from human and animal studies have been assessed.
Several in vivo studies describing the biological fate of hydroxyanthracene derivatives and the
metabolism and pharmacokinetics of anthranoid laxatives are reported in literature. Glycosidic
hydroxyanthracene derivatives have been demonstrated to remain intact until they are hydrolysed in the
gastrointestinal (GI) tract to their corresponding anthrones (aglycone anthrones). Regarding aglycone
hydroxyanthracenes, they may be absorbed intact, however, only rhein is present in the systemic
circulation. In the GI tract, remaining hydroxyanthracenes may be reduced back to the corresponding
anthrones by the microbiota. After absorption, hydroxyanthracenes such as aloe-emodin are rapidly and
totally oxidised to rhein. In the gut epithelium and liver, absorbed aglycone hydroxyanthracenes are
conjugated into corresponding glucuronides and sulfates, which are excreted in bile or urine.
The genotoxicity of hydroxyanthracene derivatives has been evaluated in numerous in vitro and
in vivo studies identiﬁed from the public literature. The available studies focused mainly on emodin,
aloe-emodin, rhein and sennosides and to lesser extent on aloe vera, senna and fructus sennae
extracts. A limited number of studies on danthron and chrysophanol were also available.
Among the extracts, only senna extracts proved to be mutagenic in the TA98 Salmonella
Typhimurium tester strain in the presence of S9 metabolism and in S. Typhimurium tester strains
TA1537 and TA98 in the absence of S9 metabolism. It also induced DNA damage in the Bacillus subtilis
rec-assay and induced dose-related increases in chromosomal aberrations in Chinese hamster ovary
(CHO) cells in the absence of S9.
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No positive results in the bacterial mutation assay for aloe vera gel and for both aloe vera whole
leaf extract (WLE) and aloe vera charcoal-ﬁltered whole leaf extract (decolourised) were observed in
S. Typhimurium strains TA98 and TA100, and Escherichia coli strain WP2 uvrA/pKM101, with and
without S9 metabolic activation. The 1,8-dihydroxyanthraquinones emodin, aloe-emodin and danthron
were shown to be mutagenic in the Tk+/ locus in mouse lymphoma L5178Y cells and consistently
clastogenic in vitro in mammalian cells interacting via intercalation into DNA with DNA topoisomerase
II and consequent inhibition of their catalytic function resulting in genotoxicity and mutagenicity with a
ranking potency greater for danthron and lower for emodin. Results of a ‘modiﬁed comet assay’
showed that pretreatments of the cells with each of these test compounds reduced the DNA damage
induced by etoposide, an inhibitor of topoisomerase II which acts through the stabilisation of the
DNA–topoisomerase complex known as the ‘cleavable complex’ in which danthron, aloe-emodin and
emodin showed capability to inhibit the non-covalent binding of bisbenzimide Hoechst 33342 to
isolated DNA and to DNA of intact mouse lymphoma L5178Y cells. On the other hand, emodin, the
least potent compound among these three anthraquinones, was also shown to induce DNA double-
strand breaks (DSB) through poisoning of topoisomerase II-cleavable complex and through inhibiting
adenosine triphosphate (ATP) hydrolysis by DNA topoisomerase II. Thus, it is not possible to exclude
also a potential mechanism of inhibition of DNA topoisomerase II through poisoning of the
DNA–topoisomerase ‘cleavable complex’. Aloe-emodin was also mutagenic in S. Typhimurium strains
TA1537, TA1538, TA97 and TA98 (all frameshift mutant sites) in the absence of S9 metabolism. While
these results further support the intercalating capability of aloe-emodin and consequent catalytic
inhibition of DNA topoisomerase II they also show the induction of frameshift mutations which, per se,
is a mutagenic event not related to the inhibition of DNA topoisomerase II.
The Panel noted that, beyond frameshift mutations, danthron also induced base-pair substitutions
in bacteria, only after exogenous metabolic activation, and oxidative DNA damage in mammalian cells,
highlighting the involvement of multiple mechanisms of genotoxicity.
In addition, aloe-emodin induced unscheduled DNA synthesis (UDS) in primary rat hepatocytes, and
DNA breakage in mouse lymphoma L5178Y cells, in NPC-039 and NPC-076 human nasopharyngeal
carcinoma cells, and SCC-4 human tongue cancer cells. These results are also compatible with a
mechanism of inhibition of DNA topoisomerase II activities.
However, although individual anthranoids induced gene mutations (frameshift and base-pair
substitutions) in bacteria, frameshift mutations and clastogenic effects in mammalian cells through
inhibition of DNA topoisomerase II, for plant extracts containing hydroxyanthracene derivatives, other
mutagenic components with different mechanisms of action appear to play a role in extract genotoxicity
and carcinogenicity. It has been demonstrated that both aloe vera WLE and aloe vera decolourised
whole leaf extract (WLD) – for which the content of hydroxyanthracene derivatives (both glycosidic and
free aglycones) was reduced by 99% compared to the WLE – induced statistically signiﬁcant and
biologically relevant increases in mutation frequencies (MF) in the mammalian cell TK+/ mutation
assay using the mouse lymphoma L5178Y cells. As revealed by 20,70-dichlorodihydroﬂuorescein
diacetate (DCF-DA) staining, intracellular reactive oxygen species (ROS) levels were increased about
5- and 15-fold in WLD- and WLE-treated cells, respectively, when compared to the concurrent control
groups. This implies that components in the WLE, in addition to the hydroxyanthracene derivatives,
could contribute to the mutagenicity of the WLE in part through a ROS-dependent mechanism. This
conclusion is further substantiated by the loss of heterozygosity (LOH) of WLE/WLD-induced mutants.
Results indicated that, while both extracts were clastogenic, their induced mutation spectra were
signiﬁcantly different, thus conﬁrming that different constituents may be responsible for the genetic
damage caused by the two preparations. These results indicate that aloe vera and senna extracts and
individual hydroxyanthracene derivatives, particularly aloe-emodin, interact with bacterial and
mammalian DNA under certain conditions in vitro.
Overall, the results of genotoxicity testing in vitro indicate that extracts of aloe vera and senna and
individual hydroxyanthracene derivatives, particularly aloe-emodin, interact with bacterial and
mammalian DNA under certain conditions in vitro.
There are several in vivo genotoxicity studies available, which include the rodent bone marrow
micronucleus assays, the mouse somatic mutation assay in fetal melanoblasts (Mouse Spot Test), the rat
bone marrow chromosome aberration assays and the in vivo/in vitro UDS assay in rat liver. The results
indicated that senna, fructus sennae extracts, sennosides and the individual 1,8-dihydroxyanthraquinones
tested were uniformly negative. However, the Panel noted that, in all these studies, no evidence of
toxicity in the target cells was observed, indicating that target tissues may not have been adequately
exposed to the test compounds. This assumption is substantiated by results of an in vivo study in rat,
Safety assessment of hydroxyanthracene derivatives
www.efsa.europa.eu/efsajournal 4 EFSA Journal 2018;16(1):5090
showing a low absorption of [14C]aloe-emodin and a rapid metabolism to rhein, an anthranoid with no
signiﬁcant genotoxic activity in a battery of in vitro and in vivo assays.
Marked and signiﬁcant increases in DNA fragmentation have been found in the colon cells of male
OF1 mice treated with aloe-emodin by oral gavage at 2,000, 1,000 and 500 mg/kg body weight (bw)
on two occasions 24 h apart in the in vivo rodent comet assay. Slight increases in DNA breakage
compared to the concurrent vehicle control values were also observed in the kidney which were
dose-related but reached statistical signiﬁcance only at the high-dose level tested. On this basis, the
limited absorption of aloe-emodin and its quick transformation to rhein (a compound devoid of
genotoxic capabilities) indicate that bone marrow may be considered as an inadequate tissue to
demonstrate a possible in vivo genotoxicity for both emodin and aloe-emodin.
Overall, the Panel considered that the in vitro genotoxicity of aloe-emodin was reproduced in the
colon in vivo, the target tissue for aloe vera WLE carcinogenicity. The Panel therefore considered that
aloe-emodin represents a genotoxic risk for humans. The Panel also considered that the presence of
other mutagenic components, in addition to hydroxyanthracene derivatives, cannot be excluded.
In vivo carcinogenicity studies were also considered relevant by the Panel for this assessment.
Overall, the results of carcinogenicity studies indicated a carcinogenic effect of a whole leaf powder of
Aloe when given to rats at dietary concentration of 4%, a level associated with diarrhoea or loose
stool, of aloe vera WLE in drinking water when given to rats at concentration of 1% or higher, and of
chrysazin given in the diet at concentrations of 0.2% and 1% to mice and rats, respectively. Apart
from tumours, exposure to these test compounds caused hyperplastic changes in the large intestine of
rats and mice. Senna extract was not carcinogenic to rats at doses up to 25 mg/kg bw per day in
drinking water. Senna preparation was not carcinogenic to rats at doses amounting to 300 mg/kg bw
per day administered by gavage but the rats developed diffuse mucosal epithelial hyperplasia in the
large intestine and caecum with an incidence increasing in a dose-dependent manner. Senna in the
diet in doses amounting to 1,260 and 1,520 mg/kg bw per day was not carcinogenic to p53+/- males
and females, respectively, but induced epithelial hyperplasia in the large intestine.
Epidemiological data suggested an increased risk for colorectal cancer associated with the general
use of laxatives, several of which contain hydroxyanthracene derivatives.
Five cohort studies were reviewed by the Panel and an increased risk for colorectal cancer was
found in all, however, only in two studies the results were statistically signiﬁcant. Based on the studies
reviewed by the European Medicines Agency (EMA) and the results of more recent large
epidemiological studies, the Panel agreed with previous evaluations that the prolonged use of laxatives
is a possible risk factor for colorectal cancer. Nevertheless, the Panel was of the view that better
designed epidemiological studies (e.g. cohort studies with large sample size and proper control for
confounding factors) that investigate the relationship between anthranoids laxatives use and colorectal
are needed.
Based on the data currently available, the Panel concluded that hydroxyanthracene derivatives
should be regarded as genotoxic and carcinogenic unless there are speciﬁc data to the contrary, such
as for rhein and that there is a safety concern for extracts containing hydroxyanthracene derivatives
although uncertainty persists.
Furthermore, the Panel was unable to provide advice on a daily intake of hydroxyanthracene
derivatives that does not give rise to concerns about harmful effects to health, for the general
population, and as appropriate, for vulnerable subgroups of the population.
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1. Introduction
Following a request from the European Commission to the European Food Safety Authority (EFSA),
the Scientiﬁc Panel on Food Additives and Nutrient Sources added to Food (ANS) was asked to provide
a scientiﬁc opinion on the safety of hydroxyanthracene derivatives from all sources in foods including
preparations such as food supplements and infusions.
This risk assessment was carried out in the framework of the procedure under Article 8(2) of
Regulation (EC) No 1925/2006 on the addition of vitamins and minerals and of certain other
substances to foods, for hydroxyanthracene derivatives, initiated by the European Commission. Article
8(2) of Regulation (EC) No 1925/2006 is referring to a possible prohibition, restriction or Community
scrutiny of a substance or ingredient by placement in Annex III, Part A, B or C of this Regulation.
1.1. Background and Terms of Reference as provided by the European
Commission
1.1.1. Background
In 2013, the European Food Safety Authority (EFSA) issued an opinion on the scientiﬁc
substantiation of a health claim related to hydroxyanthracene derivatives and improvement of bowel
function. In this opinion EFSA concluded that a cause and effect relationship has been established
between consumption of hydroxyanthracene derivatives and the improvement of bowel function (EFSA
NDA Panel, 2013) and considered it necessary to recommend certain restrictions of use. In particular,
the Panel noted that “stimulant laxatives should not be consumed continually for periods longer than
one to two weeks” and “the use of stimulant laxatives for more than two weeks requires medical
supervision”. Furthermore, EFSA recommended in the scientiﬁc opinion that the “long-term use of
stimulant laxatives should be avoided owing to the danger of electrolyte imbalance, impaired function
of the intestine, and dependence on laxatives”, and that “stimulant laxative should only be used if an
effect on bowel function cannot be achieved by a change of diet or the administration of bulk forming
agents”. EFSA based the above-mentioned recommendations and restrictions on the available evidence
obtained mainly from monographs published by the World Health Organisation (WHO) and by the
Committee on Herbal Medicinal Products (HMPC) of the European Medicines Agency (EMA), as
referenced in the EFSA opinion on the scientiﬁc substantiation of a health claim related to
hydroxyanthracene derivatives and improvement of bowel function.
In the light of the above, Member States raised concerns during discussions on the possible
authorisation of the above-mentioned health claim regarding a potential risk to consumers linked with
the consumption of hydroxyanthracene derivatives in foods.
Consequently, the Commission has initiated the procedure under Article 8 (2) of Regulation (EC)
No 1925/2006 on the addition of vitamins and minerals and of certain other substances to foods,1 for
hydroxyanthracene derivatives from all sources.
1.1.2. Terms of Reference
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20022, the European Commission
asks EFSA to:
• Review the existing scientiﬁc data on the possible link between the intake of
hydroxyanthracene derivatives and a harmful effect on health.
• Provide advice on a daily intake of hydroxyanthracene derivatives that does not give rise to
concerns about harmful effects to health, for the general population, and as appropriate, for
vulnerable subgroups of the population.
1.1.3. Interpretation of the Terms of Reference
In respect to the approach to be followed for the assessment of hydroxyanthracene derivatives, the
Panel was of the view that previous assessments, when relevant to the safety issues that triggered the
1 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins
and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38.
2 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
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Article 8 procedures, should be used as starting points for this scientiﬁc opinion. Since these
procedures are triggered by speciﬁc safety concerns of either the European Commission or the
Member States, in addressing the mandate received, it is the interpretation of the Panel that the
speciﬁc issue(s) of concern – the relationship between hydroxyanthracene derivative exposures and
colorectal cancer (CRC) – should be addressed in this opinion.
1.1.4. Deﬁnition and identiﬁcation of hydroxyanthracene derivatives
In its 2013 scientiﬁc opinion, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
refers to hydroxyanthracene derivatives as those found in the root and rhizome of Rheum palmatum L.
and/or Rheum ofﬁcinale Baillon and/or their hybrids; leaves or fruits of Cassia senna L. and/or Cassia
angustifolia Vahl; bark of Rhamnus frangula L., bark of Rhamnus purshianus D.C. and in leaves of Aloe
barbadensis Miller and/or various aloe species, mainly Aloe ferox Miller and its hybrids.
In this opinion, the term ‘hydroxyanthracene derivatives’ is restricted to those anthranoid compounds
found in the root and rhizome of Rheum palmatum L. and/or Rheum ofﬁcinale Baillon and/or their
hybrids; leaves or fruits of Cassia senna L. and/or Cassia angustifolia Vahl; bark of Rhamnus frangula L.,
bark of Rhamnus purshianus D.C. and in leaves of Aloe barbadensis Miller and/or various aloe species,
mainly Aloe ferox Miller and its hybrids and further, that are also indicated as present in the respective
EU Pharmacopeia monographs as characteristic active components of these botanicals.
The substances reported in Appendix A include – but are not limited to – those hydroxyanthracene
derivatives indicated in the respective EU Pharmacopeia monographs as characteristic active
components of these botanicals (EU Ph, 9th edition). Other structurally related compounds have been
assessed by the US National Toxicology Program (NTP) (anthraquinone, emodin) and have only been
included for the purpose of potential read across. Data on the structurally related synthetic compound
danthron (chrysazin) have also been considered suitable for read-across.
Due to the continuous revision of botanical classiﬁcations and scientiﬁc names, some differences
can be found between names present in previous assessment documents and the names used in this
opinion.
1.1.5. Identiﬁcation of safety concern triggering Article 8 procedure
In previous evaluations (EMA, 2007a,b,c,d, 2008a,b), the relationship between laxatives use and
CRC was examined and it was concluded that ‘The question of a possible carcinogenic risk of long-
term use of anthranoid-containing laxatives is still open and the results of the more recent studies are
inconsistent. Therefore the conditions determined in the pharmacovigilance actions for anthranoid-
containing laxatives have to be maintained’. In the EMA evaluation, seven epidemiological studies and
a meta-analysis were reviewed. Out of the seven epidemiological studies reviewed by EMA (Kune,
1993; Nusko et al., 1993; Siegers et al., 1993; Jacobs and White, 1998; Kune et al., 1988; Nusko
et al., 2000; Roberts et al., 2003), two studies showed an increased risk for CRC (Nusko et al., 1993;
Siegers et al., 1993). In the study of Siegers et al. (1993), subjects using anthranoids laxatives were
three times more likely to develop CRC (relative risk (RR): 3.04; 95% CI: 1.18–4.90) than subjects not
using it. Nusko et al. (1993) showed that individuals using laxatives, in which the main ingredient was
anthranoid, had an increased risk of CRC (RR (adenomas): 1.72; 95% CI: 1.46–2.01; RR for
carcinoma: 1.26; 95% CI: 0.74–2.15). The results of the meta-analysis that was conducted on 14
case–control studies showed a signiﬁcant association between CRC and laxatives use (summary risk
estimate: 1.46, 95% CI: 1.33–1.61) (Sonnenberg and M€uller, 1993). However, most of the above
epidemiological studies reviewed – including the ones in the meta-analysis – had methodological
limitations such as the use of a retrospective design, small sample size and lack of adjustment for
potential confounding factors.
The Panel is aware that in the current risk assessment a number of aspects have not been
considered, as they were deemed to fall outside the remit of the Panel and the scope of the current
mandate. The current risk assessment was performed to address questions on speciﬁc adverse effects
and not as an overall evaluation of hydroxyanthracene derivatives used in food and food supplements.
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1.2. Data and methodologies
1.2.1. Data
The Panel was not provided with a newly submitted dossier and based its evaluation on previous
evaluations (EMA, 2006, 2008a,b, 2017a,b; IARC Monographs 108, 2016), additional literature that
became available since then and the data available following public call for data.3
1.2.2. Methodologies
The assessment was conducted in line with the principles described in the EFSA Guidance on
transparency in the scientiﬁc aspects of risk assessment (EFSA, 2009) and following the relevant
existing guidance documents from the EFSA Scientiﬁc Committee.
The risk assessment was performed according to the EFSA Guidance on safety assessment of
botanicals and botanical preparations intended for use as ingredients in food supplements (EFSA
Scientiﬁc Committee, 2009).
When the test substance was administered in the feed or in the drinking water, but doses were not
explicitly reported by the authors as mg/kg body weight (bw) per day based on actual feed or water
consumption, the daily intake was calculated by the Panel using the relevant default values as
indicated in the EFSA Scientiﬁc Committee (2012) for studies in rodents or, in the case of other animal
species, by the Joint FAO/WHO Expert Committee on Food Additives (JECFA, 2000). In these cases,
the daily intake is expressed as ‘equivalent to’. When in human studies in adults (aged above
18 years), the dose of the test substance administered was reported in mg/person per day, the dose
in mg/kg bw per day was calculated by the Panel using a body weight of 70 kg as default for the adult
population as described in the EFSA Scientiﬁc Committee Guidance document (EFSA Scientiﬁc
Committee, 2012).
1.3. Information on existing assessments
Preparations containing hydroxyanthracene derivatives have been evaluated by a number of
Committees or international organisations for their potential beneﬁcial effects and/or for their potential
adverse effects as food or as medicinal products.
1.3.1. Opinion from international bodies or organisations
Evaluation performed by the European Food Safety Authority
Aloe spp., Rheum spp., Cassia spp. and Rhamnus spp. are listed in the EFSA Compendium of
Botanicals reported to contain naturally occurring substances of possible concern for human health
when used in food and food supplements (EFSA, online).4
The EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) has conducted an assessment
on the substantiation of health claims related to the hydroxyanthracene derivatives and improvement
of bowel function (EFSA NDA Panel, 2013). A cause and effect relationship has been established for
the claimed beneﬁcial effect. The NDA Panel considered that in order to obtain the beneﬁcial effect
claimed, a product should provide 10 mg hydroxyanthracene derivatives, in the adult population.
Evaluations performed by the European Medicines Agency
EMA has published some Community herbal monographs on hydroxyanthracene derivatives (Cassia
senna L. and Cassia angustifolia Valh, Rhamnus frangula L., Rhei radix, Rhamnus purshianus D.C.;
Rhamni purshianae cortex, Aloe barbadensis Mill. and Aloe various species, mainly Aloe ferox Mill. and
its hybrids), based on an assessment reports with an associated reference lists (EMA, 2007a–c, 2008a,b,
2017a,b).
For all the monographs, EMA concluded that the short-term use in case of occasional constipation
can be regarded as safe. However, the pharmacovigilance actions for anthranoid-containing laxatives
have to be maintained because further investigations are needed in regard of the carcinogenic
potential of these substances.
3 Call for data on new scientiﬁc information as regards the use of hydroxyanthracene derivatives. Published: 10 April 2017.
Available online: https://www.efsa.europa.eu/en/data/call/170410-0
4 Available online: https://www.efsa.europa.eu/en/data/compendium-botanicals
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Furthermore, the use in children below 12 years and during pregnancy or lactation is not
recommended.
Evaluation performed by the German Federal Institute for Risk Assessment (BfR)
The BfR recently issued an opinion on food supplements containing whole-leaf Aloe preparations
containing anthranoids (BfR, 2017). The BfR concluded that products which contain preparations of
unpeeled leaves of Aloe arborescens, and thereby anthranoids, do not belong to the category of
botanical food supplements which can be designated as being of ‘no safety concern’ based on current
knowledge. The BfR concluded that preparations containing anthranoids are not suitable for use in
foods, including food supplements due to the suspicion that plant-based anthranoids have a
carcinogenic effect in humans. Their assessment does not apply to preparations made from
anthranoid-free gel or inner pulp from the leaves of Aloe species (mostly Aloe barbadensis or Aloe
vera), which are commonly used in foods and cosmetics in the EU.
Evaluation performed by the International Agency for Research on Cancer (IARC)
In the 2013 monograph on ‘Some drugs and herbal products’, IARC considered that there was
inadequate evidence in humans for the carcinogenicity of Aloe vera. However, it was considered that
evidence in experimental animals for the carcinogenicity of whole leaf extract (WLE) of Aloe vera was
sufﬁciently detailed. Consequently, the WLE of Aloe vera has been classiﬁed as possibly carcinogenic to
humans and included in ‘Group 2B’.
The structurally related compound danthron (chrysazin) has also been assessed by IARC and
included in ‘Group 2B’ as a possible carcinogen to humans (IARC, 1990).
Evaluations performed by the World Health Organization (WHO)
The WHO has published monographs on the safety, efﬁcacy and quality control of Aloe, Cassia,
Frangula and Cascara (WHO, 1999) for their use as medicinal plants.
In the monographs, it is recommended that products containing anthraquinone glycosides should
not be used for longer than 1–2 weeks, due to possible incidence of electrolyte imbalance.
Furthermore, the use of these substances is contraindicated during pregnancy or lactation, except
under medical supervision, after evaluating beneﬁts and risks. Their use is contraindicated in children
under 10 years old.
1.3.2. Regulatory status and maximum limits in the EU and USA
On the basis of information gathered from the relevant food sector operators, the ANS Panel was
made aware of the regulatory status of hydroxyanthracene derivatives in some of the EU countries
(‘Documentation provided to EFSA’ n. 1 and 2).
The regulatory overview of the status of plants containing hydroxyanthracene derivatives are
described below.
In addition to the information reported below, the Panel noted that aloin is listed in Annex III, part
A (Substances which shall not be added as such to food) to Regulation (EC) No 1334/2008 on
ﬂavourings and certain food ingredients with ﬂavouring properties for use in and on foods.5
Belgium
The Belgian Royal Decree6 lists plants and their parts that are prohibited or allowed for use in food
supplements. Plants containing hydroxyanthracene derivatives that are explicitly allowed in food
supplements are listed in Table 1 (‘Documentation provided to EFSA’ n. 1).
5 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC In force OJ L 354, 31.12.2008, p. 34–50.
6 Belgian Royal Decree of 29 August 1997 on the manufacture and trade of foods composed of or containing plants or plant
preparations. Available at: http://ec.europa.eu/growth/tools-databases/tris/en/index.cfm/search/?trisaction=search.detail&yea
r=2015&num=162&mLang=EN (accessed on November 2017).
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These plants are also included in the so-called BELFRIT list, a list of plants elaborated by Belgium,
France and Italy as a common list of plants that are permitted for use in food supplements in these
countries.
Bulgaria
Ordinance No 477 covers the use of substances other than vitamins and minerals in food
supplements. Annex 4 of the Bulgarian Ordinance includes a list of botanicals which are prohibited for
use in food supplements.
Cassia acutifolia (Cassia senna), Cassia angustifolia, Frangula alnus, Rheum ofﬁcinale, Rheum
palmatum, Rhamnus cathartica, Rhamnus purshiana (Cascara), Aloe vera and Aloe ferox are not
included in the negative list, therefore they can be used in food supplements (‘Documentation
provided to EFSA’ n. 1).
Czech Republic
According to the National Decree No. 225/2008 Coll.,8 the use of Cassia acutifolia (Cassia senna),
Cassia angustifolia, Frangula alnus, Rheum ofﬁcinale, Rheum palmatum, Rhamnus cathartica and
Table 1: List of plants containing hydroxyanthracene derivatives allowed in food supplements in
Belgium (‘Documentation provided to EFSA’ n. 1)
Plant Parts of plants Condition of use
Senna alexandrina Miller Leaf, pod Recommended daily intake not exceeds 18 mg
(expressed as sennoside B);
do not administer to children (< 12 years old);
consult physician during pregnancy and lactation;
no prolonged use without professional advice
Senna italic Miller Fruit, (pod), leaf
Senna obtusifolia (L.) H.S. Irwin &
Barneby
Whole plant
Senna occidentalis (L.) Link Leaf
Senna tora (L.) Roxb. Leaf, seed
Cassia ﬁstula L. Fruit, (pod), leaf Recommended daily intake not exceeds 18 mg
(expressed as sennoside B);
do not administered to children (< 12 years old);
consult physician during pregnancy and lactation;
no prolonged use without professional advice
Frangula alnus Mill. Bark Recommended daily intake not exceeds 14 mg
(expressed as frangulin A);
do not administered to children (< 12 years old);
consult physician during pregnancy and lactation;
no prolonged use without professional advice
Frangula purshiana Cooper Bark
Rheum austral D. Don Leaf, rhizome Recommended daily intake not exceeds 25 mg
(expressed as rhein);
do not administered to children (< 12 years old);
consult physician during pregnancy and lactation;
no prolonged use without professional advice
Rheum x hydrodum Murray Root, rhizome
Rheum ofﬁcinale Baill. Root, rhizome
Rheum palmatum L. Root, rhizome
Rheum rhabarbarum L. Root, rhizome
Rheum rhaponticum L. Root, rhizome
Aloe Africana Mill. Leaf, gel, latex (juice) Recommended daily intake not exceeds 14 mg
(expressed as barbaloin);
do not administered to children (< 12 years old);
consult physician during pregnancy and lactation;
no prolonged use without professional advice
Aloe arborescens Mill. Leaf, gel
Aloe ferox Mille. Leaf
Aloe perryi Baker Leaf, gel
Aloe plicatilis (L.) Mill. Leaf, gel
Aloe vera (L.) Burm. f. Leaf
7 Bulgarian Ordinance Nr. 47/28.12.2004 on the requirements for food additives. Food Law, Promulgated SG No. 90 of 15
October 1999, Amended SG No. 80 of 12 October 2010, Amended SG No. 98 of 14 December 2010, Amended SG, No. 8 of 25
January 2011 (in Bulgarian).
8 Decree No. 225/2008 Coll., laying down requirements on food supplements and enrichment of foodstuffs, prohibits, within
labelling, attributing qualities related to preventing, treating or curing human diseases to food supplements or to refer to these
qualities. Available at: http://eagri.cz/public/web/mze/legislativa/ostatni/Legislativa-ostatni_uplna-zneni_vyhlaska-2008-225.html
(accessed on November 2017).
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Rhamnus purshiana species are prohibited in the production of foods in the Czech Republic
(‘Documentation provided to EFSA’ n. 1).
Denmark
The national Order No. 729 requires a toxicological evaluation before substances can be included in
the positive list of substances that can be used in foods or food supplements. Since hydroxyanthracene
derivatives are not listed in this national Order, these compounds cannot be included in food or food
supplements.
However, extracts that do not have a purity degree of at least 50% or are not concentrated 40
times or more fall outside the scope of the Order.
The Technical University of Denmark (DTU) has been asked to perform a toxicological evaluation of
plants in food supplements. The list contains plants considered as unacceptable, plants with a
restriction on daily use (max. level), and plants that are evaluated at a daily dose (‘Drogelisten’ (2000)
and later update March 2011).
The following plants are listed in the ‘Drogelisten’ with conditions of use, used alone and in
combination:
• Cassia acutifolia Delile or Cassia angustifolia Vahl (leaf and fruit): maximum 50 mg/day
• Rheum ofﬁcinale, Rheum palmatum (root stick): maximum 100 mg/day
• Rhamnus cathartica L. (dried berries): maximum 30 mg/day
• Rhamnus frangula L. (bark): maximum 100 mg/day
• Rhamnus purshiana (Cascara) (bark): maximum 200 mg/day
If more than one plant is included in the same products the percentage of the maximum daily dose
for each plant should be reduced relatively (‘Documentation provided to EFSA’ n. 1).
Finland
The Finnish Law 989/2007 of the Ministry of Agriculture and Forestry10 allows the use of botanicals
and other substances with a nutritional or physiological effect.
There are no legal lists specifying the permission or prohibition of botanicals in food supplements.
The evaluation is done on case-by-case basis (‘Documentation provided to EFSA’ n. 1).
France
The provisions of the EU Food Supplement Directive are transposed by the French Decree
No. 2006-352,11 which permits the use of botanicals and other bioactive substances.
The French Order of 24 June 201412 completes this Decree and establishes a list of plants that can
be used in food supplements. It also requires a toxicological assessment if the mode of preparation is
signiﬁcantly different from the traditional mode of preparation of the plant.
The plants containing hydroxyanthracene derivatives, listed in Table 2, are permitted for use in food
supplements, under speciﬁc conditions of use. France also accepts under mutual recognition the plants
that are included in the BELFRIT list (‘Documentation provided to EFSA’ n. 1).
9 Order No. 72 on the addition to food of certain substances other than vitamins and minerals (2013). Available at: http://
www.fao.org/faolex/results/details/en/?details=LEX-FAOC120080 (accessed on November 2017).
10 Finnish Law 989/2007 of the Ministry of Agriculture and Forestry. Available at: http://www.finlex.fi/ﬁ/laki/alkup/2007/20070989
(accessed on November 2017).
11 French Decree No 2006-352 of 20 March 2006 on food supplements. Available at: https://www.legifrance.gouv.fr/affichTexte.d
o?cidTexte=JORFTEXT000000638341&fastPos=1&fastReqId=487973546&categorieLien=cid&oldAction=rechTexte (accessed
on November 2017).
12 French Order of 24 June 2014. Establishing the list of plants authorized in the food complements and the conditions of their
employment. Available at: https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000029254516&fastPos=1&fa
stReqId=279617386&categorieLien=cid&oldAction=rechTextehttps://www.legifrance.gouv.fr/affichTexte.do?cidTexte=
JORFTEXT000029254516&fastPos=1&fastReqId=279617386&categorieLien=cid&oldAction=rechTexte (accessed on
November 2017).
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The quality of dietary supplements containing hydroxyanthracene derivatives in France in based on
the Belgian Regulation and used by the French supervisory authorities (Direction Generale de la
Concurrence, de la Consommation et de la Repression des Fraudes (DGCCRF)) (‘Documentation
provided to EFSA’ n. 2).
The limits of hydroxyanthracene derivatives are:
• 10 mg/day for Rhamnus purshianus, Rhamnus frangula and Aloe – expressed as aloin,
• 15 mg/day for Cassia senna L., Cassia angustifolia Vahland – expressed as sennoside B,
• 20 mg/day for Rheum palmatum L., Rheum ofﬁcinale Baillon – expressed as rhein.
Italy
Italy has adopted the BELFRIT list in its legislation.13,14 The plants listed in the Belgian Royal
Decree also are accepted for the use in food supplements in Italy, without conditions of use
(‘Documentation provided to EFSA’ n.1).
Romania
The Health Minister Order 1069/200715 permits the use of botanicals and other bioactive substances
in food supplements. The 2005 Common Order of Ministry of Health and Ministry of Agriculture, Forests
and Rural Development no. 401/244 regulates the use of botanicals in food supplements and includes
a positive and negative list of herbs and plants, and a positive list of cultivated and wild mushrooms.
Moreover, the Order 1228/2005 speciﬁes rules on the approval of food supplements containing animal
or herbal products (extracts), or in combination with vitamins and minerals.
Table 2: List of plants containing hydroxyanthracene derivatives permitted for use in food
supplements in France (‘Documentation provided to EFSA’ n. 1)
Plant Parts of plants Condition of use
Senna alexandrina Miller
Senna obtusifolia
Fruit, leaf
Seed
Hydroxyanthracene derivatives to be monitored. The labelling
should include the statement: not recommended for children aged
under 12, pregnant or breastfeeding women and not suitable for
prolonged use
Cassia ﬁstula L. Fruit, leaf Hydroxyanthracene derivatives to be monitored. The labelling
should include the statement: not recommended for children aged
under 12, pregnant or breastfeeding women and not suitable for
prolonged use
Frangula alnus Mill.
Frangula purshiana
Cooper
Bark Hydroxyanthracene derivatives to be monitored. The labelling
should include the statement: not recommended for children aged
under 12, pregnant or breastfeeding women and not suitable for
prolonged use
Rheum palmatum L.
Rheum ofﬁcinale Baill.
Root, rhizome Hydroxyanthracene derivatives and anthraquinones to be
monitored. The labelling should include the statement: not
recommended for children aged under 12, pregnant or
breastfeeding women and not suitable for prolonged use
Aloe ferox Mill.
Aloe vera (L.) Burm. f.
Leaf, gel,
latex (juice)
Hydroxyanthracene derivatives (aloins) to be monitored. The
labelling should include the statement: not recommended for
children aged under 12, pregnant or breastfeeding women and not
suitable for prolonged use
Rhamnus cathartica Bark Hydroxyanthracene derivatives (aloins) to be monitored. The
labelling should include the statement: not recommended for
children aged under 12, pregnant or breastfeeding women and not
suitable for prolonged use
13 Italian Ministry of Health. Disciplina dell’impiego negli integratori alimentari di sostanze e preparati vegetali. Gazzetta Ufﬁciale
della Repubblica Italiana 2012, 169. Available at: http://www.salute.gov.it/imgs/C_17_pagineAree_1268_listaFile_itemName_
2_file.pdf (accessed on November 2017).
14 Italian Ministry of Health. D.M. 27 marzo 2014 ‘Aggiornamento del DM 9 luglio 2012 sulla Disciplina dell’impiego negli
integratori alimentari di sostanze e preparati vegetali’. Available online: http://www.trovanorme.salute.gov.it/norme/detta
glioAtto?id=48636 (accessed on November 2017).
15 Health Minister Order No 1069/2007 on food supplements (Norma din 19/06/2007 ‘privind suplimentele alimentare’). Available
at: http://www.ms.ro/2017/01/11/notificari-suplimente-alimentare/ (accessed on November 2017).
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The following hydroxyanthracene derivatives containing plants are speciﬁcally allowed for use in
food supplements (‘Documentation provided to EFSA’ n. 1):
• Cassia acutifolia (Cassia senna), Cassia angustifolia
• Frangula alnus
• Rheum ofﬁcinale, Rheum palmatum
• Rhamnus cathartica, Rhamnus purshiana (Cascara)
• Aloe vera, Aloe ferox
Spain
The Royal Decree 1478/200916 on food supplements allows the use of botanicals and other
ingredients in food supplements. However, the authorities have not issued any list (‘Documentation
provided to EFSA’ n.1).
Sweden
The Swedish National Food Administration’s Code of Statues17 permits the use of botanicals and
other bioactive substances in food supplements. The authorities tolerate the use of other bioactive
substances in food supplements as long as they are not classiﬁed as medicines or natural remedies by
the Medicinal Products Agency.
The following plants are included in the list of the Swedish Medical Products Agency
(‘Documentation provided to EFSA’ n. 1):
• Cassia angustifolia Senna, Cassia senna. The product is generally a medicinal product. The
herb has a laxative effect.
• Frangula alnus. The product is generally a medicinal product.
• Aloe vera, Aloe ferox. The product is generally not a medicinal product. Aloe products containing
anthraquinones can be medicinal products, since these substances have a laxative effect.
The following plants are not included in this list:
• Rheum ofﬁcinale, Rheum palmatum
• Rhamnus cathartica, Rhamnus purshiana (Cascara).
United Kingdom
The Food Supplement (England) Regulations 200318 permit the use of substances with nutritional
or physiological effect in food supplements. The Regulation does not include positive and/or negative
lists of botanicals or other bioactive substances (‘Documentation provided to EFSA’ n.1).
United States
Before 2002, products containing various components of Aloe vera (aloin, aloe-emodin and
barbaloin) were considered as oral over-the-counter (OTC) laxatives and regulated by the Food and
Drugs Administration (FDA). In 2002, the FDA promulgated a regulation stating that the Aloe vera
ingredients present in OTC drugs were not ‘generally recognized as safe and effective’ or were
misbranded (FDA, 2002).19 Since the lack of safety data on Aloe vera laxative products, FDA required
all OTC Aloe vera laxative products to be withdrawn from the US market or reformulated. However,
Aloe vera may be used as a food ﬂavouring as deﬁned in FDA Regulation 21CFR172.510.
1.3.3. Overview of composition from industry
A public call for data was launched to gather information from the relevant food business
operators, on the composition of food supplements containing hydroxyanthracene derivatives.20
16 Real Decreto 191/2011, de 18 de febrero, sobre Registro General Sanitario de Empresas Alimentarias y Alimentos. Available
at: http://www.boe.es/boe/dias/2011/03/08/pdfs/BOE-A-2011-4293.pdf (accessed on November 2017).
17 Swedish National Food Administration’s Code of Statues (LIVSFS 2003:9). Available at: https://www.livsmedelsverket.
se/globalassets/om-oss/lagstiftning/berikn—kosttillsk—livsm-spec-gr-fsmp/livsfs-2003-09-kons-tom-2014-10.pdf (accessed
on November 2017).
18 The Food Supplement (England) Regulations 2003 S.I. 2003 No. 1387. Available at: http://www.legislation.gov.uk/uksi/2003/
1387/pdfs/uksi_20031387_en.pdf (accessed on November 2017).
19 Available at: https://www.fda.gov/ohrms/dockets/98fr/050902a.htm
20 https://www.efsa.europa.eu/en/data/call/170410-0
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Based on the information gathered, the Panel noted the no information was received on food
supplements containing Cascara preparations as ingredients. Only one product was reported to contain
Frangula in combination with the other botanical species and the concentration of hydroxyanthracene
derivatives in this product (expressed as glucofrangulin A) was reported to be 7%, corresponding to a
dose of 13 mg/tablet.
The Panel further noted that, according to the information provided by relevant food sectors,
following the launch of the ‘Call for data’, the majority of the products contain botanical preparations from
Cassia, Aloe and Rhubarb, alone or in combinations and that the percentage of hydroxyanthracene
derivatives in food supplements, as reported by food business operators, is variable (sennoside B 0.2–24%;
rhein 1.6–6%; barbaloin: 15–20%) (‘Documentation provided to EFSA’ n. 3, 4, 5, 6 and 7).
2. Technical data
2.1. Identity and nature of the source material
Plants containing hydroxyanthracene derivatives are numerous and belong to different botanical
families and genera. To focus the attention on the most important botanicals for the consumers, plants
used in food supplements and traditional medicine have been selected.
For food supplements, the main source of information was the so-called BELFRIT list, which
contains more than 1000 botanicals allowed in this food category.
For herbal medicinal products, the main source of information was the EMA website21 and the
European Pharmacopoeia.
Since the botanical classiﬁcation is complicated and several synonyms are associated with any
species, a short description of botanicals is reported here (Table 3), with common names and parts
used. However, detailed tables are present in Appendix B.
Table 3: Botanical classiﬁcation and short description of Aloe spp., Cassia spp., Frangula spp.,
Rhamnus spp. and Rheum spp.
Aloe spp., family: Xanthorrhoeaceae, genus: Aloe L.
Species Main common name Part/s used
Aloe africana Mill ND Leaf, leaf gel
Aloe arborescens Mill Candelabra aloe Leaf, leaf gel
Aloe ferox Mill. Cape aloe Leaf, leaf gel
Aloe perryi Baker Perry’s aloe Leaf, leaf gel
Aloe plicatilis (L.) Mill ND Leaf, leaf gel
Aloe vera (L.) Burm. F Barbados aloe Leaf, leaf gel
Cassia spp., family: Leguminosae, genus: Cassia L. or Senna Mill.
Species Main common name Part/s used
Cassia ﬁstula L. Golden shower Fruit
Cassia italica (Mill.) F.W. Andrew Port Royal senna Whole plant
Cassia mimosoides L. var. nomame Makino Cassia nomame Leaf, pod
Senna alexandrina Mill. Alexandrian senna Leaf, pod
Senna obtusifolia (L.) H.S. Irwin & Barneby Java-bean Whole plant
Senna occidentalis (L.) Link Septicweed Bark, leaf
Senna tora (L.) Roxb. Sickle senna Leaf, seed
Frangula spp. and Rhamnus spp.
spp., family: Rhamnaceae, genus: Frangula Mill. and Rhamnus L.
Species Main common name Part used
Frangula alnus Mill. Glossy buckthorn Bark
Frangula purshiana Cooper Cascara buckthorn Bark
Rhamnus alpina L. – Bark, fruit
Rhamnus cathartica L. Common buckthorn Whole plant
21 http://www.ema.europa.eu/ema/
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On the basis of the information gathered from the relevant food sector operators, a description of
the identity of the botanical sources of hydroxyanthracene derivatives is also provided in Table 4.
Based on the information received in response to a public call for data, the ANS Panel noted that
the identity of the botanical species used in food supplements is in line with the information presented
above, with the exception of cascara preparations, for which no response has been received
(‘Documentation provided to EFSA’ n. 3, 4, 5, 6 and 7).
2.2. Chemical composition
The EFSA Compendium of Botanicals (EFSA, online) was consulted to identify bioactive substances
present in the botanical species that are the subject to this opinion.
Rheum spp., family: Polygonaceae, genus: Rheum L.
Species Main common name Part used
Rheum australe D. Don ND
Rheum ofﬁcinale Baill. Chinese rhubarb
Rheum palmatum L. Chinese rhubarb
Rheum rhabarbarum L. Garden rhubarb
Rheum rhaponticum L. ND
Rheum x hybridum Murray ND
ND: no common name found.
Table 4: Information gathered from the relevant food sector operators related to the identity of the
botanical sources of hydroxyanthracene derivatives
Aloe Cassia Rhamnus Rheum
Botanical
family
Aloaceae – Aloe family
Asparagaceae
Fabaceae/
Leguminosae –
Pea family
NA Polygonaceae
Genus Aloe L. Senna Mill.– senna NA NA
Species Aloe ferox Mill. – Cape
aloe
Aloe vera L. Burm. F
Senna alexandrina
Mill.
NA Rheum palmatum L. /Rheum
ofﬁcinale Baillon
Variety NA NA NA NA
Synonyms Aloe horrida Haw.,
A. perfoliata Thunberg.,
A. pseudoferox Salm.
Dyck, A. socotrina
Masson., A. supralaevis
Haw., Pachydendron ferox
Humb. & Bonpl.,
P. supralaeve Haw
Aloe barbadensis Mill
Cassia acutifolia
Delile, Cassia
senna L., Senna
alexandrina,
Senna angustifolia
(Vahl) Batka
Senna alexandrina
Mill.
Frangula dodonei
Ard – Rhamnus
frangula L.
Rheum potaninii Losinsk,
Rheum qinlingense Y.K.
Yang, J.K. Wu & D.K. Zhang
= synonyms of Rheum
palmatum L., no synonym
are recorded for Rheum
ofﬁcinale Baill. (source: The
Plant List)
Rheum palmatum subsp.
dissectum Stapf
Rheum palmatum f. rubiﬂora
Stapf
Part used Leaves juice Leaves, fruit Bark, rhizome Leaves, roots
Geographical
origin
Continent: Africa, South
America
Country: South Africa
Continent: Asia
Country: India
Area: Rajasthan/
Gujarat
Continent: Europe
Country: –
Area: Eastern
Europe
Continent: Asia
Country: China
Area: Shanxi province
Growth and
harvesting
conditions
Wild Cultivated Wild
Stage of harvest:
before ﬂowering
Manual harvesting.
drying: natural
Wild and cultivated
Cultivation practices: time of
harvest in relation to season.
Stage of the plant growth:
after ﬂowering
NA: no information available further to request to food sector operators.
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Information on composition, as reported in the respective EU Pharmacopoeia monographs, is also
reported.
Rheum spp. Rhubarb
According to the EFSA Compendium of Botanicals (EFSA, online), roots and other underground
parts of Rheum palmatum L and Rheum ofﬁcinale Baillon, contain anthraquinones at levels ranging
from 2.2% to 6.0%. The compounds identiﬁed are emodin, palmidin C, rhein, sennoside A, sennoside
B; however, their levels are not quantiﬁed.
No other substances of possible concern for human health when present in food are reported to be
present.
Rhein is the substance used as a reference for the standardisation of rhubarb preparations included
in the EU Pharmacopeia (Reference to be added).
The whole or cut, dried underground parts of Rheum palmatum L or of Rheum ofﬁcinale Baillon or
of hybrids of these two species or of a mixture must have a minimum content of 2.2% of
hydroxyanthracene derivatives, expressed as rhein (dried drug), in order to comply with the
speciﬁcations given in the EU Pharmacopoeia for the drug ‘rhubarb’. Rhubarb is used as a starting
material for the preparation of the dry standardised extract produced by ethanol extraction. In order
to comply with the EU Pharmacopoeia requirements, the standardised extract shall have a content of
15.0–30.0% of glucofrangulins.
Cassia spp. and Senna spp.
According to the EFSA Compendium of Botanicals (EFSA, online), the leaves and the fruit of Cassia
ﬁstula L., contain chrysophanol, physcion and rhein; however their levels are not quantiﬁed.
Aloe-emodin, emodin, emodin anthrone, physcion are reported, albeit not quantiﬁed, in the seed of
Senna occidentalis (L.), alongside other phytotoxins (not further speciﬁed) (EFSA, online).
Sennoside B is the substance used as a reference for the standardisation of senna preparations
included in the EU Pharmacopeia (Reference to be added).
Dried leaﬂets of Cassia senna L. (synonym Cassia acutifolia Delile), known as Alexandrian or
Khartoum senna, or Cassia angustifolia Vahl, known as Tinnevelly senna or a mixture of the two
species must have a minimum content of 2.5% of hydroxyanthracene glycosides, expressed as
sennoside B (dried drug) in order to comply with the speciﬁcations given in the EU Pharmacopoeia for
the drug ‘senna leaf’. Senna leaf is used as a starting material for the preparation of the dry
standardised extract produced by ethanol extraction. In order to comply with the EU Pharmacopoeia
requirements, the standardised extract shall have a content of 5.0–8.0% of hydroxyanthracene
glycosides, expressed as sennoside B.
In addition to the leaf, also the dried fruit of Cassia senna L. are used for the herbal drug ‘senna
pods, alexandrian’, which must contain a minimum of 3.4% hydroxyanthracene glycosides, expressed
as sennoside B, in order to comply with the speciﬁcations given in the EU Pharmacopoeia. The drug
‘senna pods, tinnevelly’ is instead obtained by the dried fruit of Cassia angustifolia Vahl and must
contain a minimum of 2.2% hydroxyanthracene glycosides, expressed as sennoside B in order to
comply with the speciﬁcations given in the EU Pharmacopoeia.
Aloe spp.
According to the EFSA Compendium of Botanicals (EFSA, online), the leaves of Aloe vera (L)
contain aloin A and aloin B; however, their levels are not quantiﬁed. The same substances are reported
also to be present in the ‘live plants’ of Aloe ferox Mill.
Anthraquinones, aloe-emodin, aloenin, aloin A and aloin B are reported to be present in the leaves
of Aloe arborescens Mill., alongside the following other substances: esculetin, fructose, glucose,
glutamic acid, glycine, malic acid, scopoletin, serine, sucrose and vanillic acid. The levels of these
substances are not quantiﬁed. The Panel noted that these data refers to a publication (Olennikov
et al., 2010) on aloe juice, a term which should be used to describe the latex material of the pericycle
while ‘gel’ refers to the inner leaf liquid material (IARC, 2016).
Barbaloin is the substance used as a reference for the standardisation of aloe preparations included
in the EU Pharmacopeia (Reference to be added).
The concentrated and dried juice of the leaves of various species of Aloe (mainly Aloe ferox Miller
and its hybrids must have a minimum content of 18% hydroxyanthracene derivatives, expressed as
barbaloin (dried drug), to comply with the speciﬁcations given in the EU Pharmacopoeia for the drug
‘Cape aloes’.
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The drug ‘Barbados aloes’, refers instead to the concentrated and dried juice of the leaves of Aloe
barbadensis Mill. and, in order to comply with the speciﬁcations given in the EU Pharmacopoeia, it should
contain a minimum of 28% of hydroxyanthracene derivatives, expressed as barbaloin (dried drug).
Both ‘Cape aloes’ and ‘Barbados aloes’, individually or in combination are used in the EU
Pharmacopeia, as starting materials for the preparation of the dry standardised extract using boiling
water. In order to comply with the EU Pharmacopoeia requirements, the standardised dry extract shall
have a content of 19.0–21.0% of hydroxyanthracene derivatives, expressed as barbaloin.)
Frangula spp.
According to the EFSA Compendium of Botanicals (EFSA, online), the bark of Frangula alnus Mil.
(Rhamnus frangula Mil.) contains emodin anthrone, glucofrangulin A, glucofrangulin B and palmidin C;
however, their levels are not quantiﬁed.
No other substances of possible concern for human health when present in food are reported to be
present.
Glucofrangulin A is the substance used as a reference for the standardisation of frangula
preparations included in the EU Pharmacopeia (Reference to be added).
The dried bark (whole or fragmented) of the stems and branches of Rhamnus frangula L. (Frangula
alnus Miller) must have a minimum content of 7.0% of glucofrangulins, expressed as frangulin A (dried
drug), to comply with the speciﬁcations given in the EU Pharmacopoeia for the drug ‘Frangula bark’.
Frangula bark is used as a starting material for the preparation of the dry standardised extract
produced by ethanol extraction. In order to comply with the EU Pharmacopoeia requirements, the
standardised extract shall have a content of 15.0–30.0% of glucofrangulins.
Rhamnus spp.
According to the EFSA Compendium of Botanicals (EFSA, online), the bark of Frangula purshiana
Cooper (Rhamnus purshiana DC.) contains cascarosides, aloe-emodin and emodin at levels not quantiﬁed.
No other substances of possible concern for human health when present in food are reported to be
present.
Cascaroside A is the substance used as a reference for the standardisation of cascara preparations
included in the EU Pharmacopeia (Reference to be added).
The dried bark (whole or fragmented) of Rhamnus purshiana DC. must have a minimum content of
8.0% of hydroxyanthracene glycosides, of which at least 60% consists as cascarosides, both expressed
as cascaroside A (dried drug), to comply with the speciﬁcations given in the EU Pharmacopoeia for the
drug ‘Cascara’. Cascara is used as a starting material for the preparation of the dry standardised
extract produced by either boiling water or hydroalcoholic extraction. In order to comply with the EU
Pharmacopoeia requirements, the standardised extract shall have a nominal content of 8.0–25.0% of
hydroxyanthracene glycosides, and at least 60% of which must be cascarosides, expressed as
cascaroside A.
2.3. Speciﬁcations
There are no speciﬁcations for Aloe, Rhubarb, Cassia, Frangula and Cascara preparations used as
food including food supplements in EU Regulations.
Speciﬁcations, however, are available for Aloe, Rhubarb, Cassia, Frangula and Cascara when used
as medicinal plants, from the European Pharmacopeia and WHO monographs.
The Panel noted that the speciﬁcations given for medicinal plants may not be relevant or applicable
to the same botanicals when used in food, including food supplements.
On the basis of the information gathered from the relevant food sector operators following the
launch of a public call for data, the Panel was made aware of certain maximum levels for contaminants
that are applicable to the food supplements containing hydroxyanthracene derivatives (‘Documentation
provided to EFSA’ n. 3, 4, 5, 6 and 7).
No information was received on food supplements containing Rhamnus purshiana (Cascara) as
ingredient.
2.4. Manufacturing process
Speciﬁc request for information on the manufacturing process used for the preparation of the
botanical ingredients used in food supplements containing hydroxyanthracene derivatives was included
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in the call for data launched. The information received was complemented by the Panel with data
retrieved in the published literature.
Extraction methods
According to the information provided by the interested parties, there is no standardised method
for the extraction of hydroxyanthracene derivatives. In some cases, the extraction is performed by
using ethanol or water (at different percentages); in other cases, an extraction solvent is not used
since the plants are naturally dried (‘Documentation provided to EFSA’ n. 4, 5, 6 and 7).
The aloe vera industry produces different commercial raw materials including bitters, gels, WLE
powders and so-called jelly. There are two distinct layers in aloe leaves: the green outer leaf rind and
the soft, colourless inner gel parenchyma (Figure 1). Processing techniques vary according to what
part of the leaf is required for a particular product/use, especially with regard to the bitters and gels.
Some products comprise pure gel, while others are based on various mixtures of gel and bitters,
depending on of the product (Boudreau et al., 2013).
Hydroxyanthracene derivatives are primarily found in the aloe latex, the exudate found in between
the inner leaf, i.e. the clear, central parenchymatous tissues of the aloe leaf, and the rind.
The inner leaf is the part of the plant typically used to derive the aloe gel, a liquid product with
wide application in the food industry. Aloe gel differs from aloe juice, the latter being obtained from
the leaf without the removal of the rind (IASC, 2009).
Different commercial preparations are obtained from aloe vera, depending on the parts of the plant
used and the processes applied. The terminology used to name the different preparations does not
always allow a clear identiﬁcation of the material and the processes applied. Owing to their laxative
properties, the presence of hydroxyanthracene derivatives in the preparations in-tended for use in
foods is controlled and limited by adding puriﬁcation steps in the manufacturing process of products
intended for use in foods. The International Aloe Science Council has established a quality standard for
their certiﬁcation program of not more than 10 ppm (10 mg/kg) aloin A and B for all aloe vera leaf
juice ingredients for use in products intended for oral consumption (IASC, online).
In the whole leaf juice process, the entire aloe vera leaf is cut and ground into a slurry which is
subsequently pressed to obtain a liquid. Hydroxyanthracene derivatives are removed by passing through
a series of press ﬁlters with carbon coated plates. This step is also known as decolourisation process.
The aloe vera juice is continually passed through a ﬁlter press until 99.9% or more of the aloin is
removed (IASC, online).
The presence of hydroxyanthracene derivatives in the aloe juice can be minimised by a second
manufacturing process which uses the inner leaf as the starting material. In this method, the outer leaf
rind is separated and discarded from the inner pulp before expressing the juice. A further
decolourisation step with activated carbon may also be implemented even in this process.
There is no single method that is regarded as standard for the extraction of bioactive compounds
from aloe (Chandegara and Varshney, 2013; Choche et al., 2014). Leaves show losses of biological
activity beginning at 6 h following harvest and most biological activities are completely lost after 24 h
when stored at ambient temperatures. The processing must be completed within 36 h of harvesting
the leaves (Chandegara and Varshney, 2013; Choche et al., 2014). Exudate from the cut leaf base of
Aloe spp. contains a high concentration of anthraquinone compounds. The maximum recoverable aloin
Figure 1: Aloe leaf cross section. Anthraquinones are mainly located in the outer leaf pulp (from
Rahman et al., 2017; Copyright © 2017 by the authors, CC BY)
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was estimated to be 24 h after harvest by Soxhlet extraction (SE) of dry gel particles of size
0.42–0.841 mm using methanol 5% (w/w) as a solvent (Choche et al., 2014; Dhodare et al., 2015).
Anthraquinones are usually removed from the Aloe commercial products used in food applications. In
the whole leaf processing method, the aloe liquid is passed through several ﬁlters in order that aloin
and aloe-emodin can be removed (Ahlawat and Khatkar, 2011), as well as any microscopic traces of
leaves, sand or other particles. A comparison of various processing methods and the effect on aloin
concentration was presented by Chandegara and Varshney (2013). The highest content of aloin
(32 mg/kg) is obtained by a roller method, followed by a leaf splitter method (18 mg/kg) and a
hand-ﬁlleting method (6 mg/kg), while the lowest content of aloin is obtained by a whole leaf method
(1 mg/kg).
In 2003, Cohen patented a method for extracting aloin from aloe juice or other products of
industrial utility. In his patent (EP-A-374 890), Cohen describes a procedure that consists of two steps.
In the ﬁrst step, an aliphatic diol or triol is added to the yellow aloe juice or other aloin-containing
derivative of the juice. Following the ﬁrst step, a concentration is performed. The second step includes
the extraction that is followed by recrystallisation from an alcohol. The solvent used for the extraction
can be either ethyl acetate or acetone. According to the author, this method leads to a greater yield
(60%) compared to other usual methods of extraction of aloin.
According to Zhao et al. (2011), the most common methods for the extraction of anthraquinone
compounds in rhubarb are maceration extraction (ME), heat reﬂux extraction (HRE), SE and
microwave-assisted extraction (MAE). In his study, response surface methodology (RSM) was used to
optimise ultrasonic-assisted extraction (UAE). RSM is a statistical technique that investigates the
different variables (simultaneously) and their interactions. Here, three variables were investigated: time
and temperature of the extraction and percentage concentration of the solvent used (methanol). The
software predicted that the optimum methanol concentration, extraction time and extraction
temperature were 83.6%, 33.2 min and 67.1°C, respectively. All three factors contributed to the
extraction of the anthraquinones.
Conventional extraction techniques such as ME or SE are essentially based on the extracting power of
different solvents and the application of heat and/or mixing. These methods are still much in use as they
are simple and inexpensive. However, they are often time-consuming and require large solvent volumes.
In contrast, some of the most recently developed methods have deﬁnite advantages (Duval et al., 2016).
Many authors compared conventional and novel methods for extraction efﬁciency of the
anthraquinones. Arvindekar et al. (2015) used various solvents like petroleum ether, chloroform, ethyl
acetate and ethanol in the extraction of two different kinds of samples (powder and acid hydrolysed)
from Rheum emodi. Various sample-to-solvent ratios were examined (1:4, 1:8, 1:10, 1:15, 1:20, 1:25,
1:32). The best solvent appeared to be ethanol, indicating maximum solubility for both kinds of
samples. The best sample-to-solvent ratio was 1:20. In general, the selection of the solvent offers the
ability to control the selectivity of the method (Duval et al., 2016).
Different conventional methods for extraction of hydroxyanthracene derivatives are described in the
literature. Among these are maceration-assisted extraction, reﬂux-assisted extraction, sublimation-
assisted extraction and SE.
According to Duval et al. (2016), maceration is the most popular method for the extraction of
anthraquinones. Arvindekar et al. (2015) studied the extraction of anthraquinones from R. emodi. Solid
R. emodi and its acid hydrolysate were suspended in ethanol, separately. After intermittent shakings
and a resting period, the extracts were centrifuged, diluted in methanol (1:100) and injected for
high-performance liquid chromatography (HPLC) analyses. Locatelli et al. (2012), Sakulpanich and
Gritsanapan (2008) and Zhao et al. (2015), as referred by Duval, mention the use of water and protic
solvents, as well as acidic hydrolysis to release aglycone forms or ethyl acetate to achieve the
extraction of anthraquinone dimers (Donfack et al., 2014 as referred by Duval et al., 2016).
Pulverised and hydrolysed samples of R. emodi were transferred to an ethanol-containing
round-bottom ﬂask (RBF) and reﬂuxed for respective time intervals on water bath. The extracts were
centrifuged, diluted in methanol (1:100, except t0 1:10) and injected for HPLC analysis. In order to
extract the 1,8-dihydroxyanthraquinones by sublimation process, 1 g of thoroughly dried powder and
the acid hydrolysate were transferred in a 50-mL RBF attached to a reﬂux condenser (length > 1 m)
with cold water circulation and placed in a heating mantle. The ﬂask was strongly heated (8–10 min),
until yellow fumes ceased from the sample. On cooling to room temperature, divided portions of
100 mL ethanol were used to dissolve the sublimed 1,8-dihydroxy anthraquinone (DHAQ) adhered the
walls of condenser and volume was made to 100 mL of which 0.1 mL was diluted with methanol
(1:100) and subjected to HPLC (Arvindekar et al., 2015).
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In the study of Arvindekar, the same two kinds of samples were soxhleted in 100 mL of ethanol for
three time intervals. The extracts were centrifuged, diluted in methanol (1:100, except t0 1:10) and
injected for HPLC analysis (Arvindekar et al., 2015). According to Duval et al. (2016), in SE the solvent
is heated to boil; this is the reason it has to be replaced continuously, until the plant material is
completely exhausted. The method is considered very effective. The use of SE for the extraction of
aloin from aloe vera was also studied by Choche et al. (2014).
Novel methods are also reported in the literature, such as ultrasound-assisted extraction (UAE),
MAE, pressurised liquid extraction (PLE), super/subcritical ﬂuid extraction and use of ionic liquids (ILs).
Zhao et al. (2011) realised ultrasonic extraction of anthraquinone compounds in rhubarb at a
frequency of 40 kHz for a certain time and at different temperatures. Methanol was used as a solvent
and the solid to solvent ratio was 1/15. The material size was 0.2–0.5 m. The quantiﬁcation was
achieved by HPLC with ultraviolet detection (HPLC-UV), where the temperature and wavelength were
set at 30°C and 254 nm, respectively.
In the method described by Arvindekar et al. (2015), two samples (one powdered and one
hydrolysed) were suspended in ethanol and immersed in an ultrasonic bath. After 0, 15, 30 and
45 min sonication, the extracts were centrifuged, diluted in methanol (1:100, except t0 1:10) and
injected for HPLC analysis.
According to Duval et al. (2016), the temperature, in UAE, varies from 55 to 67°C and the time
from 30 to 60 min. As a solvent, ethanol (or ethanol–water mixture) is used due to its low cost and
non-toxicity. However, acetone and methanol appeared to be more effective. According to Duval, there
are several studies that show the greater efﬁciency of this method compared to the conventional
methods of extraction of anthraquinones.
Bhosle et al. (2015) also investigated the use of UAE and its efﬁciency compared to the classical
solvent extraction techniques used for the extraction of bioactive compounds from natural sources.
The extraction took place at 25°C, 15.7 W for 45 min. As a solvent, acetone was used based on the
polarity of anthraquinones. However, the use of an ethanol–water mixture as a solvent provided
greater anthraquinone extraction yield. According to the author, UAE method of extraction provides
increased yield, compared to other methods, such as stirred batch and soxhlet extraction. A
temperature of 40°C for 30 min as the optimum parameters for UAE was reported in another
publication (Jawade and Chavan, 2013).
Wang (2008) developed a differentiated method called ultrasonic nebulisation extraction (UNE) for
the extraction of anthraquinones from Rheum palmatum L. In contrast to the general application of
ultrasonic baths, in this study, an ultrasonic humidiﬁer was used for the extraction. As a solvent,
ethanol was used, although methanol provided better yields. After the extraction, the sample was
dried and re-dissolved using ethanol A capillary electrophoresis system (sodium dodecyl sulfate micellar
electrokinetic chromatography (SDS-MEKC) system) equipped with a UV detector was used for the
separation and determination of anthraquinones. Comparing the different methods of extraction
(maceration, reﬂux extraction, stirring and UAE), the author concluded that UAE displays greater
efﬁciency, while it minimises the energy cost and time of extraction.
According to Duval et al. (2016), the MAE takes place in temperatures between 60 and 120°C for a
very short time (7.5–15 min). Srikanth et al. (2011) noticed that MAE led to higher yield of calcium
sennosides compared to conventional heating. It is also indicated that increasing the power of the
microwaves increases yield, while the solvent consumption and the time required are reduced.
A temperature of 75–150°C is commonly used for pressurised hot water extraction (PHWE).
Vazquez et al. (2015) and Pongnaravane et al. (2006), as referred by Duval et al. (2016), used
temperatures from 170 to 200°C. According to Vasquez, the increase of temperature from 120 to
170°C provides better extraction. The pressure also varies but is not considered a critical parameter.
The extraction can be static or dynamic. An increase of the water ﬂow rate up to 5 mL/min can
increase the extraction yield of total anthraquinones (Duval et al., 2016).
Super/subcritical ﬂuid extraction (SFE) mainly uses supercritical carbon dioxide as an extraction
solvent. The best conditions were: 30% ethanol in SF at 200 bar and 60°C. The main advantage of
SFE compared to the other extraction methods is the use of low temperatures that prevents
degradation or oxidation of speciﬁc compounds due to high temperature (Duval et al., 2016).
Anthraquinones such as aloe-emodin, physcion, emodin or rhein that have hydroxyl or carboxylic acid
groups are not good candidates for SFE using pure CO2 (Shamsipur et al., 2008 as referred by Duval
et al., 2016).
In a study, the extraction of ﬁve anthraquinones from rhubarb using ionic liquid-based ultrasonic/
microwave-assisted extraction (IL-UMAE) was investigated. According to the author, IL-UMAE showed
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greater efﬁcacy and decreased extraction time, when compared to conventional methods of extraction
of anthraquinones, such as UAE, MAE and HRE (Lu et al., 2011).
Tan et al. (2012) also investigated the use of ILs in the extraction of anthraquinones from aloe.
Ionic liquid-based aqueous two-phase systems (ILATPS) are considered more efﬁcient and
environmentally friendly, compared to other liquid–liquid extraction methods (Tan et al., 2012).
In another study, the same author used an alcohol/salt ATPS to purify anthraquinones extracted
from aloe vera. In this study, 5.0 mL distilled water, 2.0 mL alcohol, a given amount of salt (NH4)2SO4
was chosen as the phase-forming salt) and 0.1 mL aloe anthraquinones solution were mixed. After
complete dilution of the salt, the mixture separated in two phases and the anthraquinone rich phase
was removed by a syringe and treated with magnesium acetate–methanol solution. Under weakly basic
conditions, the anthraquinone solution turns to red. The total anthraquinone concentration was
determined using a UV–Vis spectrophotometer. The concentration of anthraquinones in the salt-rich
phase was determined by mass balance. The author concluded that the alcohol/salt system is an
efﬁcient method in the puriﬁcation of active compounds in natural plant or biomolecules (Tan et al.,
2013).
Other methods of extraction were retrieved from the literature and are summarised below.
A method described by Su and Ferguson (1973) to extract and separate anthraquinone aglycones
and glycosides from cascara (Frangula spp.) and senna (Cassia spp. and Senna spp.) is based on the
ability of the aglycones, unlike glycosides, to dissolve in chloroform, as well as on the fact that the
hydroxyanthracene derivatives and their glycosides can be found in the plant material free or
combined as salts. The procedure started with maceration of the ground plant. After drying, several
extractions followed, using chloroform, alcohol and ethanol. The separation was realised using two
different chromatographic techniques for glycosides and aglycones, because of their different solubility.
This basically means that the aglycones had to be hydrolysed from glycosides prior to the
chromatographic separation.
Shi et al. (2007) proposed cloud point extraction (CPE) as a simple and effective method for the
extraction and preconcentration of anthraquinones, prior to the use of high-performance liquid
chromatography with diode-array detection (HPLC-DAD) for their determination. As an organic solvent
for the extraction, a non-ionic surfactant, oligoethylene glycol monoalkyl ether (Genapol X-080), was
used. Shi used rhubarb which was pulverised and sieved prior the manufacture. UAE was used to
extract the hydroxyanthracene derivatives from the plant powder. The extracts were then centrifuged
and the supernatant was ﬁltered and analysed by HPLC. In comparison to the other organic solvents,
Genapol X-080 showed greatest efﬁciency. The CPE method showed good reproducibility and is also
considered as an environmental friendly and simpliﬁed method.
The method of decoction applied by Sakulpanich and Gritsanapan (2008) includes only the use of
distilled water for the extraction of anthraquinones from Cassia ﬁstula, for several times. In his study,
Sakulpanich used also percolation, where the pulp was moistened with ethanol and then transferred in
a percolator adding alcohol, as well as other conventional methods of extraction (maceration and
soxhlet extraction). The author concluded that decoction is the ideal method for the extraction of
anthraquinones from C. ﬁstula, according to its yield performance.
Mehta and Laddha (2009) proposed a simple method for the extraction of rhein from senna (Cassia
angustifolia) leaves. According to this method, the leaves were powdered and a mixture of ethanol–
water was added to the powder. The mixture was warmed and HCl was added. Subsequently, a
biphasic system was produced by the use of toluene and was boiled for 6 h. After cooled and ﬁltered,
the liquid and organic phases were separated. Another treatment with toluene was applied and 10%
aqueous sodium hydrogen carbonate solution was applied until the aqueous layer ceased to show the
characteristic pink colour. The aqueous layer was acidiﬁed and the precipitate was collected. A dark
yellow compound was obtained. Borntrager’s reagent was used for the detection of anthraquinones
(also referred by Sakulpanich and Gritsanapan, 2008). The compound was identiﬁed as rhein after
chemical tests and spectral studies. For use in large scale extraction, the method needs further
optimisation.
Yang et al. (2014) proposed a new gas-assisted three-liquid-phase extraction system (GATE) for the
separation of emodin and rhein from herbal extract. In this study, the system consists of butyl acetate,
PEG4000 and ammonium sulfate. In contrast to traditional three-liquid-phase extraction, where
mechanical or magnetic agitation are used, solutes with surface activity are absorbed on or dissolved
in the surface of ascending bubbles in the aqueous phase. According to the author, GATE provides
better separation with lower consumption of polymer and organic solvent.
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In another study, Shi et al. (2014) proposed an improved liquid–liquid extraction for the extraction
of anthraquinones from herbal mixtures. In this improved method, the mixture is extracted, also with
ethyl acetate–butanol (1:2, v/v), but this time under stirring and then allowed to separate. The solvent
is again evaporated by reduced pressure. The yellow residue is then dissolved in acetone and the
procedure followed is the same as for the conventional method. The improved liquid–liquid extraction
provided higher yield and lower variability.
According to the author, among different solvents tested (ethyl acetate, ethyl acetate–butanol,
chloroform, dichloromethane and chloroform–butanol), the ethyl acetate–butanol (1:2, v/v) solution
showed higher extraction efﬁciency. The method used for the identiﬁcation and quantiﬁcation of the
target components in the mixture was reverse phase-high-performance liquid chromatography
(RP-HPLC) coupled with a photodiode array (PDA) detector.
Cao et al. (2015) investigated the use of a magnetic solid-phase extraction (MSPE) method
combined with ultra-high-performance liquid chromatography coupled with quadrupole time-of-ﬂight
tandem mass spectrometry (UHPLC-Q-TOF/MS) for the preconcentration of ﬁve active compounds in
rhubarb (Rheum palmatum L). The method was based in the use of chemically modiﬁed graphene
sheets, combined with Fe3O4 nanoparticles and a large delocalised two-electron system, which serves
as a good absorbent for aromatic analytes, like anthraquinones. According to the author, the method
displayed high sensitivity and selectivity, as well as high recovery.
Other extraction methods referred by the different authors are high-speed counter current
technology (HSCCC) and solid-phase extraction (SPE) (Shi et al., 2014), enzyme digestion and pulsed
electric ﬁeld (Arvindekar et al., 2015). As well as, microextraction methods like dispersive liquid–liquid
microextraction (DLLME), single drop microextraction (SDME), solid-phase microextraction (SPME) and
its coupled technologies (Shi et al., 2014).
Puriﬁcation and identiﬁcation methods that have been used for the target anthraquinones, include
HPLC, ultra-pressure liquid chromatography (UPLC), capillary zone electrophoresis (CZE),
electrochromatography, microemulsion electrokinetic chromatography (MEC), HPLC with mass
spectrometry (HPLC–MS), gas chromatography with MS (GC–MS) and thin-layer chromatography (TLC)
(Shi et al., 2014).
2.5. Stability of the botanical or botanical preparation used as an
ingredient in food supplements
Speciﬁc request for information on the stability of the botanical or botanical preparation used as an
ingredient in food supplements was included in the call for data launched. The information received
was complemented by the Panel with data retrieved in the published literature.
According to the information provided by the interested parties, food supplements containing
hydroxyanthracene derivatives have a shelf-life ranging from 24 to 36 months. The products should be
kept closed (5–25°C), away from sources of heat, light and moisture (‘Documentation provided to
EFSA’ n. 3, 4, 5, 6 and 7).
The effect of thermal treatments (50, 60, 70, 80 and 90°C) on polysaccharides and barbaloin
content in gel juice from Aloe vera was evaluated by Chang et al. (2006). The highest decrease in the
content of barbaloin was observed after 10 h treatment at 90°C. No effects were reported at 60°C for
1 h of thermal process. The highest decrease in the content of polysaccharides was demonstrated
after 10 h treatment at 50°C and 90°C. Signiﬁcant effects (p < 0.05) were also showed at 60°C while
samples treated at 70 and 80°C did not report signiﬁcant changes compared to the initial samples
used as controls. A similar trend was noted in a different experiment with an extended period of
treatment (until 70 h). Samples treated at 50°C showed the greatest effects following by 60°C and
90°C. It has been also noted that during the thermal treatments, the colour of aloe vera gel juice
changed from whitish to slight yellow to brownish.
The effects of pH, temperature and light conditions on the stability of aloin A were evaluated by
Ding et al. (2014). Thermal treatment experiments were performed at 4, 30, 50 and 70°C at a
constant pH value (pH = 7.0). The highest loss (90%) in the content of aloin A was showed at 70°C
within 6 h. The amount of aloin A decreased by 90% after treatment at 50°C within 12 h while at
30°C more than 50% of aloin A decreased within 1 day. At 4°C, aloin A was relatively stable for 1 day
showing 10% of loss; however, within 14 days more than 60% were degraded. Light had no effects on
the stability of aloin A during the experiment period (14 days). The effects of pH on aloin A stability
were also evaluated. A series of pH values (2.0, 3.0, 5.0, 7.0 and 8.0) were applied to the degradation
experiment. A signiﬁcant decrease in stability was observed at higher pHs. Aloin A showed good
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stability at pH 2.0 for 14 days with only 6% loss. At pH 8.0, the content of aloin A decreased after 6 h
to 93% and after 12 h only 2% of aloin A remained. In general, it has been demonstrated a
remarkable decrease in aloin A content with the increase of pH values while acid condition ensured
excellent stability of aloin A. The degradation products of aloin A were also analysed in this study by
HPLC system. Aloe-emodin, elgonica-dimers A and B were found to be the major degradation products
of aloin A at pH 5.0 or below. 10-Hydroxyaloins A and B were formed under any condition except at
pH 2.0 and 3.0, and they were mainly formed under high temperature and at any light conditions.
Pellizzoni et al. (2011) investigated the stability during storage at different conditions of
anthraquinones and acetylated mannans (acemannans) in prepared and commercial gel and whole leaf
homogenates from A. barbadensis and A. arborescens and in common household preparations from
traditional medicine (Father Zago’s recipe). The aloin content in the household preparation stored at
+4°C resulted more stable (degradation time, DT50 = 108 days) than in all the whole leaf homogenates
tested, including those with antimicrobial or antioxidant agents. Additionally, the samples at +4°C were
more stable than those at room temperature. The aloin content in whole leaf-based commercial
products was stable for the whole 70 days of testing. In all cases, aloe-emodin was detected in traces
and sporadically, suggesting that it is not the direct oxidative or microbial degradation product of aloin.
Generally, aloin and b-polysaccharides showed poor stability in most of the conditions tested with the
exception of samples prepared according to traditional medicine (Father Zago’s recipe) that were found
to be stable at 4°C. Concerning the colour of aloe gel, it changed slightly from whitish to brownish
after 2 days of storage at room temperature. When aloe gel was stored at 4°C, the colour change took
7 days to occur. Stabilised gel commercial preparations stored at room temperature showed colour
change after 22 days of storage. The whole leaf homogenate changed colour from dark green to light
green in all samples analysed, while the colour of the whole leaf-based commercial product and that of
the household preparation remained stable when stored at 4°C.
The shelf-life and colour change kinetics of Aloe vera gel powder packed in three different
packaging materials has been evaluated by Ramachandra and Rao (2013): biaxially oriented
polypropylene (BOPP), polypropylene (PP) and laminated aluminium foil (AF). The study demonstrated
that during storage under accelerated storage conditions (38  1°C, 90  1% relative humidity), the
predicted shelf-life of dehumidiﬁed air-dried aloe vera gel was 33.87, 42.58 and 51.05 days in BOPP,
PP and AF pouches. The colour change of powder during storage followed ﬁrst-order reaction kinetics
with a rate constant of 0.0444 per day for AF, 0.075 per day for BOPP and 0.0498 per day for PP. The
results of this study suggested that AF is better suited than BOPP and PP for packaging of dried Aloe
vera gel powder.
Vargas et al. (2002) demonstrated that ethanol solutions of aloe-emodin, emodin and rhein are
photolabile by visible light (390–500 nm) under aerobic conditions. The photolysis was followed by
monitoring the changes in ultraviolet–visible (UV–Vis) and ﬂuorescence spectra at regular interval of
20 min of irradiation. In particular, the results showed that photolability of the ethanol solutions of
aloe-emodin and emodin is higher than for rhein.
Gulia et al. (2010) studied the effects of convective drying on various parameters (yield, ash
content, pH, crude fat, crude protein, crude ﬁbre, wettability and water absorption capacity) of Aloe
vera leaves powder. Aloe vera leaves were treated at different temperatures (50, 60, 70, 80°C) in hot
air oven and powdered. No signiﬁcant difference (p < 0.5) for tested physicochemical parameters was
observed at different processing temperatures. The HPLC analysis demonstrated that aloin content was
temperature-dependent since aloin decreased from 10.6 to 1.7 ppm as the temperature increased
from 50 to 80°C. The study showed that the aloe powder obtained at 70°C had better physicochemical
and functional properties than the samples obtained at other different temperatures selected for the
study.
Miranda et al. (2009) investigated the effects of temperature (50, 60, 70, 80 and 90°C) on a series
of parameters using Aloe vera gel such as proximal composition, water activity (aw), pH, acidity,
non-enzymatic browning, surface colour, vitamin content (C and E) and mineral content. The stability
of tested nutritional and functional quality parameters in rehydrated A. vera gel depended mostly on
the temperature used during the drying process, with increased nutrient loss observed at 80 and 90°C.
According to the authors, drying temperatures for A. vera gel between 60 and 70°C would ensure
acceptable commercial quality with features as similar as possible to those of fresh product.
Goppel and Franz (2004) investigated the degradation pathways of known constituents of
powdered Senna spp. leaves and commercial methanolic Senna spp. leaf extract depending on
different storage conditions and packaging. The analysis was performed using HPLC-PDA detection.
In the crude plant material, sennosides were degraded to sennidine monoglycosides, while rhein
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8-O-glucoside was hydrolysed to rhein by enzymatic processes. Degradation of the anthranoid
compounds was not due to the same pathways in the investigated commercial extracts, where only
unspeciﬁc alterations of all compounds were observed. Forced decomposition of tested preparations
under high temperature caused oxidative decomposition of the sennosides to rhein-8-O-glucoside.
Furthermore, ﬂavonoid glucosides decomposition was observed with an apparent increase in the
content of ﬂavone aglycones. According to the authors, this may due to the fact that industrial
processes like alcoholic extraction denature enzymes needed for the degradation reactions.
Lainonen et al. (1988) investigated the effect of different storage conditions on the chemical
stability of sennoside A and B in water solutions, measured by the HPLC method. The variables in
storage conditions were pH, time and temperature (room temperature or 100°C). It has been
demonstrated that the chemical stability of sennosides in aqueous solutions was low and
pH-dependent (best stability at pH 6.5 with t90% = 8.4 months and the poorest at pH 8.0 with
t90% = 2.5 months) and temperature-dependent (t50% = 2 h; t90% = 0.31 h after heating at 100°C
under reﬂux. Note t50% and t90% is the time interval needed to decrease the content of testing
substance to 50% and 90% of the starting concentration, respectively. t90% value is commonly used as
an expiration time for drug products). There was also a clear difference in the disappearance rate
between sennoside A and sennoside B. The initial ratio of sennoside A to sennoside B was 1.90 and
the ﬁnal ratio after 3.5 years was 1.66 at pH 5.5 and 2.42 at pH 8.0. The pharmacopoeial assay
methods for sennoside in senna products based on colorimetric measurement was also performed and
no decline in the drug content is observed during the 4.6 years of storage. The authors concluded that
the transformation products also have light absorption at the same wavelength as sennosides.
Chewchinda et al. (2013) evaluated the effects of different storage conditions on the content of
rhein in Cassia ﬁstula pod pulp decoction extracts, using the HPLC method. Three batches of C. ﬁstula
pod pulp decoction extract were stored in glass vials and AF bags at the accelerated (40°C  2°C/75%
RH  5% RH) and real-time storage conditions (30°C  2°C /75% RH 5% RH) for 6 months. The
rhein contents remained more than 95% when compared with the initial amount. Moreover, the ﬁnding
showed no signiﬁcant differences on the chemical stability of the extracts kept in glass vials and in
aluminium foil bags.
2.6. Use and use levels
Food supplements
The EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), in its 2013 Scientiﬁc Opinion on
the ‘substantiation of a health claim related to hydroxyanthracene derivatives and improvement of
bowel function’, noted the established effects of a daily dose of 10 mg/day hydroxyanthracene
derivatives per day on the short-term alleviation of occasional constipation and the mechanism by
which hydroxyanthracene derivatives exert an effect on bowel function (i.e. stimulation of colonic
motility through the enhancement of colonic transit which reduces ﬂuid absorption from the faecal
mass and increases in the permeability across the colonic mucosa which results in an increase in the
water content in the large intestine), either from the root and rhizome of Rheum palmatum L. and/or
Rheum ofﬁcinale Baillon and/or their hybrids, and/or from the leaves or fruits of Cassia senna L.
and/or Cassia angustifolia Vahl, and/or from the bark of Rhamnus frangula L and/or from the bark of
Rhamnus purshianus D.C. and/or from Aloe barbadensis Miller and/or various aloe species, mainly Aloe
ferox Miller and its hybrids. The target population of these products is adults.
A request was sent to relevant food business operators, asking for information on the
recommended doses of food supplements containing hydroxyanthracene derivatives marketed in the
EU.
The Panel noted that the recommended daily doses when used as a food supplement are extremely
variable, ranging from 2.25 to 24.83 mg/day for sennoside B (information retrieved for a total of 16
products; in 9 products, sennoside B was used as the unique ingredient); from 1.95 to 78.8 mg/day
for rhein (information retrieved for a total of 37 products; in 24 products, rhein was used as the
unique ingredient), from 13 to 26 mg/day for glucofrangulin A (information retrieved for a total of 2
products; in 1 product, frangulin A was used as the unique ingredient), from 1.2 to 24 mg/day for
aloin (barbaloin) (information retrieved for a total of 4 products, where barbaloin was used as the
unique ingredient), from 17.9 to 51 mg/day for aloin A+B (information retrieved for 1 product, where
aloins A and B where used in combination with other hydroxyanthracene derivatives) (‘Documentation
provided to EFSA’ No. 3, 4, 5, 6, 7).
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Medicinal products
According to the EMA monographs, the maximum daily dosage should not exceed 30 mg of
hydroxyanthracene derivatives in medicinal products used as a laxative for adults, elderly and
adolescents over 12 years. According to the EMA monographs, the patient has to be informed that the
correct individual dose is the smallest required producing a comfortable soft-formed motion.
Normally, it is sufﬁcient to take an anthranoid-containing laxative up to two to three times a week.
The use for more than 1–2 weeks requires medical supervision (Konsensuspapier expertenforum,
1999).
2.7. Exposure
2.7.1. Exposure via food supplements
Exposure to hydroxyanthracene derivatives from food supplements has been estimated from the
recommended daily doses of food supplements as provided by the interested parties following the
launch of a public ‘Call for data’ (see Section 2.6).
As suggested by the Scientiﬁc Committee of EFSA (EFSA Scientiﬁc Committee, 2012) a body weight
of 70 kg has been used in this opinion as the default value to express the exposure results in mg/kg
bw per day in adults.
Maximum daily exposure to hydroxyanthracene derivatives is reported below:
• Exposure to sennoside B was estimated up to 0.35 mg/kg bw per day, corresponding to
24.83 mg/person per day for a 70-kg adult.
• Exposure to rhein was estimated up to 1.12 mg/kg bw per day, corresponding to
78.8 mg/person per day for a 70-kg adult.
• Exposure to glucofrangulin A was estimated up to 0.37 mg/kg bw per day, corresponding to
26 mg/person per day for a 70-kg adult.
• Exposure to barbaloin was estimated up to 0.34 mg/kg bw per day, corresponding to
24 mg/person per day for a 70-kg adult.
• Exposure to aloin A+B was estimated up to 0.72 mg/kg bw per day, corresponding to
51 mg/person per day for a 70-kg adult.
The Panel noted that the recommended daily doses provided by the interested parties are
extremely variable. In order to calculate the worst-case scenario, the highest number in the range was
used for the calculation. The Panel further noted that the concentrations of single hydroxyanthracene
derivatives used in the food supplements vary also depending whether used alone or in combination
with other hydroxyanthracene derivatives.
The Panel noted that exposure to aloe-emodin and emodin is not known due to lack of data
provided by the interested parties.
Exposure in young children was not performed since the use of food supplements containing
hydroxyanthracene derivatives is not recommended in this population category.
2.7.2. Exposure via normal diet
The Panel noted that parts of plants containing hydroxyanthracene derivatives may be part of the
normal diet. However, no data on the concentrations of hydroxyanthracene derivatives present in the
parts of the plants consumed were made available to the Panel by interested parties following a call
for data.
3. Biological and toxicological data
3.1. Absorption, distribution, metabolism and excretion (ADME)
EMA (2008a,b) reported several studies describing the biological fate of hydroxyanthracene
derivatives and the metabolism and pharmacokinetics of anthranoid laxatives. According to this report,
glycosidic hydroxyanthracenes such as barbaloins, sennosides are not absorbed in the upper gut. In
humans, they pass into the colon unmodiﬁed after oral ingestion. Human intestinal ﬂora is able to
break down O-glycosides easily but only to some extent C-glycosides of most anthranoids.
Aloe-emodin-9-anthrone is the main active metabolite, which acts speciﬁcally on the colon. In
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comparison to anthrones, anthraquinones are absorbed to a much larger extent in the upper gut. After
absorption, aglycones are distributed over the different tissues in the body and excreted in urine and
bile as glucuronides and sulfates. The Panel noted that several studies, carried out on the biological
fate of hydroxyanthracene derivatives and metabolism and pharmacokinetics of anthranoid laxatives,
have been reported by EMA (2008a,b). However, the Panel further noted that many studies have been
become available since then and are reported in this opinion.
3.1.1. Administration of preparations and extracts
Animal studies
The pharmacokinetics of rhein was determined in rats orally administered an oriental herbal
medicine Onpi-to that included 1.24% of rhein equivalents derived from sennoside A, sennoside B,
rhein 8-O-glucopyranoside and rhein. Plasma, urinary and biliary (in bile duct cannulated animals)
levels of rhein were determined. Following oral doses of 125, 250 and 500 mg Onpi-to/kg bw, the
plasma rhein levels peaked at 8.3–20.0 min. The area under the curve (AUC; 0–48 h) values were
dose-dependent. As determined 48 h after administration, cumulative urinary excretion of
unconjugated and conjugated rhein was 3.14% and 38.21% of the dose, respectively. The cumulative
biliary excretion of unconjugated rhein accounted for 1.34% of the dose (Takizawa et al., 2003).
Shia et al. (2011) investigated the pharmacokinetics and tissue distribution of anthraquinones
following twice daily administration of 2.0 mL rhizome of Rheum palmatum decoction/kg bw to rats
reaching a total of seven doses (0.5 g of rhizome/mL decoction). In this decoction, the most abundant
anthraquinone (free and conjugated) was rhein (910 lg/mL, mainly in the free form) and the least
was physcion (200 lg/mL). Serum and tissue specimens were assayed for contents of anthraquinones
by HPLC before and after hydrolysis with b-glucuronidase or sulfatase. In serum, rhein free form was
present in all specimens, emodin free form existed only transiently in the early phase after dosing,
whereas the free forms of aloe-emodin, chrysophanol and physcion were not detected. Glucuronides/
sulfates of aloe-emodin, rhein, emodin and chrysophanol predominantly existed in bloodstream, while
no trace of physcion glucuronides/sulfates were detected. The tissue contents of each anthraquinone
free form ranged as follows: kidney > liver > lung for rhein (generally 10- to 15-fold higher
concentrations than other anthraquinones), kidney and liver > lung for aloe-emodin; liver > lung for
emodin; only traces of chrysophanol in kidney and liver. In investigated organs, the concentration of
rhein free form in kidney was the highest (24 lg/g) and even much higher than serum concentration
(14 lg/mL). Considering conjugate concentrations, no traces of them were found in liver. Only traces
of rhein, aloe-emodin, emodin sulfates were found in lung. Both glucuronides and sulfates of rhein,
aloe-emodin, emodin and chrysophanol were present in kidney, but in much lower concentrations. In
brain, neither unconjugated forms nor their glucuronides/sulfates were detected.
The study of Zhang et al. (2013) compared the pharmacokinetics of aloe-emodin, rhein and emodin
in plasma of rats after oral administration (10 mL/kg bw) of a rhubarb extract (the concentrations
were not reported). A liquid chromatography with mass spectrometry (LC–MS) method was developed
and validated for the determination of the plasma concentrations of the three analytes. Following
administration of rhubarb extract, area under the plasma concentration–time curve (AUC 0–12 h)
values clearly indicated that rhein was the most abundant circulating hydroxyanthracene derivatives,
by comparison to aloe-emodin (77 times lower) and emodin (103 times lower).
A liquid chromatography with tandem mass spectrometry (LC–MS/MS) method was developed for
simultaneous determination of aloe-emodin, rhein, emodin, chrysophanol and physcion and their
conjugates in plasma (Wu et al., 2014a). Rats (n = 6) received a rhubarb extract at a dose of
10.0 mL/kg (5.0 g extract/kg bw) by gavage. One gram of extract contained, respectively, 1.24, 3.16,
0.86, 2.85 and 2.30 mg rhein, chrysophanol, physcion, emodin and aloe-emodin. The concentrations
of the total circulating forms (free and respective conjugates) of each anthraquinone were measured.
AUC (0–36 h) of total aloe-emodin, emodin, chrysophanol and physcion in rat plasma were lower (by
11.3, 1.9, 4.7 and 6.1 times, respectively) than those of rhein (14.5 lM h). According to the authors,
conjugates were the dominant in vivo circulating forms of hydroxyanthracene derivatives from rhubarb
and rhein appeared to be the most abundant anthraquinone in rat plasma.
Overall, the Panel noted that in rats receiving rhubarb preparations or extracts, free and conjugated
forms of aloe-emodin, rhein, emodin and chrysophanol were detected in plasma, with rhein being by
far the major circulating hydroxyanthracene. Among the organs, kidneys, liver and lungs contained the
highest concentrations of free and conjugated rhein, aloe-emodin, emodin and chrysophanol. Rhein
was mainly excreted as free form in urine and as conjugates in bile.
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Human studies
As reported in EMA (2008a,b), Krumbiegel and Schulz (1993) investigated the kinetics of rhein and
aloe-emodin from senna laxatives in man. Therapeutic doses of the two laxatives Agiolax (four single
doses of 6.3 g granulate containing 13.23 mg anthranoids including 7.62 mg rhein and 0.38 mg
aloe-emodin) and Sennatin (two tablets containing 20.36 mg anthranoids including 13.06 mg rhein
and 0.4 mg aloe-emodin) were daily administered to 10 volunteers for 4 days. Rhein plasma
concentrations showed the highest level of 156 ng/mL (after Agiolax) and peak maxima at 3–5 h and
10–11 h after dosing likely due to absorption of free rhein and then to rhein released from prodrugs
(e.g. sennosides) by intestinal bacterial metabolism, respectively. Aloe-emodin though co-administered
in measurable amounts was not detectable in any plasma sample.
Lee et al. (2003) identiﬁed the main active compounds of Rhei undulati Rhizoma and determined
the pharmacokinetic parameters of anthraquinones absorbed in man. Each volunteer (9 men/3
women) was administered 100 mg of Rhei undulati Rhizoma extract/kg bw. The amounts of
aloe-emodin, rhein, emodin and chrysophanol in the extract were 1,179, 167, 2,257 and 8,494 lg/g of
the dried herb, respectively. The anthraquinone levels in plasma were determined using TLC, HPLC and
LC–MS analysis without previous deconjugative hydrolysis. Rhein was the only hydroxyanthracene
derivative detected in plasma and its elimination half-life was estimated as 3.38 h.
Overall, in humans receiving senna laxatives or rhubarb extract, rhein was the main
hydroxyanthracene detectable in plasma. Rhein was also observed in volunteers treated with a rhubarb
extract containing 7- to 50-fold higher concentrations of aloe-emodin, emodin and chrysophanol than
that of rhein.
3.1.2. Administration of aglycone hydroxyanthracenes
Rhein
Absorption
As reported in EMA (2008a,b), animal experiments using 14C-rhein or 14C-rhein anthrone
administered into the caecum of rats demonstrated absorption lower than 10% of the dose (De Witte
and Lemli, 1988a,b).
The pharmacokinetics of 14C-rhein was determined after intravenous (0.16 mg/kg bw), oral or
intracaecal administration (0.78 mg/kg bw) to male rats (Lang, 1988). Radioactivity from 14C-rhein was
absorbed after oral or intracaecal administration by about 50–60%. In most organs, the radioactivity
was lower than in plasma with very low levels in testes and brain, the highest values were found in the
kidneys. In bile, there were mainly two conjugated metabolites of rhein, whereas in urine larger
amounts of rhein and one or two additional metabolites (conjugates) were detected.
Sund and Elvegard (1988) investigated the intestinal absorption and metabolism of rhein. Everted
sacs of rat jejunum and colon were ﬁlled with Krebs–Henseleit solution on the serosal side, and bathed
at the mucosal side with the same solution containing either danthron or rhein. After 60 min,
incubation at 37°C, solutions and gut tissues were analysed by HPLC for parent rhein and metabolites.
Only small amounts of unchanged drug were present on the serosal side of jejunum and colon while in
both tissues, danthron was present as glucuronide or sulfate conjugates. In jejunum, conjugates were
mainly secreted into the lumen. In the colon, glucuronoconjugates were absorbed and remained in the
tissue, whereas sulfoconjugates were secreted into the lumen. Rhein was more slowly taken up and
metabolised, but seemed otherwise to behave as danthron.
Distribution
The in vitro interactions of serum albumins such as human serum albumin (HSA) and bovine serum
albumin (BSA) with emodin, rhein, aloe-emodin and aloin were assessed using ﬂuorescence quenching
and absorption spectroscopic techniques (Bi et al., 2005). The results obtained revealed that there
were strong binding afﬁnities of these anthraquinones to HSA and BSA.
Metabolism
Dahms et al. (1997) elucidated the oxidative and conjugative metabolism of 14C-labelled or -
unlabelled rhein, using in vitro and in vivo studies in dogs, rabbits, rats and human volunteers. In vitro
experiments with subcellular liver fractions of rats and rabbits revealed the presence of three
monohydroxylated metabolites of rhein, a bishydroxylated derivative of rhein and quinoid metabolites.
HPLC–MS/MS analysis of urine samples of all investigated species detected the hydroxylated
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metabolites as glucuronides. Two isomeric phenolic glucuronides and sulfates or glucosides of rhein
were found as major conjugates in urine of all species. Furthermore, acyl glucuronides of rhein and
monohydroxylated rhein were identiﬁed in human urine whilst two phenolic glucosides were found in
dog and human urines.
The in vitro glucuronidation of puriﬁed rhubarb anthraquinones (aloe-emodin, emodin, chrysophanol,
physcion, rhein) was investigated by using liver and intestinal microsomes from rats and humans and
human recombinant uridine 50-diphospho-glucuronosyltransferases (UDP-glucuronosyltransferases) (Wu
et al., 2014b). All anthraquinones formed monoglucuronides. Glucuronidation showed an absolute
preference towards b-OH, followed by a-OH and b-alcoholic OH (aloe-emodin) while the activity was
decreased greatly with a b-COOH (rhein). Only slight differences between organs and species were
observed in the overall glucuronidation activity and regioselectivity of anthraquinones tested. Human
recombinant UGT1A9 (UGT=UDP-glucuronosyltransferase) showed the highest activity and similar
regioselectivity to that of human liver microsomes while UGT2B7 and UGT2B15 isoforms showed high
activity towards b-OH.
Song et al. (2009) compared the metabolism of rhein, emodin, aloe-emodin, chrysophanol and
physcion in rat liver microsomes. Different metabolic reactions for anthraquinones were dependent on
the substituent group in the skeleton. Hydrogenation and methyl substitution on the benzene ring
(e.g. to produce 2-methylrhein) were the major metabolic reactions for rhein.
Regarding the metabolism by bacteria of rhein, De Witte et al. (1992) observed that in caecal
contents of rats, rhein was reduced into rhein anthrone, by 23.5%. The in vitro reduction capacity of
the caecal content of conventional rats was drastically decreased (to 0.2% and 5.2%) by oral
administration to rats of antibiotics. According to the authors, rhein is reduced in caecal content to the
highly reactive and labile rhein anthrone, accounting for the in vivo disappearance of dihydroxy-
anthranoid equivalents in routine analysis after oral administration of anthraquinones to animals.
Excretion
As above mentioned in pharmacokinetic studies (De Witte and Lemli, 1988a,b; Lang, 1988), orally
administered 14C-rhein was mainly excreted in urine and bile as radiolabelled conjugates. After
intracaecal administration, 14C-rhein was recovered as conjugates in faeces and urine (53% and 37%
of the dose, respectively).
The transfer of rhein in milk was investigated in the rhesus monkey by Cameron et al. (1988). An
HPLC method was developed to measure rhein in milk and plasma. Samples from two lactating rhesus
monkeys were taken over 48 h after oral administration of sennosides (1 mg/kg bw). Detectable rhein
levels were found in plasma (25–144 ng/mL) between 2 and 12 h and in milk (225–829 ng/mL)
between 4 and 12 h after administration. However, rhein excretion in milk seems to be far below the
dose necessary to elicit a laxative effect in the suckling offspring.
EMA (2008a,b) reported the study of Faber and Strenge-Hesse (1988) investigating the excretion of
rhein into human breast milk. Twenty post-partum women received daily doses of 5 g of a
standardised senna laxative (Agiolax containing 15 mg sennosides) for 3 days. The concentration of
rhein in milk samples from every lactation during 24 h post-dose varied between 0 and 27 ng/mL with
values below 10 ng/mL in 94%. Based on median values, 0.007% of the dose of sennoside would be
excreted in breast milk. None of the breast-fed infants had an abnormal stool consistency. According
to the authors, assuming a complete conversion of sennosides to rhein in the mother, the amount of
rhein delivered to the infant is by the factor 103 below the rhein intake of the mother.
Overall, when administered orally to animals, rhein may be reduced to rhein-anthrone in the large
intestine. Around 50–60% of the dose of rhein is absorbed intact and then conjugated in intestine and
liver.
Emodin
Absorption, distribution and excretion
Absorption, tissue distribution, metabolism and excretion of 14C-emodin were studied after a single
oral administration (approx. 50 mg/kg) to rats (Bachmann and Schlatter, 1981). Radioactivity in most
organs decreased signiﬁcantly between 3 and 5 days. In kidneys, however, the 14C activity was still
equivalent to 4.33 mg/kg emodin after 5 days. Urinary excretion amounted to 18% and 22% of the
dose in 24 and 72 h, respectively. Metabolites in pooled urine (0–72 h) were mostly free emodin and
emodic acid (16% dose). In faeces, 48% and 68% dose was excreted after 24 and 120 h, mostly as
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free anthraquinone form. In two bile duct cannulated rats, biliary excretion amounted to 49% of the
dose within 15 h; 70% of the biliary radioactivity was in the form of conjugated emodin.
Intravenous or oral administration (10 mg/kg bw) of emodin to rabbits resulted in a serum proﬁle
described by a two-compartment model (Liang et al., 1995). The elimination half-life was 227 min.
Oral administration of emodin resulted in negligible serum concentration. The authors considered the
bioavailability of emodin very low. Emodin was found to be highly bound (99.6%) to serum protein.
Metabolism
Song et al. (2009) compared the metabolism of ﬁve anthraquinone derivatives from rhubarb (rhein,
emodin, aloe-emodin, chrysophanol and physcion) by using rat liver microsomes. Monohydroxylation in
the exocyclic methyl group was the major metabolic modiﬁcation for emodin.
Liu et al. (2010) determined the metabolism of emodin by using in vitro and in situ disposition
models of the intestine and liver. Liver microsomes (mice, rats, guinea pigs, dogs and humans), rat
intestinal microsomes and a rat intestinal perfusion model were used. A mixed system of oxidation and
glucuronidation reaction was used to determine the main pathway of metabolism of emodin by using
male rat liver microsomes with both oxidation and glucuronidation reaction cofactors. Emodin
glucuronidation in liver microsomes was species-dependent. In the rat intestine, excretion rates of
emodin-3-O-glucuronide were signiﬁcantly higher in duodenum and jejunum than in ileum and colon.
According to the authors, emodin was considered rapidly glucuronidated and this would be the major
reason of its poor bioavailability. Glucuronidation rates obtained using liver microsomes from various
experimental animals correlated well with those in human liver microsomes.
As above mentioned, the glucuronidation of aloe-emodin, emodin, chrysophanol, physcion, rhein
was investigated in liver and intestinal microsomes from rats and humans (Wu et al., 2014b). Emodin
was rapidly glucuronidated, with an absolute positional preference at the b-OH, leading to a
b-glucuronide accounting for > 95% of three glucuronides formed in rat and human microsomes.
Overall, the bioavailability of emodin is low, probably because of a rapid glucuronidation occurring
in both intestinal wall and liver.
Aloe-emodin
The intestinal uptake and metabolism of aloe components were determined by using in vitro
intestinal absorption models (Park et al., 2009). Caco-2 cell and rat everted gut sac were incubated
with aloe-emodin ranging from 5 to 50 lM. As quantiﬁed using HPLC, the percentage of absorption of
aloe-emodin ranged from 6.60 to 11.32%. Up to 18–38% of aloe-emodin was absorbed as
glucuronidated or sulfated form. The absorption rates were generally similar in the two models. These
results would suggest that a signiﬁcant amount is conjugated during the absorption process.
As reported in EMA report (2008), Lang (1993) investigated the general metabolism of aloe-emodin
in rats orally administered with 4.5 mg 14C-aloe-emodin/kg bw. As evaluated by TLC in plasma
collected 1.5, 3 and 6 h post-administration, only 4.5% of the radioactivity was identiﬁed as free
aloe-emodin with maximum plasma values reached at 1.5–3 h following the administration. Free rhein
and various conjugates represented 21.6% and 72.3% of the radioactivity. Half-life of the radioactivity
in blood was about 50 h. Maximum concentrations of radioactivity in plasma were about three times
higher than those in ovaries and 10 times higher than those in testes, whereas liver, kidney and
intestinal tract showed higher concentrations than plasma. Twenty to thirty per cent of the
administered radioactivity was excreted in urine and the rest in faeces. According to the authors,
following oral administration, aloe-emodin is quickly oxidised to rhein and further conjugated.
Song et al. (2009) compared the metabolism of ﬁve anthraquinone derivatives from rhubarb (rhein,
emodin, aloe-emodin, chrysophanol and physcion) by using rat liver microsomes. Different metabolic
reactions for anthraquinone derivatives were dependent on the substituent group in the skeleton.
Aloe-emodin was mainly metabolised through a methylation reaction.
The pharmacokinetics and metabolism of aloe-emodin were investigated in intravenously (5.0 mg/
kg bw) or orally (40 mg/kg bw) administered rats (Yu, 2016). The serum concentrations of aloe-
emodin and its metabolite rhein were determined by the HPLC method prior to and after hydrolysis
with b-glucuronidase and sulfatase/b-glucuronidase. When aloe-emodin was given intravenously, the
major molecules in blood were aloe-emodin glucuronides and rhein sulfates. When aloe-emodin was
administered orally, only traces of aloe-emodin (below limit of quantiﬁcation (LOQ)) were detected in
the serum at the very early phase, whereas aloe-emodin glucuronides and rhein glucuronides were the
major circulating molecules. The authors concluded that aloe-emodin was not absorbed per se and the
Panel agreed with this conclusion.
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As mentioned above, the glucuronidation of rhubarb anthraquinones (aloe-emodin, emodin,
chrysophanol, physcion and rhein) was investigated in liver and intestinal microsomes from rats and
humans (Wu et al., 2014b). In the case of aloe-emodin, the presence of a b-alcoholic OH group leads
to a unique glucuronidation occurring at the a-OH.
Overall, following oral absorption, aloe-emodin is quickly oxidised to rhein and further conjugated.
In plasma, only traces of free aloe-emodin were detected whereas aloe-emodin glucuronides and rhein
glucuronides were the major circulating molecules.
3.1.3. Administration of glycosidic hydroxyanthracenes
As mentioned by EMA (2008a,b) and according to Witte and Lemli (1990), anthrone-glycosides
remain intact to the large intestine, where aglycones are released by bacterial hydrolysis of the sugar.
The intestinal bacterial ﬂora also accounts for the reduction of anthraquinone aglycones to the
corresponding anthrones. After absorption, anthranoids are mainly conjugated into glucuronide and
sulfate derivatives, which appear in urine and bile.
Sennosides
The glycosidic sennosides are not absorbed, only the b-glycosidase of the bacteria of the large
intestine is able to hydrolyse them to sennidins. These sennidins are further cleaved to the active
metabolite (rhein anthrone) by the bacteria. Aglycones are absorbed in the upper gut and
glucuronidated in the liver. Excretion of sennosides and their known metabolites is mainly via the
faeces up to 92.8%. In experimental animal studies, up to 6% of orally administered doses of
sennosides anthranoids could be found intact in the urine and faeces (EMA, 2008a,b).
Absorption
Using the Caco-2 human colonic cell line as an in vitro model, the bioavailability of dianthrones
(sennosides A and B and their aglycones sennidins A and B) was studied in apical to basolateral
(absorptive) and basolateral to apical (secretive) directions (Waltenberger et al., 2008). The absorption
in apical to basolateral direction was poor, whereas the transport was higher in the secretory direction,
indicating a signiﬁcant efﬂux of the (poorly) absorbed compounds in the intestinal lumen.
Metabolism
Hattori et al. (1988) isolated microbial enzymes from Peptostreptococcus intermedius that catalysed
the electron transfer from NADH to FAD, FMN or benzyl viologen, which reduced sennosides and
sennidins to 8-glucosyl-rhein anthrone and rhein anthrone, respectively.
Aloins
As reported above (section on aloe-emodin), Park et al. (2009) determined the intestinal uptake
and metabolism of aloe components including aloin using two in vitro intestinal absorption models. The
percentage of absorption of aloin ranged from 5.51% to 6.60%, with 18% of this was present as
glucuronidated or sulfated metabolites. The absorption rate of aloin was generally similar in the two
models.
A strictly anaerobic bacterium, Eubacterium sp. BAR, was isolated by Che et al. (1991) from human
faeces as one of the intestinal bacteria capable of metabolising aloin (barbaloin) to aloe-emodin
anthrone).
Overall, glycosidic hydroxyanthracenes are negligibly absorbed intact. Glycosidic hydroxyanthracenes
are hydrolysed in the gastrointestinal (GI) tract into the corresponding aglycones which are absorbed
and subject to conjugation in the intestine and liver and excreted in bile and urine.
3.1.4. Conclusion on ADME
Glycosidic hydroxyanthracene derivatives remain intact and until they are hydrolysed in the GI tract
to their corresponding anthrones (aglycone anthrones). Regarding aglycone hydroxyanthracenes, as
demonstrated in animals, may be absorbed intact, however only rhein is present in the systemic
circulation.
In the GI tract, remaining hydroxyanthracenes may be reduced back to the corresponding
anthrones by the microbiota.
After absorption, hydroxyanthracenes such as aloe-emodin are rapidly and totally oxidised to rhein. In
the gut epithelium and liver, absorbed aglycone hydroxyanthracenes are conjugated into corresponding
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glucuronides and sulfates, which are excreted in bile or urine. An overview of the metabolism of
aglycone and glycosidic hydroxyanthracenes is reported in Figure 2.
The Panel considered that animal models in general reﬂect the fate of hydroxyanthracenes in
humans.
3.2. Toxicological data
3.2.1. Genotoxicity
In vitro studies
Aloe vera extracts and/or gels
In the study by Morimoto et al. (1982), crude extracts of Aloe ferox Mill. in water or methanol were
assessed for their genotoxicity in a bacterial reverse mutation test (Ames test) using the Salmonella
Typhimurium tester strains TA98 and TA100 and in the Bacillus subtilis rec-assay (DNA repair test)
using the mutant strain M45 rec- (unable to repair DNA damage) and the wild-type strain H17 rec+ as
control at dose levels of 10 mg/plate and 6 mg/disk, respectively. The Ames test was performed both
in the absence and presence of an exogenous rat liver S9 metabolism. The results obtained indicated
that only water extracts of Aloe ferox Mill. induced a genotoxic effect in the Bacillus subtilis rec-assay.
However, the Panel noted that the set of S. Typhimurium tester strains was insufﬁcient to detect
potential genotoxins. On this basis, the Ames test performed is of limited relevance for risk assessment
of water or methanol Aloe ferox Mill extracts.
Extracts from the Aloe vera leaf pulp (3 g in 5 mL physiological solution) were not able to
signiﬁcantly decrease survival of wild-type Escherichia coli or defective repair mutants (recA, xthA,
uvrA, wild-type/rfa, uvrA/rfa) tester strains both in the absence and presence of UV-A radiation.
However, DNA single strand breaks were observed in the pUC 9.1 plasmid when incubated with 3, 30
and 300 lg/mL aloe vera leaf pulp extract (Paes-Leme et al., 2005). The Panel noted that chemical
characterisation of the extracts was not performed and that the assays employed are not validated
and are not included in the current OECD guidelines for genotoxicity testing.
In the study by Sehgal et al. (2013), the genotoxicity of a commercial decolourised WLE that
contained approximately aloin A at 0.9 ppm, aloin B at 1.3 ppm and aloe-emodin at 0.2 ppm was
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evaluated in the S. Typhimurium reverse mutation assays with tester strains TA98 and TA100 and
E. coli SOS DNA damage-repair assay both in the absence and presence of S9 metabolic activation.
Concentrations applied ranged from 21-fold concentrated extract to 20-fold diluted and negative
results were observed in both assays. However, the Panel noted that both studies are of limited
relevance since in the reverse mutation assay only two S. Typhimurium tester strains were used and
that SOS DNA damage-repair assay is not currently used for genetic toxicology testing.
In the study by Williams et al. (2010), a tan powder derived from mucilaginous parenchymal cells
found in the inner central area of the Aloe vera (L.) leafs manufactured using a proprietary extraction
process in which the aloe latex contaminant (containing anthraquinones) was substantially reduced
(including aloin, aloeresin A) and referred to as Qmatrix®, was assessed for its genotoxicity in a
bacterial reverse mutation test (Ames test) using the S. Typhimurium TA98, TA100, TA1535, TA1537
and the E. coli WP2 uvrA tester strains and in a chromosomal aberration assay in Chinese hamster
lung (CHL) cells. Both studies were performed in the absence and presence of rat liver S9 metabolic
activation. Concentrations of 185, 556, 1,667, 5,000 and 10,000 lg/plate and 2,500, 5,000 and
10,000 lg/mL were used in the two assays, respectively, and negative results were observed.
However, the Panel noted that the outcome of these studies is only relevant for Aloe vera extracts
deprived of anthranoid compounds.
In the study by Boudreau et al. (2013), two different samples of Aloe vera gel were tested over a
dose range of 100–10,000 lg/plate in S. Typhimurium strains TA97, TA98, TA100 and TA1535, with
and without 10% or 30% induced rat or hamster liver S9 mix and up to the limit dose of
6,000 lg/plate in S. Typhimurium strains TA98 and TA100, or E. coli strain WP2 uvrA/pKM101, with or
without 10% induced rat liver S9, respectively, and no evidence of mutagenicity was seen. Similarly,
aloe vera WLE (native) and aloe vera charcoal-ﬁltered whole leaf extract (decolourised) were assayed
for mutagenicity up to concentrations of 6,000 lg/plate in S. Typhimurium strains TA98 and TA100,
and E. coli strain WP2 uvrA/pKM101, with and without 10% induced rat liver S9; no evidence of
mutagenicity was observed in any of the three strains, with or without S9.
In the study by Guo (2014), the mutagenicity of the aloe vera WLE and aloe vera WLD was
investigated using the mouse lymphoma assay. The intracellular reactive oxygen species (ROS) levels
in the mouse lymphoma cells treated with the extracts were evaluated. In order to identify the mode
of action for mutation induction, the loss of heterozygosity (LOH) in induced mutants was also
evaluated. The objective of this investigation aimed to provide insights on the identity and mechanisms
of potential mutagenic components of the aloe vera extracts, since in a 2-year cancer bioassay in
rodents with a preparation of aloe vera WLE administered in drinking water showed clear evidence of
carcinogenic activity. The WLD extract was obtained through activated carbon adsorption to remove
the phenolic components of aloe vera WLE such as anthraquinone C-glycosides, anthrones and free
anthraquinones. HPLC analysis revealed that the major difference between WLE and WLD was the
content of anthraquinones and anthrones. WLE was reported to contain approximately 14–15 mg/g
aloin A, the principal anthraquinone in aloe latex, while WLD contained approximately 0.01–0.05 mg/g
of it. Both WLE and WLD extracts showed dose-related cytotoxic and biologically relevant mutagenic
effects in mouse lymphoma cells after treatment for 24 h in the absence of S9 metabolism, but in
different concentration ranges with WLE showing a positive response at lower concentrations than
WLD.
The concentration at which WLD induced signiﬁcant increases in mutation frequency compared to
the concurrent negative control was less than twice that required for WLE-induced mutagenicity. Since
the anthraquinone component was reduced by 99% relative to WLE, this indicates that other
components in the mixtures, in addition to hydroxyanthracene derivatives, have a mutagenic capability
(at least, in the near complete absence of hydroxyanthracene derivatives) This conclusion is further
substantiated by the molecular analysis of induced mutations by assessing the LOH involving the TK
and the D11Mit42 loci which indicate that, while both extracts were clastogenic, their induced mutation
spectra were signiﬁcantly different, thus conﬁrming that different constituents may be responsible for
the genetic damage caused by the two preparations. In this respect, the intracellular ROS levels were
also determined using 20,70-dichlorodihydroﬂuorescein diacetate (DCF-DA) staining. After 4-h exposure,
the ROS levels of WLE and WLD groups were increased about 5- and 15-fold, respectively, when
compared to the concurrent control groups, thus indicating that WLD generated much more ROS than
WLE.
The authors concluded that components other than the hydroxyanthracene derivatives (e.g.
pro-oxidant) were contributing to the genotoxicity of Aloe vera extract in vitro.
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Senna extracts
In the study by Morimoto et al. (1982), crude extracts from senna (Cassia angustifolia Vahl) in
water or methanol were assessed for their genotoxicity in a bacterial reverse mutation test (Ames test)
using the S. Typhimurium TA98 and TA100 and in the Bacillus subtilis rec-assay (DNA repair test) using
the mutant strain M45 rec- (unable to repair DNA damage) and the wild type strain H17 rec+ as
control at dose levels of 5 mg/plate and 6 mg/disk, respectively. The Ames test was performed both in
the absence and presence of an exogenous rat liver S9 metabolism. The results obtained indicated
that methanol senna extracts induced DNA damage in the Bacillus subtilis rec-assay and were
mutagenic in the S. Typhimurium TA98 tester strain in the presence of S9 metabolism. The
Panel noted that, despite the set of S. Typhimurium tester strains was limited a genotoxic effect was
anyway detected. The Panel also noted that the Bacillus subtilis rec-assay is not adequately validated
and not currently used in genotoxicity testing.
In the study by Heidemann et al. (1993), senna extracts (10.1% content of hydroxyanthracene
derivatives) were tested for their capability to induce gene mutation in a bacterial reverse mutation
test (Ames test) using the S. Typhimurium TA98, TA100, TA1535, TA1537 and the E. coli WP2 uvrA
tester strains test and in the mammalian cell hypoxanthine-guanine phosphoribosyl transferase (HPRT)
mutation assay using V79 cells. Induction of chromosomal aberrations in Chinese hamster ovary (CHO)
cells was also assessed. All assays were performed both in the absence and presence of S9 metabolic
activation. In the bacterial mutation test and mammalian cell HPRT mutation assay, treatments were
performed up to concentration of 5,000 lg/plate and 5,000 lg/mL, respectively. In the chromosome
aberration assay, no indication about dose level employed was reported. However, according to the
authors, the studies were performed according to the relevant OECD TG guideline no 471, no. 476 and
no. 473, respectively, valid at the time and according to the Good Laboratory Practice (GLP)
requirements. The results obtained indicated that senna extract was positive for the induction of gene
mutation in S. Typhimurium TA1537 tester strain in the absence of S9 metabolism and in tester strain
TA98 in the absence and presence of S9 metabolism. The induction of gene mutation was dose-
dependent. In the V79 gene mutation, HPRT assay negative results were observed in the absence of
S9 metabolism up to cytotoxic concentrations while equivocal results were observed in its presence
since some mutants were outside the historical control range values but only at cytotoxic
concentrations. In the chromosome aberration test, positive results for the induction of structural
chromosome aberrations were observed both in the absence and presence of S9 metabolism. In the
ﬁrst case, the increases were also dose-dependent, and in the latter, the increases were only observed
at the highest concentration.
Emodin
In the study by Mueller et al. (1996), emodin was tested for its capability to induce gene mutation
and micronuclei in the mouse lymphoma L5178Y cells locus TK+/. In both cases, treatment with
emodin was performed for 4 h with dose levels of 37, 55.5, 74 and 111 lM in the absence of S9
metabolic activation and post-treatment cells were collected at appropriate sampling times. Results
obtained indicated that emodin induced dose-related increases of gene mutation frequency and
micronuclei compared to the concurrent negative controls. Although the authors did not perform
statistical evaluation of data, the Panel noted that increases observed over concurrent negative
controls for both gene mutation and micronuclei were sufﬁciently high to conclude for a genotoxic
outcome. For the induction of micronuclei, the authors further analysed the presence of stainable
kinetochore protein (CREST serum) in order to distinguish between clastogenicity and aneugenicity
mode of action. The results obtained indicated that the majority of emodin-induced micronuclei did not
provide kinetochore signals (94%) indicating that the compound acted as a clastogen. The
Panel agreed with this conclusion. Furthermore, based on the assumption that the genotoxicity of
emodin might have been related to its ability to intercalate DNA like many known DNA topoisomerase
II inhibitors, the authors evaluated this hypothesis, accordingly, in a cell-free decatenation assay and in
the comet assay in mouse lymphoma L5178Y cells. The results obtained indicated that emodin
inhibited catalytically DNA topoisomerase II rather than poisoning them through the formation of the
‘cleavable complex’. The Panel agreed also with this conclusion.
In the study by Chen et al. (2010), emodin was evaluated for its capability to induce DNA damage
by comet assay in human tongue cancer (SCC-4) cells following treatments at dose levels of 20, 30
and 40 lM for 24 h, in the absence of S9 metabolic activation only. The authors showed signiﬁcant
increases in DNA fragmentation at the two higher dose levels (30 and 40 lM). However, the
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Panel noted that the study bears shortcomings which include the use of a long treatment (24 h) only
and, a marked reduction of cell viability and consequent elevated cytotoxicity linked to excessive DNA
damage that could have interfered with Comet analysis.
Aloe-emodin
In the study by Heidemann et al. (1996), aloe-emodin was assessed for its genotoxicity in a
bacterial reverse mutation test (Ames test) using the S. Typhimurium TA98, TA100, TA1535, TA1537
and the E. coli WP2 uvrA tester strains test and in the mammalian cell HPRT mutation assay using V79
cells. Induction of chromosomal aberrations in CHO cells was also assessed. All assays were performed
in the absence and presence of S9 metabolic activation. In the bacterial mutation assay, no indication
about dose levels employed was reported. However, according to the authors, the studies were
compliant with the relevant OECD TG guideline no 471, no. 476 and no. 473, respectively, valid at the
time and the GLP requirements. The results obtained indicated that aloe-emodin was positive for the
induction of gene mutation, in three independent experiments, in S. Typhimurium TA1537, TA1538 and
TA98 tester strains in the absence of S9 metabolism and in tester strain TA1538 in its presence.
However, in the mammalian cell HPRT mutation assay in V79 cells, no induction of gene mutation was
observed. In one independent experiment, at an intermediate dose level both in the absence and
presence of S9 metabolic activation slight increases in the number of mutants compared to the
concurrent negative controls. These increases, which were not reproduced in two additional
independent experiments, were considered by the authors as not biologically relevant. The
Panel agreed with this conclusion. In the chromosome aberration test, positive results for the induction
of structural chromosome aberrations were observed both in the absence and presence of S9
metabolism at dose levels of 18.7–75.0 and 37.5–75.0 lg/mL, respectively, where the increases were
also dose-dependent.
In the study by Mueller et al. (1996), aloe-emodin was tested for its capability to induce gene
mutation and micronuclei in the mouse lymphoma L5178Y cells locus TK+/-. In both cases, treatment
with aloe-emodin was performed for 4 h with dose levels of 37, 55.5, 74 and 111 lM in the absence of
S9 metabolic activation and post-treatment cells were collected at appropriate sampling times. Results
obtained indicated that emodin induced dose-related increases of gene mutation frequency and
micronuclei compared to the concurrent negative controls. Although the authors did not perform
statistical evaluation of data, the Panel noted that increases observed over concurrent negative
controls for both gene mutation and micronuclei were sufﬁciently high to conclude for a genotoxic
outcome. For the induction of micronuclei, the authors further analysed the presence of stainable
kinetochore protein (CREST serum) in order to distinguish between clastogenicity and aneugenicity
mode of action. The results obtained indicated that the majority of aloe-emodin-induced micronuclei
did not provide kinetochore signals (94%) indicating that the compound acted as a clastogen. The
Panel agreed with this conclusion. Furthermore, based on the assumption that the genotoxicity of
aloe-emodin might have been related to its ability to intercalate DNA like many known DNA
topoisomerase II inhibitors, the authors evaluated this hypothesis, accordingly, in a cell-free
decatenation assay and in the comet assay in mouse lymphoma L5178Y cells. The results obtained
indicated that aloe-emodin inhibited catalytically DNA topoisomerase II rather than poisoning them
through the formation of the ‘cleavable complex’. The Panel agreed also with this conclusion.
In the study by Chen et al. (2010), aloe-emodin was evaluated for its capability to induce DNA
damage by comet assay in human tongue cancer (SCC-4) cells following treatments with aloe-emodin
at dose levels 25, 50 and 100 lM for 24 h in the absence of S9 metabolic activation only. The authors
showed signiﬁcant increases in DNA fragmentation at the higher dose level (100 lM) only. However,
the Panel noted that the study bears signiﬁcant shortcomings which include an inappropriate long
treatment (24 h), a marked reduction of cell viability and consequent elevated cytotoxicity linked to
excessive DNA damage that could have interfered with Comet analysis at higher dose levels. In
addition, the ‘comet length’ used to measure the extent of DNA fragmentation in this study is usually
not recommended (OECD TG. 489). On this basis, the results obtained cannot be considered reliable.
Danthron
Danthron was reported to be mutagenic to the S. Typhimurium frameshift strain TA1537, with and
without metabolic activation (Brown and Brown, 1976; Liberman et al., 1982; as reported in IARC
Monograph vol. 50, 1990). In the presence of exogenous metabolic activation, it was also mutagenic
to the S. Typhimurium base-pair substitution detecting strains TA2627 (Tikkanen et al., 1983), TA102
(Levin et al., 1984) and TA104 (Chesis et al., 1984) (as reported in IARC, 1990).
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In the study by Mueller et al. (1996), danthron was tested for its capability to induce gene
mutation and micronuclei in the mouse lymphoma L5178Y cells locus TK+/. In both cases, treatment
with danthron was performed for 4 h with dose levels of 21, 42, 63, 84 and 111 lM in the absence of
S9 metabolic activation and post-treatment cells were collected at appropriate sampling times. Results
obtained indicated that emodin induced dose-related increases of gene mutation frequency and
micronuclei compared to the concurrent negative controls. Although the authors did not perform
statistical evaluation of data, the Panel noted that increases observed over concurrent negative
controls for both gene mutation and micronuclei were sufﬁciently high to conclude for a genotoxic
outcome. For the induction of micronuclei, the authors further analysed the presence of stainable
kinetochore protein (CREST serum) in order to distinguish between clastogenic and aneugenic modes
of action. The results obtained indicated that the majority of danthron-induced micronuclei did not
provide kinetochore signals (94%) indicating that the compound acted as a clastogen. The
Panel agreed with this conclusion. Furthermore, based on the assumption that the genotoxicity of
danthron might have been related to its ability to intercalate DNA like many known DNA topoisomerase
II inhibitors, the authors evaluated this hypothesis, accordingly, in a cell-free decatenation assay and in
the comet assay in mouse lymphoma L5178Y cells. The results obtained indicated that danthron
inhibited catalytically DNA topoisomerase II rather than poisoning them through the formation of the
‘cleavable complex’. The Panel agreed also with this conclusion.
The in vitro genotoxicity of danthron was further investigated by Zhang et al. (2011). In this study,
danthron was tested in an Ames test, a cytokinesis-block micronucleus assay and a comet assay in
Balb/c 3T3 cells. In the Ames test, danthron was only mutagenic towards strain TA102, speciﬁcally
sensitive to oxidative mutagens, in the presence of exogenous metabolic activation system (S9 mix).
When NADP was substituted with NAD in the S9 mix, the mutagenicity towards TA102 was unaffected.
The addition of dicumarol, a DT-diaphorase inhibitor, signiﬁcantly suppressed the mutagenicity of
danthron in TA102, indicating the involvement of the quinones dehydrogenase DT-diaphorase in its
metabolic activation. In Balb/c 3T3 cells, danthron increased both the frequency of micronucleated
cells and comet tail length and Olive tail moment in a dose-dependent manner in the dose range
25–100 lg/mL, with and without S9. The authors concluded that 3T3 cells were capable of
endogenous activation of danthron. The increases in ROS and in 8-hydroxydeoxyguanosine levels and
the reduction in glutathione (GSH) levels in 3T3 cells were dose dependent. According to the authors,
these results indicate that oxidative stress may be a major contributing pathway in the genotoxicity of
danthron.
Overall, the available experimental data indicate that danthron is genotoxic through multiple
mechanisms, such as DNA topoisomerase II poisoning, intercalation into DNA and ROS generation.
Rhein
In the study by Heidemann et al. (1993) rhein (stated purity 98.5-99.7%) was tested for its
capability to induce gene mutation in a bacterial reverse mutation test (Ames test) using the S.
Typhimurium TA98, TA100, TA1535, TA1537 and the E. coli WP2 uvrA tester strains test and in the
mammalian cell TK+/ mutation assay using the mouse lymphoma L5178Y cells. Induction of
chromosomal aberrations in Chinese hamster ovary (CHO) cells was also assessed. All assays were
performed both in the absence and presence of S9 metabolic activation. In the bacterial mutation test,
treatments were performed up to concentration of 5,000 lg/plate while in the chromosomal aberration
up to the limit of solubility, but no dose levels are reported as in the mammalian cell TK+/- mutation
assay. However, according to the authors, the studies were performed in compliance with the relevant
OECD TG guideline no 471, no. 476 and no. 473, respectively, valid at the time and according to GLP
requirements. The results obtained indicated that rhein did not show genotoxic capabilities in any of the
assays performed in all treatment conditions. A signiﬁcant increase in the number of mutants at the
intermediate dose level in the presence of S9 metabolic activation in the mammalian cell TK+/
mutation assay was not reproduced in an independent experiment and was within the historical control
range values and therefore considered of no biological relevance. The Panel agreed with this conclusion.
In the study by Chen et al. (2010), rhein was evaluated for its capability to induce DNA damage by
comet assay in human tongue cancer (SCC-4) cells following treatments with emodin at dose levels 25,
50 and 100 lM for 24 h in the absence of S9 metabolic activation only. The authors showed signiﬁcant
increases in DNA fragmentation at the two higher dose levels (50 and 100 lM). However, the
Panel noted that the study bears signiﬁcant shortcomings which include a long treatment (24 h), a
marked reduction of cell viability and consequent elevated cytotoxicity linked to excessive DNA damage
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that could have interfered with Comet analysis. On this basis, the results obtained are considered to
be of limited reliability.
Sennosides
In the study by Heidemann et al. (1993), sennosides (a mixture of sennosides A + B in the range
of 75.0–82.2% and sennosides C + D in the range of 3.7–4.3%) were tested for their capability to
induce gene mutation in a bacterial reverse mutation test (Ames test) using the S. Typhimurium TA98,
TA100, TA1535, TA1537 and the E. coli WP2 uvrA tester strains test and in the mammalian cell TK+/
mutation assays using the mouse lymphoma L5178Y cells. Induction of chromosomal aberrations in
CHO cells was also assessed. All assays were performed both in the absence and presence of S9
metabolic activation. In the bacterial mutation test and in the chromosomal aberration assay in CHO
cells, treatments were performed up to concentration of 5,000 lg/plate and 9,000 lg/mL, respectively.
In the mammalian cell TK+/- mutation assay using the mouse lymphoma L5178Y cells, no indication
about dose level employed was reported. However, according to the authors, the studies were
compliant with the relevant OECD TG guideline no 471, no. 476 and no. 473, respectively, valid at the
time and the GLP requirements. The results obtained indicated that sennosides did not induce gene
mutation in the bacterial reverse mutation test (Ames test) and the mammalian cell TK+/- mutation
assay and chromosomal aberration in CHO cells both in the absence and presence of S9 metabolism
when tested up to cytotoxic concentrations.
Chrysophanol
In the study by Mengs et al. (2001), chrysophanol was tested for its ability to induce chromosomal
aberrations in CHO cells both in the absence and presence of S9 metabolic activation up to
concentration of 30 lg/mL, the solubility limit. The results obtained indicated that chrysophanol did
not induce any signiﬁcant increase in the frequency of aberration-bearing cells, compared to the
concurrent solvent control values. The Panel noted that only a short treatment (2 h) was used in the
absence of S9 metabolism and judged the results as limited.
In vivo studies
Aloe vera extracts and/or gels
In the study by Williams et al. (2010), a tan powder derived from mucilaginous parenchymal cells
found in the inner central area of the Aloe vera (L.) leafs manufactured using a proprietary extraction
process in which the aloe latex contaminant (containing anthraquinones) was substantially reduced
(including aloin, aloeresin A) and referred to as Qmatrix®, was assessed for its genotoxicity in a mouse
bone marrow micronucleus test. Qmatrix® dissolved in sterile distilled water was administered to
groups of six male ICR mice by oral gavage at doses of 1,250, 2,500 and 5,000 mg/kg per day once
daily for two consecutive days. Animals were administered the Qmatrix® in sterile distilled water via
gavage. The animals were sacriﬁced 24 h following the second test compound administration. For each
animal, a minimum number of 2,000 polychromatic erythrocytes (PCE) was scored for the induction of
micronuclei. The results obtained indicated that Qmatrix® did not induce any statistically signiﬁcant
increases in the incidence of micronucleated PCE and that the PCE/(PCE + NCE) ratio in the test
substance treatment groups was not substantially changed compared to the concurrent control group
indicating that test compound was not systemically available nor did it exert a sufﬁcient bone marrow
toxicity to elicit a potential genotoxic response. On this basis, the Panel noted that the study is of
limited relevance for risk assessment, since the potentially DNA reactive compounds were reduced in
the manufacturing process, being the content of aloin reported in the ﬁnal preparation to be less than
10 lg/g ratio. The Panel considered the results of this study reliable but limited to extracts that are
devoid and/or puriﬁed of anthranoids.
Fructus sennae
In the study by Heidemann et al. (1993), fructus sennae (2.51% content of hydroxyanthracene
derivatives) was assayed for its ability to induce gene mutation in NMRI mice by the Mouse Spot Test
and micronuclei and structural chromosomal aberrations in the bone marrow cells of Wistar rats.
Groups of 4–8 male and female animals were treated with suspensions of fructus sennae in 0.3–0.5%
tragacanth by oral gavage at 100 or 1,000 mg/kg bw for the Mouse Spot Test and at dose levels up to
1,000 mg/kg in the bone marrow chromosome aberration assay in rat and at 1,500 mg/kg in the bone
marrow micronucleus test in rats. The studies included concurrent solvent and positive control animal
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groups. Micronuclei and chromosomal aberrations were determined at 24, 48 and 72 h and 6, 24 and
48 h from the beginning of treatment, respectively. In the latter case, intraperitoneal injections of
colchicine at 2 mg/kg bw, 2.5 h before sacriﬁce were also performed. For the Mouse Spot Test, female
animals were treated on day 9 of pregnancy and the F1 offspring was checked for colour spots
3 weeks after birth. A minimum number of 50 metaphases or 1,000 PCE per animal were scored for
induction of chromosomal aberrations and micronuclei, respectively. The results obtained indicated that
fructus sennae did not induce any signiﬁcant increase in the genetically relevant spots compared to the
concurrent control in the Mouse Spot Test nor micronuclei. No induction of chromosomal aberration
was observed up to dose level of 1,000 mg/kg and no toxicity was observed. The Panel noted that the
studies, though performed according to the standard protocols at the time bear some shortcomings
which include the scoring of limited number of PCE in the micronucleus test (1,000 PCE/animal) and
no evaluation of the ratio between PCE and normochromatic erythrocytes (NCE) to assess bone
marrow toxicity was reported. In addition the maximum dose level of 1,000 mg/kg used in the
chromosome aberration assay which did not elicit any toxicity in the target tissue appears to be low
since in the micronucleus test a higher dose level (1,500 mg/kg bw) with no reported bone marrow
toxicity was employed. This suggests that the bone marrow was not sufﬁciently exposed to the test
compound. Furthermore, the Panel noted that the Mouse Spot Test is not currently used/
recommended in genotoxicity testing for induction of gene mutation in vivo and that the relevant
OECD Guideline 484 has been permanently withdrawn on 2 April 2014. Overall, the Panel considered
these studies to be of insufﬁcient reliability for risk assessment.
Senna extracts
In the study by Mengs et al. (1999), dried aqueous extracts from Tinnevelly senna pods were
assessed for the induction of micronuclei in the bone marrow of NMRI mice. The main anthranoids
contained in the extracts were rhein, aloe-emodin and emodin present at 5.96%, 0.287% and 0.014%
respectively. Extracts were administered once by oral gavage at a dose level of 2,000 mg/kg (rhein,
aloe-emodin and emodin equal to 119, 5.74 and 0.28 mg/kg bw, respectively) and animals were
sacriﬁced at 24 and 48 h from treatment. Plasma levels of the different anthranoids were also
determined in a satellite experiment following administration of aqueous extracts at 2,000 mg/kg bw
to six male and six female NMRI mice. Three animals each of both genders were sacriﬁced at 1 and
3 h from treatment. For all compounds detected, plasma maximum levels were found after 1 h. The
highest values were 3.4 lg/mL for rhein and 0.065 lg/mL for aloe-emodin in female mice. The
concentrations of emodin were in all cases below the limit of quantiﬁcation. No induction of
micronuclei was observed at any experimental test point. However, the Panel noted the low levels of
anthranoids administered and the absence of any reduction of the ratio between PCE and NCE
erythrocytes in the treated animal groups compared to the concurrent control animal groups.
Sennosides
In the study by Heidemann et al. (1993), sennosides (a mixture of sennosides A + B in the range
of 75.0–82.2% and sennosides C+D in the range of 3.7–4.3%) were assessed for their potential
induction of micronuclei in the bone marrow of male and female NMRI mice in two independent
experiments following treatment by oral gavage. In the ﬁrst experiment, animals received a single
dose of 1,500 mg/kg bw while in the second experiment animals received two administration of
2,500 mg/kg bw 24 h apart. In both cases, sampling of bone marrow cell was performed at 24, 48
and 72 h from the last administration and 1,000 PCE per animal were analysed for the presence of
micronuclei. The ratio of PCE to NCE was also carried out. The results obtained indicated that
sennosides did not increase the frequencies of micronuclei in the test substance treatment groups
compared to the concurrent negative controls and no toxicity was observed. However, the Panel noted
that no raw data are reported in the publication and that at present the study appears to be
inadequate for assessment of genotoxicity since only 1,000 PCE per animal were scored for the
presence of micronuclei (against 4,000 currently requested) and no proof of absorption or target tissue
exposure were present. On this basis, the Panel considered the results obtained to be of insufﬁcient
reliability for risk assessment of sennosides.
Emodin
In the study by Mengs et al. (1997), emodin (purity 99%) was assessed for the induction of
micronuclei in the bone marrow of NMRI mice following a single administration by oral gavage at a
dose level of 2,000 mg/kg as a suspension (in 0.3% aqueous tragacanth). The study included solvent
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and positive control animal groups and sacriﬁce of animals was performed at 24 and 48 h from
treatment. A minimum number 2,000 PCE per animal were scored for micronuclei. The ratio between
PCE and NCE to assess bone marrow toxicity was also calculated. Plasma levels of emodin was also
determined in a satellite experiment following administration of test substance at 2,000 mg/kg bw to
four male and four female NMRI mice. Animals were sacriﬁced at 1 and 3 h from treatment. Plasma
levels of emodin ranged from 73 to 190 lg/mL within 3 h. No induction of micronuclei was observed
at any experimental test point. However, the Panel noted that despite the presence of emodin in
plasma (73–190 lg/mL within 3 h) the mean number of NCE in the emodin treatment group was not
increased as compared to the mean values of NCE of the concurrent solvent controls, indicating that
emodin had no cytotoxic effects on bone marrow cells and no proof of exposure of target issue were
present. Overall, the Panel considered these studies to be of insufﬁcient reliability for risk assessment.
Aloe-emodin
In the study by Heidemann et al. (1996), aloe-emodin (purity 99.4–99.9%) was assayed for its
ability to induce gene mutation in NMRI mice by the Mouse Spot Test and micronuclei and structural
chromosomal aberrations in the bone marrow cells of Wistar rats. An in vivo/vitro unscheduled DNA
synthesis (UDS) study in primary hepatocytes of Wistar rats was also performed. Groups of 4–8 male
and female animals were treated with aloe-emodin by oral gavage at 200 and 2,000 mg/kg bw for the
Mouse Spot Test and at dose levels up to 2,000 mg/kg in the bone marrow chromosome aberration
assay in rat and at 1,500 mg/kg in the bone marrow micronucleus test in rats. For UDS, dose levels of
100 and 1,000 mg/kg were used. The studies included concurrent solvent and positive control animal
groups. Micronuclei and chromosomal aberrations were determined at 24, 48 and 72 h and at 6, 24
and 48 h from the beginning of the treatment, respectively. In the latter case, intraperitoneal
injections of colchicine at 2 mg/kg bw, 2.5 h before sacriﬁce were also performed. For the Mouse Spot
Test, female animals were treated on day 9 of pregnancy and the F1 offspring was checked for colour
spots 3 weeks after birth. For UDS, after a treatment period of 4 and 16 h, animals were
anaesthetised and during liver perfusion were sacriﬁced. Primary hepatocyte cultures were set up and
3H-thymidine was added for 4 h in order to detect UDS by autoradiography. A minimum number of 50
metaphases or 1,000 PCE per animal were scored for induction of chromosomal aberrations and
micronuclei, respectively, and 100 cells per animal were analysed for UDS. The results obtained
indicated that aloe-emodin did not induce any signiﬁcant increase in the genetically relevant spots in
the F1 offspring (210 and 458 animals at 200 and 2,000 mg/kg bw) compared to the concurrent
control in the Mouse Spot Test. No micronuclei, chromosomal aberrations or UDS were observed at
any dose level or sampling time assayed. No reduction of PCE/NCE ratio or mitotic indices were
observed at any experimental point in the micronucleus and chromosomal aberration assays,
respectively, indicating that target tissue exposure could not be demonstrated. The Panel noted that
the studies, although performed according to the standard protocols at the time bear some
shortcomings which include the scoring of limited number of PCE in the micronucleus test (1,000 PCE/
animal against 4.000 currently requested) and only one or two dose levels were used. Furthermore,
the Panel noted that the Mouse Spot Test is not a validated test and is presently considered obsolete
and that no raw data were reported. Overall, the Panel considered these studies to be of insufﬁcient
reliability for risk assessment.
In the study by Nesslany et al. (2009), aloe-emodin (purity 95.59%, Extrasynthese, Genay, France)
was assayed for its capability to induce DNA fragmentation in the colon and kidney of male OF1 mice.
Groups of ﬁve male mice were treated with aloe-emodin by oral gavage on two occasions 24-h apart
at dose levels of 500, 1,000 and 2,000 mg/kg bw as a suspension in 0.5% carboxymethylcellulose
(CMC 0.5%). The study included concurrent solvent and positive control animal groups. Negative
control received the vehicle only and the positive control groups (four animal each) were dosed once,
either intravenously with streptozotocin at 20 mg/kg (kidney) or orally with dimethylhydrazine at
20 mg/kg bw (colon). Between 3 and 6 h from the last treatment, animals were anesthetised and
maintained under deep anaesthesia before collecting cells from each target organ. The viability of cells
in the resulting cell suspensions was evaluated using the trypan blue exclusion technique and
preparation of slides to be assessed for DNA breakage followed standard recommendations (Tice
et al., 2000; Hartmann et al., 2003; Burlinson et al., 2007). At least 150 randomly selected cells per
animal (50 cells per slide) were analysed at 250x magniﬁcation using a ﬂuorescence microscope
connected to the Comet Image-analysis System (Kinetic Imaging Ltd., Liverpool, UK). The Olive tail
moment (OTM) was used to evaluate DNA damage. OTM values from the three replicate slides were
pooled and the median was calculated. The mean of medians and standard errors of the mean were
Safety assessment of hydroxyanthracene derivatives
www.efsa.europa.eu/efsajournal 39 EFSA Journal 2018;16(1):5090
calculated for each group and log-transformed before statistical analyses. The results obtained
indicated that aloe-emodin induced marked and statistically signiﬁcant increases in OTM values in the
colon at all dose levels used compared to the concurrent vehicle control values. The observed
increases were 2.2, 2.4 and 2.1 greater than the concurrent vehicle control value at the low-,
intermediate- and high-dose level, respectively. Increases in OTM values compared to the concurrent
vehicle control were also observed in kidney. These increases were dose-related but statistical
signiﬁcance was only reached at the highest dose level tested. The Panel noted that the study
complied with the international recommendations at the time and essentially lined up to the current
OECD TG 489 ‘In vivo mammalian alkaline Comet Assay’.
The main ﬁgures of in vitro and in vivo genotoxicity studies are reported in Tables 5 and 6.
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Table 5: Summary of in vitro genotoxicity studies evaluated in the present opinion
Test material
Mutagenicity
assay
Test object Reported result Reference Comments
Aloe vera
extracts and/or
gels
Bacterial reverse
mutation
Salmonella Typhimurium TA98 and TA100 Negative(a) Morimoto et al.
(1982)
Limited reliability.
Set of S. Typhimurium strains not complete
DNA repair Bacillus subtilis rec-assay Positive(c)
(only for water
extracts)
Insufﬁcient reliability.
Test system not adequately validated and not
currently used/recommended in genotoxicity testing
DNA repair E. coli wild-type or defective repair
mutants (recA, xthA, uvrA, wild-type/rfa,
uvrA/rfa) tester strains
Negative(c) Paes-Leme et al.
(2005)
Insufﬁcient reliability.
Test system not adequately validated and not
currently used/recommended in genotoxicity testing
Bacterial reverse
mutation
S. Typhimurium TA98 and TA100 Negative(a) Sehgal et al.
(2013)
Limited reliability.
Set of S. Typhimurium strains not complete
DNA damage E. coli strain containing a transgene for
b-galactosidase downstream of the SOS-
DNA repair promoter system
Negative(c) Insufﬁcient reliability.
Test system not adequately validated and not
currently used/recommended in genotoxicity testing
Bacterial reverse
mutation
S. Typhimurium TA1535, TA1537, TA98,
TA100 and E. coli WP2 uvrA
Negative(a) Williams et al.
(2010)
Reliable, but limited to extracts which are devoid
and/or puriﬁed of anthranoids
Bacterial reverse
mutation
S. Typhimurium TA1535, TA97, TA98,
TA100 and E. coli WP2 uvrA
Negative(a) Boudreau et al.
(2013)
Reliable.
Chromosome
aberrations
Chinese hamster lung (CHL) cells Negative(a) Williams et al.
(2010)
Reliable, but limited to extracts which are devoid
and/or puriﬁed of anthranoids
Mammalian cell
gene mutation
Mouse lymphoma L5178Y cells (TK locus) Positive(c) Guo (2014) Reliable.
Senna extracts Bacterial reverse
mutation
S. Typhimurium TA98 and TA100 Positive(a) Morimoto et al.
(1982)
Reliable.
Although the set of S. Typhimurium strains was not
complete, a positive effect was detected
DNA repair Bacillus subtilis rec-assay Positive(b) Insufﬁcient reliability.
Test system not adequately validated and not
currently used/recommended in genotoxicity testing
Safety assessment of hydroxyanthracene derivatives
www.efsa.europa.eu/efsajournal 41 EFSA Journal 2018;16(1):5090
Test material
Mutagenicity
assay
Test object Reported result Reference Comments
Emodin Bacterial reverse
mutation
S. Typhimurium TA98, TA100, TA1535,
TA1537
E. coli WP2 uvrA
Positive in
TA1537(c) and
TA98(a)
Heidemann
et al. (1996)
Reliable.
Mammalian cell
gene mutation
Chinese hamster (V79) cells
(HPRT locus)
Negative(c)
Equivocal(b)
Heidemann
et al. (1996)
Reliable.
Valid Chinese hamster ovary (CHO) cells Positive(a) Reliable.
Gene mutation and
micronuclei
Mouse lymphoma L5178Y cells (TK locus) Positive(c) Mueller et al.
(1996)
Reliable.
Micronucleus
induction
Mouse lymphoma L5178Y cells Positive(c) Reliable.
Alkaline comet
assay
Human tongue cancer (SCC-4) cells Positive(c) Chen et al.
(2010)
Limited reliability.
Only a long treatment (24 h) performed with
possible elevated cytotoxicity associated.
Aloe-emodin Bacteria reverse
mutation
S. Typhimurium TA98, TA100, TA1535,
TA1537
E. coli WP2 uvrA
Positive
(TA1537, TA1538
and TA98)(c) and
TA1538(b)
Heidemann
et al. (1996)
Reliable.
Mammalian cell
gene mutation
Chinese hamster (V79) cells
(HPRT locus)
Negative(a) Reliable.
Chromosomal
aberrations
Chinese hamster ovary (CHO) cells Positive(a) Reliable.
Mammalian cell
gene mutation
Mouse lymphoma L5178Y cells (TK locus) Positive(c) Mueller et al.
(1996)
Reliable.
Micronucleus
induction
Mouse lymphoma L5178Y cells Positive Reliable.
Alkaline comet
assay
Human tongue cancer (SCC-4) cells Positive(c) Chen et al.
(2010)
Limited reliability.
Only a long treatment (24 h) performed with
possible elevated cytotoxicity associated
Danthron Mammalian cell
gene mutation
Mouse lymphoma L5178Y cells (TK locus) Positive(c) Mueller et al.
(1996)
Reliable.
Micronucleus
induction
Mouse lymphoma L5178Y cells Reliable
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Test material
Mutagenicity
assay
Test object Reported result Reference Comments
Bacterial reverse
mutation
S. Typhimurium TA97, TA98, TA100,
TA102
Positive
(TA102)(b)
Zhang et al.
(2011)
Reliable.
Though the set of S. Typhimurium strains was not
complete, a positive effect was detected
Micronucleus
induction
Balb/c 3T3 cell line Positive(a) Reliable.
Though treatments were only performed for 24 h, a
positive effect was anyway found
Comet assay Balb/c 3T3 cell line Positive(a) Limited reliability.
Only a long treatment (24 h) performed with
possible elevated cytotoxicity associated
Rhein Bacterial reverse
mutation
S. Typhimurium TA98, TA100, TA1535,
TA1537 and E. coli WP2 uvrA
Negative(a) Heidemann
et al. (1993)
Reliable
Mammalian cell
gene mutation
Mouse lymphoma L5178Y cells
(TK locus)
Negative(a) Reliable.
Chromosomal
aberrations
Chinese hamster ovary (CHO) cells Negative(a)
Alkaline comet
assay
Human tongue cancer (SCC-4) cells Positive(c) Chen et al.
(2010)
Limited reliability.
Only a long treatment (24 h) performed with
possible elevated cytotoxicity associated
Sennosides Bacterial reverse
mutation
S. Typhimurium TA98, TA100, TA1535,
TA1537 and E. coli WP2 uvrA
Negative(a) Heidemann
et al. (1993)
Reliable.
Mammalian cell
gene mutation
Mouse lymphoma L5178Y cells Negative(a) Reliable.
Chromosomal
aberrations
Chinese hamster ovary (CHO) Negative(a) Reliable.
Chrysophanol Chromosomal
aberrations
Chinese hamster ovary (CHO) cells Negative(a) Mengs et al.
(2001)
Mengs et al. (2001)
(a): With and without metabolic activation.
(b): With metabolic activation.
(c): Without metabolic activation.
(d): Reliability of genotoxicity studies:
1. Reliability
• Limited reliability (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and/or limited documentation).
• Insufﬁcient reliability (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system).
• Reliability cannot be evaluated (e.g. insufﬁcient documentation, short abstract only, too little experimental details provided).
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Table 6: Summary of in vivo genotoxicity studies evaluated in the present opinion
Test
material
Mutagenicity assay Test object Route Dose
Reported
result
Reference Comments(a)
Aloe vera
extracts
and/or gels
Micronucleus formation ICR, male
mouse bone
marrow cells
Oral
gavage/
1,250, 2,500,
5,000 mg/kg bw
once daily on two
consecutive days
Negative Williams
et al. (2010)
Insufﬁcient reliability.
No evidence or demonstration that target tissue was
sufﬁciently exposed
Fructus
sennae
Mouse spot test
(Induction of different
mutations in target genes
which control the
pigmentation of the coat
hairs in melanoblasts)
NMRI mice
melanoblasts
in developing
embryos
Oral
gavage
100 and
1,000 mg/kg bw
(single
administration)
Negative Heidemann
et al. (1993)
Insufﬁcient reliability.
No evidence or demonstration that target tissues were
sufﬁciently exposed. The Mouse Spot Test is not currently
used/recommended in genotoxicity testing for induction
of gene mutation in vivo.
The relevant OECD Guideline 484 has been permanently
withdrawn on 2 April 2014
Micronucleus formation Wistar male
and female
rat bone
marrow cells
Oral
gavage
15,00 mg/kg bw
(single
administration)
Negative Insufﬁcient reliability.
No evidence or demonstration that target tissue was
sufﬁciently exposed.
A limited number of PCE in the micronucleus test (1,000
PCE/animal) and no evaluation of the ratio between
polychromatic and normochromatic erythrocytes to assess
bone marrow toxicity
Chromosome aberrations Wistar male
and female
rat bone
marrow cells
Oral
gavage
Up to 1,000 mg/
kg bw
(single
administration)
Negative Insufﬁcient reliability.
No evidence or demonstration that target tissue was
sufﬁciently exposed.
No bone marrow toxicity observed.
Selection of the highest dose level (1,000 mg/kg bw) not
consistent with the highest dose level used for the
micronucleus test (1,500 mg/kg bw)
Senna
extracts
Micronucleus formation NMRI male
and female
mouse bone
marrow cells
Oral
gavage
2,000 mg/kg bw
(single
administration)
Negative Mengs et al.
(1999)
Insufﬁcient reliability.
No evidence or demonstration that target tissue was
sufﬁciently exposed.
No bone marrow toxicity observed.
Maximum plasma levels of aloe-emodin and emodin, two
components genotoxic in vitro were 0.065 lg/mL and
below the limit of detection (LOD), respectively.
Only 2,000 PCE/animal) were scored for evaluation of
micronuclei induction
Safety assessment of hydroxyanthracene derivatives
www.efsa.europa.eu/efsajournal 44 EFSA Journal 2018;16(1):5090
Test
material
Mutagenicity assay Test object Route Dose
Reported
result
Reference Comments(a)
Sennosides Micronucleus formation Bone marrow
of male and
female NMRI
mice
Oral
gavage
2,500 mg/kg bw
(twice 24 h apart)
Negative Heidemann
et al. (1993)
Insufﬁcient reliability.
No evidence or demonstration that target tissue was
sufﬁciently exposed.
No bone marrow toxicity observed.
A limited number of PCE (1,000 PCE/animal) was scored
Emodin Micronucleus
formation
NMRI male
and female
mouse bone
marrow cells
Oral
gavage
2,000 mg/kg bw
(single
administration)
Negative Mengs et al.
(1997)
Insufﬁcient reliability.
No evidence or demonstration that target tissue was
sufﬁciently exposed.
No bone marrow toxicity observed.
Only 2,000 PCE/animal were scored for evaluation of
micronuclei induction.
Only one dose level
Aloe-emodin Mouse spot test
(Induction of different
mutations in target genes
which control the
pigmentation of the coat
hairs in melanoblasts)
NMRI mice
melanoblasts
in developing
embryos
Oral
gavage
200 and
2,000 mg/kg bw
(single
administration)
Negative Heidemann
et al. (1996)
Insufﬁcient reliability.
No evidence or demonstration that target tissues were
sufﬁciently exposed.
The Mouse Spot Test is not currently used/recommended
in genotoxicity testing for induction of gene mutation
in vivo.
The relevant OECD Guideline 484 has been permanently
withdrawn on 2 April 2014
Micronucleus formation Wistar male
and female
rat bone
marrow cells
Oral
gavage
1,500 mg/kg bw
(single
administration)
Negative Insufﬁcient reliability.
No evidence or demonstration that target tissue was
sufﬁciently exposed.
A limited number of PCE (1,000 PCE/animal) were scored
for evaluation of micronuclei induction.
Only one dose level administered.
No bone marrow toxicity observed
Chromosome aberrations Wistar male
and female
rat bone
marrow cells
Oral
gavage
200, 666 and
2,000 mg/kg bw
(single
administration)
Negative Insufﬁcient reliability.
No evidence or demonstration that target tissue was
sufﬁciently exposed.
Only two dose level administered.
No bone marrow toxicity observed
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Test
material
Mutagenicity assay Test object Route Dose
Reported
result
Reference Comments(a)
In vivo/vitro unscheduled
DNA synthesis
Primary
hepatocytes
of Wistar rats
Oral
gavage
100 and
1,000 mg/kg bw
(single
administration)
Negative Insufﬁcient reliability.
No evidence or demonstration that target tissue was
sufﬁciently exposed.
Only two dose level administered.
Not recommended as an adequate in vivo follow-up study
in genotoxicity testing (EFSA, 2017)
DNA fragmentation Colon and
kidney cells
of male OF1
mice
Oral
gavage
500, 1,000 and
2,000 mg/kg
(twice 24 h apart)
Positive
(colon);
Weakly
positive
(kidney)
Nesslany
et al. (2009)
Reliable.
Essentially compliant with the current OECD Guideline
489 ‘in vivo mammalian alkaline comet assay’
bw: body weight; PCE: polychromatic erythrocytes.
(a): Reliability of genotoxicity studies:
• Reliable.
• Limited reliability (e.g. if certain aspects are not in accordance with OECD guidelines or current standards and/or limited documentation).
• Insufﬁcient reliability (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards and/or inappropriate test system).
• Reliability cannot be evaluated (e.g. insufﬁcient documentation, short abstract only, too few experimental details provided).
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Discussion on genotoxicity
In this opinion, the genotoxicity of hydroxyanthracene derivatives has been evaluated in numerous
in vitro and in vivo studies identiﬁed from the public literature. The available studies focused mainly on
emodin, aloe-emodin, rhein and sennosides and to lesser extent on aloe vera, senna and fructus
sennae extracts. A limited number of studies on danthron and chrysophanol were also available.
Among the extracts, only senna extracts proved to be mutagenic in the TA98 S. Typhimurium tester
strain in the presence of S9 metabolism (Morimoto et al., 1982), in S. Typhimurium tester strain ta
1537 and TA98 in the absence of S9 metabolism (Heidemann et al., 1993). It also induced DNA
damage in the Bacillus subtilis rec-assay (Morimoto et al., 1982) and induced dose-related increases in
chromosomal aberrations in CHO cells in the absence of S9 (Heidemann et al., 1993).
No positive results in the bacterial mutation assay for aloe vera gel and for both aloe vera WLE and
aloe vera charcoal-ﬁltered whole leaf extract (decolourised) were observed in S. Typhimurium strains
TA98 and TA100, and E. coli strain WP2 uvrA/pKM101, with and without S9 metabolic activation
(Boudreau et al., 2013). The 1,8-dihydroxyanthraquinones emodin, aloe-emodin and danthron were
shown to be mutagenic in the Tk+/ locus in mouse lymphoma L5178Y cells (Mueller et al., 1996) and
consistently clastogenic in vitro in mammalian cells interacting via intercalation into DNA with DNA
topoisomerase II and consequent inhibition of their catalytic function resulting in genotoxicity and
mutagenicity with a ranking potency greater for danthron and lower for emodin.
This was demonstrated by the results of a ‘modiﬁed comet assay’ which showed that pretreatments
of the cells with each of these test compounds reduced the DNA damage induced by etoposide, an
inhibitor of topoisomerase II which acts through the stabilisation of the DNA–topoisomerase complex
known as the ‘cleavable complex’ (Mueller et al., 1996) and following ﬁndings by Mueller and Stopper
(1999) in which danthron, aloe-emodin and emodin showed capability to inhibit the non-covalent
binding of bisbenzimide Hoechst 33342 to isolated DNA and to DNA of intact mouse lymphoma L5178Y
cells. On the other hand, emodin, the least potent compound among these three anthraquinones, was
also shown to induce DNA double-strand breaks (DSB) through poisoning of topoisomerase
II-cleavable complex and through inhibiting adenosine triphosphate (ATP) hydrolysis by DNA
topoisomerase II (Li et al., 2010). Thus, it is not possible to exclude also a potential mechanism of
inhibition of DNA topoisomerase II through poisoning of the DNA–topoisomerase ‘cleavable complex’.
Aloe-emodin was also mutagenic in S. Typhimurium strains TA1537, TA1538, TA97 and TA98, (all
frameshift mutant sites) in the absence of S9 metabolism. While these results further support the
intercalating capability of aloe-emodin and consequent catalytic inhibition of DNA topoisomerase II
they also show the induction of frameshift mutations which, per se, is a mutagenic event not related
to the inhibition of DNA topoisomerase II.
In this respect, the Panel noted that, beyond frameshift mutations, danthron also induced base-pair
substitutions in bacteria, only after exogenous metabolic activation, and oxidative DNA damage in
mammalian cells, highlighting the involvement of multiple mechanisms of genotoxicity.
In addition aloe-emodin induced UDS in primary rat hepatocytes (Westendorf et al., 1990), and
DNA breakage in mouse lymphoma L5178Y cells (Mueller et al., 1996), in NPC-039 and NPC-076
human nasopharyngeal carcinoma cells (Lin et al., 2007) and SCC-4 human tongue cancer cells (Chen
et al., 2010). These results are also compatible with a mechanism of inhibition of DNA topoisomerase
II activities.
However, although individual anthranoids induced gene mutations (frameshift and base-pair
substitutions) in bacteria, frameshift mutations and clastogenic effects in mammalian cells through
inhibition of DNA topoisomerase II, for plant extracts containing hydroxyanthracene derivatives, other
mutagenic components with different mechanisms of action appear to play a role in extract
genotoxicity and carcinogenicity as reported in the study by Guo (2014). In this study, both aloe vera
WLE and aloe vera WLD – for which the content of hydroxyanthracene derivatives (both glycosidic and
free aglycones) was reduced by 99% compared to the WLE induced statistically signiﬁcant and
biologically relevant increases in mutation frequencies (MF) in the mammalian cell TK+/- mutation
assay using the mouse lymphoma L5178Y cells. As revealed by DCF-DA staining, intracellular ROS
levels were increased about 5- and 15-fold in WLD- and WLE-treated cells, respectively, when
compared to the concurrent control groups. This implies that components in the WLE, in addition to
the hydroxyanthracene derivatives, could contribute to the mutagenicity of the WLE in part through a
ROS-dependent mechanism. This conclusion is further substantiated by the LOH of WLE/WLD-induced
mutants. Results indicated that, while both extracts were clastogenic, their induced mutation spectra
were signiﬁcantly different, thus conﬁrming that different constituents may be responsible for the
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genetic damage caused by the two preparations. These results indicate that aloe vera and senna
extracts and individual hydroxyanthracene derivatives, particularly aloe-emodin, interact with bacterial
and mammalian DNA under certain conditions in vitro.
However, for risk assessment, in vivo studies are requested to conclude on potential genotoxic
hazard and in this respect, a number of in vivo studies were available which included rodent bone
marrow micronucleus assays, mouse somatic mutation assay in fetal melanoblasts commonly identiﬁed
as Mouse Spot Test, rat bone marrow chromosome aberration assays and in vivo/in vitro UDS in rat
liver performed by oral gavage for aloe-emodin and fructus sennae extracts (Heidemann et al., 1996).
Data from rodent bone marrow micronucleus tests were also available for emodin (Mengs et al.,
1997), senna extracts (Mengs et al., 1999) and sennosides (Heidemann et al., 1993) following oral
administration. The results obtained indicated that senna, fructus sennae extracts, sennosides and
individual 1,8-dihydroxyanthraquinones tested were uniformly negative in any of the different
endpoints analysed, following high acute exposure by oral gavage. However, in all cases, no evidence
of toxicity in the target cells was observed, indicating that target tissues could have not been
adequately exposed to the test compounds. This assumption is substantiated by results of an in vivo
study in rats (Lang, 1993), where [14C]aloe-emodin, was shown to be hardly absorbed and quickly
metabolised to rhein which was found to be non-mutagenic in a battery of in vitro and in vivo assays
(Westendorf et al., 1990; Heidemann et al., 1996; Mengs and Heidemann, 1993).
On the other hand, Nesslany et al. (2009) found marked and signiﬁcant increases in DNA
fragmentation in the colon cells of male OF1 mice treated with aloe-emodin by oral gavage at 2000,
1000 and 500 mg/kg bw on two occasions 24 h apart in the in vivo rodent comet assay. Slight
increases in DNA breakage compared to the concurrent vehicle control values were also observed in
the kidney which were dose-related but reached statistical signiﬁcance only at the high-dose level
tested. On this basis, the limited absorption of aloe-emodin and its quick transformation to rhein
(a compound devoid of genotoxic capabilities) indicate that bone marrow may be considered as an
inadequate tissue to demonstrate a possible in vivo genotoxicity for both emodin and aloe-emodin.
Overall, the Panel considered that the in vitro genotoxicity of aloe-emodin was reproduced in the colon
in vivo (Nesslany et al., 2009), the target tissue for aloe vera WLE carcinogenicity (Boudreau et al.,
2013). The Panel therefore considered that aloe-emodin represents a genotoxic risk for man. The
Panel also considered that the presence of other mutagenic components, in addition to
hydroxyanthracene derivatives, cannot be excluded.
3.2.2. Short-term and subchronic toxicity
Aloe Vera
Short-term (16-day) and subchronic (14-week) toxicity studies have been conducted in two rodent
species (mice and rats) within the US NTP on WLE of Aloe barbadensis Miller (Aloe Vera) (NTP, 2013).
Mice
Groups of B6C3F1/Ncrt mice (4/sex per group, 7 weeks old) received for 14 days 0, 0.5%, 1.0%,
1.5%, 2% or 3.0% (wt/wt) of aloe vera gel (malic acid content of 116–212 mg/g, aloin A content
of 1.1–1.4 mg/g), aloe vera decolourised whole leaf (malic acid content of 215–258 mg/g, aloin A
content of 0.06–0.2 mg/g no further information provided on chemical composition) or aloe vera
non-decolourised WLE (malic acid content of 188–197 mg/g, aloin A content of 14.1–15.9 mg/g) in
drinking water (NTP, 2013). Additional groups (4/sex per group) received the same concentrations of
the Aloe vera extracts for the same duration period and were used to study metabolism. According to
EFSA ‘Guidance on default values to be used in the absence of measured data’ (EFSA Scientiﬁc
Committee, 2012), these dietary concentration were equivalent to 0, 11.25, 22.5, 33.75, 45,
67.5 mg/aloin A/kg bw per day for aloe vera gel; 0, 1.17, 2.34, 3.51, 4.68, 7.02 mg/aloin A/kg bw per
day for aloe vera decolourised whole leaf and 0, 135, 270, 405, 540, 810 mg/aloin A/kg bw per day
for aloe vera non-decolourised WLE.22
All mice survived to the scheduled termination. Dose-related decreases in the GI transit time were
recorded at week 1 in males receiving aloe vera WLE. No treatment-related changes were observed in
the examined organs.
22 For these calculations, the mean content of aloin A was calculated as follows: 1.25 mg/g for aloe vera gel, 0.13 mg/g for aloe
vera decolourised whole leaf and 15 mg/g for aloe vera non-decolourised whole leaf extract.
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Groups of B6C3F1 mice (12/sex per group, 6 to 7 weeks old) received 0, 1%, 2% or 3% (wt/wt)
of aloe vera non-decolourised whole leaf extract (the bulk material malic acid content of
170.7–192.9 mg/g, aloin A content of 12.6–14.4 mg/g) in drinking water for 13 consecutive weeks
(NTP, 2013). These concentrations provided (as reported by the authors of the study) 0, 3,700, 7,300
and 9,100 mg aloe vera non-decolourised whole leaf extract/kg bw per day for males and 0, 3,700,
7,600, and 9,500 mg aloe vera non-decolourised whole leaf extract/kg bw per day for females,
corresponding to 0, 49.95, 98.55 and 122.85 mg aloin A/kg bw per day for males and 0, 49.95, 102.6
and 128.25 mg aloin A/kg bw per day for females.23 Additional groups (12/sex per group) received 0%
or 3% of the aloe vera WLE and were used for metabolism study. All mice survived to the scheduled
termination. Body weights and feed intake of male and female mice from the treated groups were
comparable to controls. Water intake was statistically signiﬁcantly higher than that of controls for male
and female mice from 1%- and 2% groups on day 30, and in 2% group on day 60. Signiﬁcant
dose-related increases in water intake were reported only for females on day 90. Water intake of males
and females in the metabolism study was did not differ from that in controls. The haematology and
clinical chemistry results in the treated groups were within the reference values for laboratory mice. GI
transit times of 3% group males and females were similar to those of controls with exception of a
transient increase in transit time at week 8 for males from 3%-dose group. The absolute and relative
organ weights of males and females exposed to Aloe vera non-decolourised whole leaf extract were
similar to those in controls with exception slightly but statistically signiﬁcantly increased relative liver
weight, absolute and relative spleen and kidney weights in the 1%-dose group females, and of relative
kidney weight in the 3%-dose group females. Although within physiological ranges, the 24-h urine
levels of creatinine and microprotein were statistically signiﬁcantly increased compared with controls.
The increased incidences and severities of goblet cell hyperplasia in the caecum and large intestine
were reported for males and females from groups exposed to the test material as compared to controls.
Rats
Groups of F344/N rats (4/sex per group, 7 weeks old) received for 14 days 0, 0.5%, 1.0%, 1.5%,
2% or 3.0% (wt/wt) of aloe vera gel (malic acid content of 116-212 mg/g, aloin A content of 1.1 to
1.4 mg/g), Aloe vera decolourised whole leaf (malic acid content of 215–258 mg/g, aloin A content of
0.06–0.2 mg/g) or aloe vera non-decolourised WLE (malic acid content of 188–197 mg/g, aloin A
content of 14.1–15.9 mg/g) in drinking water (NTP, 2013). According to EFSA ‘Guidance on default
values to be used in the absence of measured data’ (EFSA Scientiﬁc Committee, 2012), these dietary
concentration were equivalent to 7.56, 15.12, 22.68, 30.24, 45.36 mg/aloin A/kg bw per day for aloe
vera gel; 0, 0.78, 1.56, 2.34, 3.12, 4.68 mg/aloin A/kg bw per day for aloe vera decolourised whole
leaf and 0, 90, 180, 270, 360, 540 mg/aloin A/kg bw per day for aloe vera non-decolourised WLE.24
Additional groups (4/sex per group) received the same concentrations of the aloe vera extracts for
the same duration period and were used to study metabolism. At necropsy, the heart, liver, right
kidney, lungs/bronchi, spleen, right testis and thymus were weighed. Microscopic examination was
performed on thyroid, parathyroid glands, liver, thymus, lung and kidney from the control group and
high-dose groups receiving the aloe vera WLE and on all gross lesions. All rats survived to the
scheduled termination. No treatment related to non-neoplastic lesions was reported.
Groups of F344/N rats (12/sex per group in the core study, 6 weeks old) received 0, 1%, 2%
or 3% (wt/wt) of aloe vera non-decolourised WLE (the bulk material malic acid content of
170.7–192.9 mg/g, aloin A content of 12.6–14.4 mg/g) in drinking water for 13 consecutive weeks.
These concentrations provided (as reported by the authors of the study) 0, 1.1, 2.7 and 3.8 g aloe
vera non-decolourised whole leaf extract/kg bw per day for males and 0, 1.3, 4.0, and 3.2 g aloe vera
non-decolourised whole leaf extract/kg bw per day for females, corresponding to 0, 14.8, 36.45 and
51.3 mg aloin A/kg bw per day for males and 0, 18.72, 54 and 43.2 mg aloin A/kg bw per day for
females.23 Additional groups (12/sex per group) received 0 or 2% of the aloe vera WLE and were used
for metabolism study. Two males and four females from 2% and ﬁve males and eight females from the
3% aloe vera non-decolourised whole extract groups died or were euthanised due to morbidity before
the scheduled termination. Mean ﬁnal body weights and body weight gains of males from all dose
groups and of females from 2%- and 3% groups were statistically signiﬁcantly lower than the controls.
Statistically signiﬁcantly decreased feed intake for males and females from all dose groups was
23 For these calculations, the mean content of aloin A (13.5 mg/g) was used.
24 For these calculations, the mean content of aloin A was calculated as follows: 1.26 mg/g for aloe vera gel, 0.13 mg/g for aloe
vera decolourised whole leaf and 15 mg/g for aloe vera non-decolourised whole leaf extract.
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recorded in the 4th week and for males from the 2% and 3% groups in the 13th week. Mean water
intake in all male groups and in 2% females on days 60 and 90 was statistically signiﬁcantly increased
as compared to the controls. Despite higher water intake in Aloe vera non-decolourised whole leaf
extract exposed groups decreased urine production was recorded in the 2% group in males on days
30 and 60 and on day 90 in females only. Urinary protein and 24-h glucose levels were increased in
males and females at 30 days and at 60 days in males only. Urine 24-h creatinine levels were
statistically signiﬁcantly decreased at 30, 60 and 90 days in males and at 30 and 60 days in females.
Haematology examination revealed increased erythrocyte counts and a twofold increase in leukocytes
counts in 2% group of males and females compared to the controls. The increase in leukocytes was
due to increase of neutrophils. Cholesterol and albumin levels were signiﬁcantly lower than those in
the control group. GI transit times were decreased in aloe vera non-decolourised WLE exposed male
and female rats. For 2% group, transit time of male rats was 4.3 vs 11.5 h in the controls and of
females 6.2 vs 11 h. Statistically signiﬁcant lower absolute weights of brain, liver, heart, spleen and
thymus were recorded for males and female from 2%- and 3% groups compared to the controls. At
necropsy, increased incidence of mesenteric lymph node enlargement was recorded in the 2% and 3%
groups of both sexes but no information on statistical signiﬁcance was given. According to the authors,
microscopic examination showed lymphoid hyperplasia of the mesenteric lymph nodes in all treated
groups with the severity markedly increased in the 2%- and 3%-dose groups but no information on
statistical signiﬁcance was given. The incidence of Goblet cell hyperplasia of the large intestine was
increased in males and females from the treated groups compared to controls, but no information on
statistical signiﬁcance was given.
Emodin
Short-term (16-day) and subchronic (14-week) toxicity studies have been conducted in two rodent
species (mice and rats) within the US NTP on emodin (NTP, 2001).
Mice
Groups of B6C3F1 mice (5/sex per group, 6 weeks old) received for 15 (males) or 16 (females)
days 0, 600, 2000, 5,500, 17,000 or 50,000 mg emodin/kg diet (equal to daily doses of 0, 120, 400,
1,200 or 3,800 mg emodin/kg bw per day for males and to 0, 140, 530, 1,600 or 5,000 mg emodin/kg
bw per day for females; no calculation of the dose was done for the highest dietary concentration
because of high mortality in this group) (NTP, 2001). Discolouration (yellow or orange) of the urine
was observed in all groups and of the fur in groups receiving 5,500 mg emodin/kg diet or greater. Two
males from 17,000 mg emodin/kg diet group and one female each from groups of 5,500 mg emodin/
kg diet or greater 20,000 mg emodin/kg diet, manifested diarrhoea. None of mice from the 50,000 mg
emodin/kg diet survived to the end of the study. Body weights of males and females from 17,000 mg
emodin/kg diet group were signiﬁcantly lower than in controls. Macroscopic changes were seen in
gallbladder and kidneys. The authors reported the following statistically signiﬁcant differences in
relative organs weights compared to the control group: (a) lower absolute and thymus weights of
males and females from 5,500 and 17,000 mg emodin/kg diet groups, (b) increased relative weights
of testis of males from 17,000 mg emodin/kg diet group, and (c) increased relative weights of kidneys
of females from 17,000 mg emodin/kg diet group. There were also differences in relative weights of
other organs but the authors attributed these to body weight differences. The microscopic changes
observed in males and females were: inﬂammation of gallbladder from 5,500 mg emodin/kg diet or
higher groups, golden yellow crystalline material in gallbladders in 17,000 mg emodin/kg diet group,
and renal changes such as crystalline material and associated inﬂammation, necrosis, and ﬁbrosis from
5,500 mg emodin/kg diet or higher groups.
In another study, groups of B6C3F1 mice (10/sex per group, 6 weeks old) received for 14
consecutive weeks 0, 312.5, 625, 1,250, 2,500 or 5,000 mg emodin/kg diet (equal to daily doses of 0,
50, 100, 190, 400 or 800 mg emodin/kg bw per day for males and to 0, 60, 130, 240, 500, or
1,100 mg emodin/kg bw per day for females) (NTP, 2001). All mice survived until termination.
Statistically signiﬁcantly lower body weights and body weight gains were recorded for males from
2,500 and 5,000 mg emodin/kg diet groups as compared to controls. Discolouration (yellow or orange)
of urine, skin and fur was seen in all groups. Coloured faeces were seen in males from groups
receiving dietary doses of 321.5, 2,500 or 5,000 mg emodin/kg and in females treated with 1,250 mg
emodin/kg diet or greater. Diarrhoea was seen in the two high-dose groups of males and in females
treated with 1,250 mg emodin/kg diet or greater. Sperm motility and vaginal cytology results from all
treatment groups were not statistically signiﬁcantly different from the controls. The authors reported
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the following differences in relative organs weights compared to the control group: (a) increased
relative kidney weights of males from 1,250 mg emodin/kg diet group, (b) increased relative lung
weights of males from 625 mg emodin/kg diet or greater group, (c) increased relative liver weights of
females treated with 625 mg emodin/kg diet or greater. There were also differences in relative weights
of other organs but the authors attributed these to body weight differences. According to the authors,
the microscopic change related to treatment with emodin was nephropathy. The incidence and severity
of nephropathy were statistically signiﬁcantly increased in male and female mice treated with
1,250 mg emodin/kg diet or higher dietary doses. The incidence of renal tubule pigmentation was
statistically signiﬁcantly increased in males exposed to 625 mg emodin/kg diet or higher dietary doses
and in females exposed to a dietary dose of 1,250 mg/kg diet or higher.
Rats
Groups of F344/N rats (5/sex per group, 6 weeks old) received for 15 (males) or 16 (females) days
0, 600, 2,000, 5,500, 17,000 or 50,000 mg emodin/kg diet (equal to daily doses of 0, 50, 170, 480,
1,400 or 3,700 mg/kg bw per day for males and to 0, 50, 160, 460, 1,250 or 2,000 mg/kg bw per day
for females) (NTP, 2001). Three females from the highest dose group died before termination.
Emaciation and inactivity were recorded for females from the highest dose group. All males and most
females from 17,000 and 50,000 mg emodin/kg diet had diarrhoea. Discolouration of fur (pink to
yellow) was seen in males and females from dietary dose groups of 2,000 mg emodin/kg diet or
greater, of anus area (reddish-brown) in males and females from dietary dose groups of 17,000 and
50,000 mg emodin/kg diet, and of urine (pink to yellow) in females from all treated groups. Feed
intake in all treated groups of either sex was lower compared to controls. Body weighs and body
weight gains were statistically signiﬁcantly lower in males and females receiving dietary doses of
5,500 mg emodin/kg diet or greater. The reported statistically signiﬁcant differences in organs weights
compared to the control group were for males: (a) decreased absolute and increased relative kidney
weights from 17,000 and 50,000 mg emodin/kg diet groups, (b) increased relative testis weight from
5,500 mg emodin/kg diet group or greater, (c) decreased absolute thymus weights from 5,500 mg
emodin/kg diet group or greater, and decreased relative thymus weight from 17,000 and 50,000 mg
emodin/kg diet groups. For females, differences in organ weights included (a) increased relative kidney
weights from 17,000 and 50,000 mg emodin/kg diet groups, (b) decreased absolute thymus weight
17,000 and 50,000 mg emodin/kg diet groups, and decreased relative thymus weight in 50,000 mg
emodin/kg diet group. At necropsy, kidneys from some of the animals from two highest dose groups
were mottled and contained yellowish foci. Microscopic changes in the kidneys, recorded in one male
and two females from 17,000 mg emodin/kg diet group and two males and ﬁve females from
50,000 mg emodin/kg diet group were suppurative inﬂammation, ﬁbrosis, renal tubule epithelial
hyperplasia, renal tubule dilatation and necrosis. The severity of these changes appeared to increase in
a dose-dependent manner. In some renal tubules, elongated clefts were seen presumably after the
presence of crystals of emodin or a metabolite.
In another study, groups of F344/N rats (10/sex per group in the core study and 10/sex per group
in a special study; 6 weeks old) received for 14 consecutive weeks 0, 312.5, 625, 1,250, 2,500 or
5,000 mg emodin/kg diet (equal to daily doses of 0, 20, 40, 80, 170 or 300 mg emodin/kg bw per day
for males and females) (NTP, 2001). Statistically signiﬁcantly decreased feed intake was recorded only
in the ﬁrst week for males in the two high-dose groups and for females in the highest dose group.
Statistically signiﬁcantly lower body weights and body weight gains were recorded for males from
2,500 and 5,000 mg emodin/kg diet groups and for females from 1,250 mg emodin/kg diet group or
greater. Discolouration of fur (yellow to red) was observed in all groups. Coloured faeces were
observed only in one male from 5,000 mg emodin/kg diet group. Diarrhoea was observed in all
exposed groups at various times. Statistically signiﬁcantly increased platelet counts were recorded for
males and females from 2,500 mg emodin/kg diet group and in segmented neutrophils counts in
females from 2,500 and 5,000 mg emodin/kg diet groups. The oestrus cycle length was increased in
females from groups exposed to 1,250 mg emodin/kg diet or 5,000 mg emodin/kg diet. The sperm
motility was not statistically signiﬁcantly different in the treated males as compared to controls. The
statistically signiﬁcant differences in organs weights compared to the control group were for males: (a)
increased relative kidney weights from 1,250 mg emodin/kg diet group or greater, (b) increased
relative lung weights from 625 mg emodin/kg diet or greater, (c) increased relative testis weights from
2,500 and 5,000 mg emodin/kg diet groups. For females, differences in organ weights included (a)
increased relative kidney weights from 625 mg emodin/kg diet group or higher, and of absolute kidney
weights in the 5,000 mg emodin/kg diet group, (b) increased relative liver weights from 625 mg
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emodin/kg diet group or higher, (c) increased absolute thymus weights of females from 2,500 and
5,000 mg emodin/kg diet groups. The differences in other organs weights were considered by the
authors of the study as incidental and not related to treatment. According to the authors, treatment-
related microscopical changes were in the kidneys. These included (a) pigment in renal tubules in
males and females from 1,250 mg emodin/kg diet group or greater, and the severity of pigmentation
increased with the dietary doses, and (b) increased incidences of hyaline droplets in the cortical
epithelial cytoplasm in all male groups and in females from 312.5, 625 or 1,250 mg emodin/kg diet
groups.
Sennosides
Mice
Groups of male and female C57BL/6NTac mice (N = 5/sex per group, 6–7 weeks old at the start)
received in basal diet 0, 625, 1250, 2500, 5000 or 10000 mg senna/kg diet (equal to 0, 115, 245, 490,
975 and 2,075 mg/kg bw per day for males and 0, 160, 310, 625, 1,190 and 2,570 mg/kg bw per day
for females) for 29 days (Surh et al., 2013). The content of active components of the used senna was
reported as: 0.7% (wt/wt) sennoside A, 1.3% sennoside B, 0.06% sennidin A and 0.03% sennidin B.
All mice survived to the scheduled termination. Body weight was comparable to that in controls and
feed intake was similar between all groups. No apparent treatment-related clinical symptoms were
reported. Absolute heart weights in all male groups and relative heart weights in males treated with
115, 975 and 2,075 mg senna/kg bw per day were lower than in the control group. Epithelial
hyperplasia was recorded in the caecum and colon of all treated groups of males and in the caecum,
colon and rectum of females receiving 625 mg senna/kg bw per day or higher.
3.2.3. Chronic toxicity and carcinogenicity
Aloe vera extracts
Feeding studies were in two rodent species (mice and rats) within the US NTP on aloe vera WLE
(NTP, 2013; Boudreau et al., 2013).
Mice
Groups of B6C3F1 mice (48/sex per group, 6 weeks old) received aloe vera non-decolourised WLE
(the bulk material malic acid content of 186–203 mg/g, aloin A content of 5.7–7.2 mg/g) in drinking
water at concentrations of 0, 1%, 2% or 3% (wt/wt) for 104 weeks. These concentrations provided
(as reported by the authors of the study) 0, 2.94, 6.95 and 11.76 g aloe vera non-decolourised whole
leaf extract/kg bw per day for males and 0, 2.18, 6.28 and 11.83 g aloe vera non-decolourised whole
leaf extract/kg bw per day for females, corresponding to 0, 18.7, 44.82 and 75.85 mg aloin A/kg bw
per day for males and 0, 14.06, 40.5 and 76.3 mg aloin A/kg bw per day for females.25
The survival of the controls and treated groups of either sex was comparable. The body weights of
males in the treated groups were lower than in the controls through the study but the differences did
not exceed 10% of the control body weights. The mean body weights of all treated male groups were
statistically signiﬁcantly lower compared to the controls (the 1% group 40.9 g (p < 0.01); the 2%
group 40.7 g. (p < 0.01); the 3% group 40.3 g (p < 0.001) vs 43.2 g). The body weights of treated
female groups throughout the study and the mean for the study period were not statistically
signiﬁcantly lower compared to the controls. Feed intake of the controls and treated groups of either
sex was comparable. Polydipsia was observed in all male and female treated groups compared to the
controls throughout the study. Mean daily water intake (g/day) in the 1%, 2% and 3% groups was for
males 12.0 (p < 0.05), 14.2 (p < 0.01), 15.8 (p < 0.001) vs 7.8 in the control group, and for females
8.3 (p < 0.001), 11.7 (p < 0.001), 14.1 (p < 0.001). When expressed in g/kg bw per day, although
markedly increased in a dose-dependent manner the water intake of males and females was not
statistically different from the controls (males: 181, 294, 348 and 392; females: 147, 218, 314 and 394
in the controls, 1%, 2% and 3% groups). The treatment-related statistically signiﬁcantly increased
incidence of goblet cell hyperplasia of the large intestine was recorded for males and females. The
incidences in the control, 1%, 2% and 3% groups were: (a) in the ascending colon of males 2/44
(4%), 16/44 (36%), 20/45 (44%), 19/42 (45%) and of females 1/44 (2%), 15/43 (35%), 20/44
(46%), 25/43 (58%); (b) in the transverse colon of males 4/47 (9%), 14/44 (32%), 21/45 (47%),
25 For these calculations, the mean content of aloin A (6.45 mg/g) was used.
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22/43 (51%) and of females 2/42 (5%), 18/42 (43%)23/44 (52%), 26/43 (61%); (c) in descending
colon of males 0/47 (0%), 7/44 (16%), 12/45 (27%), 17/43 (40%) and of females 0/43 (0%), 4/43
(9%), 7/44 (16%), 17/43 (40%); (d) large intestine all site goblet cell hyperplasia of males 4/47 (9%),
17/44 (39%), 22/45 (49%), 22/44 (50%) and of females 3/43 (7%), 19/43 (44%), 24/44 (55%), 28/43
(65%). The incidence of mesenteric lymph node cellular inﬁltration was statistically signiﬁcantly
increased only in males from 3% group (6/43 (14%) vs 0/48 (0%) in the controls). No treatment-
related neoplastic changes were recorded in this study. The Panel considered hyperplastic changes in
the large intestine as attributable to the treatment with Aloe vera non-decolourised WLE.
Rats
Groups of F344/N rats (48/sex per group, 6 to 7 weeks old) received aloe vera non-decolourised
whole leaf extract (the bulk material malic acid content of 186–203 mg/g, aloin A content of
5.7–7.2 mg/g) in drinking water at concentrations of 0, 0.5%, 1% or 1.5% (wt/wt) for 104 weeks.
These concentrations provided (as reported by the authors of the study) 0, 0.25, 0.62 and 1.136 g
aloe vera non-decolourised whole leaf extract/kg bw per day for males and 0, 0.33, 0.73, and 1.28 g
Aloe vera non-decolourised whole leaf extract/kg bw per day for females, corresponding to 0, 0.25,
0.65 and 1.136 mg aloin A/kg bw per day for males and 0, 0.33, 0.73 and 1.28 mg aloin A/kg bw per
day for females.25
The survival of the controls and treated groups of either sex was comparable except for females
from the 1.5% group for which the survival was statistically signiﬁcantly reduced (91.9 vs 95.7 weeks
in the control group). Mean body weights of males and females showed statistically signiﬁcantly
dose-related decreases throughout the study. Mean body weights for the study in 0%, 0.5%, 1% and
1.5% groups were 457.5 g, 452.2 g, 436.6 g (p < 0.001) and 412.7 g (p < 0.001) for males and
276.7 g, 276.4 g, 260.1 (p < 0.001) and 238.5 g (p < 0.001) for females. Feed intake was statistically
signiﬁcantly decreased in the high-dose males and in mid- and high-dose females (g/day for males:
18.9, 18.5, 18.6, 17.8 p < 0.001 and for females 13.5, 13.3, 13.0 p < 001, 12.3 p < 0.001). Polydipsia
was notable in males from 1% and 1.5% groups and in females from 1.5% group. Mean daily water
intake (g/day) in the 0.5%, 1% and 1.5% groups was for males 22.5, 27.0 (p < 0.001), 31.0
(p < 0.001) vs 21.7 in the control group, and for females 18.2, 19.1, 20.4 (p < 0.01). When expressed
in g/kg bw per day, although increased in a dose-dependent manner the water intake of males and
females was not statistically different from the controls (males: 47.6, 49.7, 61.8 and 75.1; females:
64.8, 65.7, 73.4 and 85.3 in the controls, 0.5%, 1% and 1.5% groups). Noteworthy microscopic
non-neoplastic changes were reported in the large intestine and associated mesenteric lymph nodes of
the treated groups of both sexes. Statistically signiﬁcant dose-related increases in the incidences of
mucosal hyperplasia of the proximal, ascending, transverse and descending colon and caecum were
reported for males and females. The incidences in the control, 0.5%, 1%, and 1.5% male groups
were: (a) for the proximal colon: 0/44 (0%), 29/44 (65.9%), 36/46 (78.3%), 32/41 (78.0%); (b) for
the caecum: 0/47 (0%), 4/48. (8.3%), 17/47 (36.2%), 27/48 (56.3%); (c) for the ascending colon:
0/47 (0%), 40/48 (83.3%), 35/46 (76.1%), 39/46 (84.8%); (d) for the transverse colon: 0/47 (0%),
40/48 (83.3%), 33/46 (71.8%), 42/46 (91.3%) and (e) for the descending colon: 0/47 (0%), 17/48
(35.4%), 18/46 (39.1%), 27/47 (57.4%). The incidences in the control, 0.5, 1, 1.5% female groups
were: (a) for the proximal colon: 0/43 (0%), 30/45 (66.7%), 33/42 (78.6%), 32/39 (82.1%); (b) for
the caecum 0/47 (0%), 4/48 (8.3%), 17/47 (36.2%), 27/48 (56.3%); (c) for the ascending colon:
0/47 (0%), 40/48 (83.3%), 35/46 (76.1%), 39/46 (84.4%); (d) for the transverse colon: 0/47 (0%),
40/48 (83.3%),33/46 (71.1%) and (e) for the descending colon: 0/47 (0%), 17/48 (35.4%), 18/46
(39.1%), 27/47 (57.4%). Furthermore, statistically signiﬁcant dose-related increases in the incidences
of mucosal hyperplasia were reported for the forestomach, glandular stomach, ileum, and rectum of
females and for the glandular stomach, jejunum and rectum of males. In mesenteric lymph nodes,
signiﬁcant dose-trend incidence increases were reported for cystic degeneration for both sexes. The
incidences were 8/47 (17%), 11/48 (22.9%), 42/48 (87.5%), 41/48 (85.4%) for males and 0/46 (0%),
16/47 (34%), 40/48 (83.3%), 43/47 (91.5%) in the control, 0.5%, 1% and 1.5% groups. For males
also, a signiﬁcant dose-trend increased incidences were reported for hyperplasia in mesenteric lymph
nodes: 0/47 (0%), 0/48 (0%), 1/48 (2.1%), 4/48 (8.3%) (linear trend test p < 0.01). In the caecum,
signiﬁcant dose-trend increases in the incidences of dilatation (linear trend test p < 0.001) were
reported for males and females.
The neoplastic changes, considered by the authors as treatment-related, were observed in the
large intestine. These were adenomas and carcinomas conﬁned within the mucosal wall and they did
not metastasize to regional mesenteric lymph nodes or more distal sites. For males, statistically
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signiﬁcant dose-related increases in the incidence of adenomas were reported in the proximal,
ascending and transverse colon, and in the caecum and the incidences were statistically signiﬁcantly
higher in the 1% and 1.5% groups compared to the control group. The incidences of adenomas in the
control, 0.5%, 1%, and 1.5% male groups were: (a) for the proximal colon: 0/44 (0%), 0/44 (0%),
7/46 (15%, p < 0.05), 10/41 (24%, p < 0.01); (b) for caecum: 0/46 (0%), 0/45 (0%), 8/48 (17%,
p < 0.01), 8/48 (17%, p < 0.001); (c) for ascending colon: 0/47 (0%), 0/47 (0%), 19/48 (40%,
p < 0.001, 8/46 (17%, p < 0.01) and (d) for transverse colon: 0/47 (0%), 0/47 (0%), 6/47 (13%,
p < 0.05), 3/47 (6%). Statistically signiﬁcant dose-related increases in the incidence of carcinomas
were reported in the proximal and ascending colon of males but the statistical signiﬁcance in the
incidence was recorded only in the ascending colon in the 1.5% group. The incidences of carcinomas
in the control, 0.5%, 1%, and 1.5% male groups were: (a) for the proximal colon: 0/44 (0%), 0/44
(0%), 4/46 (9%), 4/41 (10%); (b) for caecum: 0/46 (0%), 0/45 (0%), 1/48 (2%), 2/48 (4%); (c) for
ascending colon: 0/47 (0%), 0/47 (0%), 4/48 (8%), 8/46 (17%) p < 0.01; and (d) for transverse
colon: 0/47 (0%), 0/47 (0%), 1/47 (2%), 1/47 (2%). Signiﬁcant dose-related increases in the
incidences for all adenomas, all carcinomas or all adenomas and all carcinomas of the large intestine,
and statistically signiﬁcantly higher incidences for the 1% and 1.5% male groups compared to the
control group were reported. The incidences of tumours of the large intestine (all sites) in the control,
0.5%, 1% and 1.5% male groups were (a) for all adenomas: 0/47 (0%), 0/48 (0%), 26/48 (54%,
p < 0019) and 23/48 (48%, p < 0.001); (b) for all carcinomas: 0/47 (0%), 0/48 (0%), 10/48 (21%,
p < 0.001), 14/48 (29%, p < 0.001) and (c) for all adenomas and all carcinomas: 0/47 (0%), 0/48
(0%), 28/48 (58%, p < 0.001), 31/48 (65%, p < 0.001).
For females, statistically signiﬁcant dose-related increases in the incidence of adenomas were
reported in the proximal and ascending colon, and in the caecum. The incidences were statistically
signiﬁcantly higher in the proximal colon in the 1% and 1.5% groups and in the ascending colon and
the caecum in the 1% group compared to the control group. The incidences of adenomas in the
control, 0.5%, 1%, and 1.5% female groups were: (a) for the proximal colon: 0/43 (0%), 0/45 (0%),
4/42 (10%, p < 0.05), 5/39 (13%, p < 0.05); (b) for caecum: 0/47 (0%), 0/48 (0%), 1/47 (2%), 6/48
(13%, p < 0.05) and (c) for ascending colon: 0/47 (0%), 0/48 (0%), 1/46 (2%), 5/46 (11%,
p < 0.05). Carcinomas were observed in the proximal colon only. There was a statistically signiﬁcant
dose-related increase in their incidences and a statistically signiﬁcantly higher incidence was reported
in the 1.5% group compared to the control group. The incidences of carcinomas in the proximal colon
were 0/43 (0%), 0/45 (0%), 2/42 (5%), 4/39 (10%, p < 0.05) in the control, 0.5%, 1% and 1.5%
female groups, respectively. For all adenomas, all carcinomas, or all adenomas or carcinomas of the
large intestine signiﬁcant dose trend increases in their incidences were reported and the incidence of
all adenomas or all adenomas or all carcinomas were statistically signiﬁcantly higher in the 1% and
1.5% groups compared to the control group. For all carcinomas a statistically signiﬁcantly higher
incidence was recorded only in the 1.5% group compared to the control. The incidences of tumours of
the large intestine (all sites) in the control, 0.5%, 1%, and 1.5% female groups were (a) for all
adenomas: 0/48 (0%), 0/48 (0%), 6/48 (13%, p < 0.05), and 13/48 (27%, p < 0.001), (b) for
all carcinomas: 0/48 (0%), 0/48 (0%), 3/48 (6%), 4/48 (8%, p < 0.05), and for all adenomas and all
carcinomas: 0/48 (0%), 0/48 (0%), 8/48 (17%, p < 0.01), 15/48 (31%, p < 0.001). The authors
considered that laboratory rodents did not develop spontaneous neoplasms of the colon and therefore
that ‘the combined results from this study suggest that the long-term exposure of the rats to the Aloe
vera whole-leaf extract induced insult to the intestinal tract and caused a progression of lesion types
from goblet cell hyperplasia to mucosal hyperplasia to adenoma and carcinoma in the large intestine’
(Boudreau et al., 2013). The authors concluded that under conditions of this bioassay ‘there was a
clear evidence of carcinogenic activity of nondecolorized a whole leaf extract of aloe vera in male and
female F344/N rats based upon increased incidences of adenomas and carcinomas of the large
intestine’. The Panel considered that the long-term exposure of rats to Aloe vera non-decolourised
whole leaf extract at concentrations of 1% and 1.5% (wt/wt) in drinking water resulted in
development of adenomas and carcinomas in the large intestine.
In a study by Matsuda et al. (2008), four groups of Wistar Hanover rats (10–14/sex per group,
6 week of age at the start of the study) received 0%, 0.16%, 0.8% or 4% of whole leaf powder of
Aloe (Aloe arborescens Miller var. natalensis Berger, content of aloin 0.83% and of 1.91% of aloenin)
in the diet for 1 year. These dietary concentrations of the whole leaf powder of Aloe provided,
according to the authors, the test compound in mean daily doses of 87.70  6.08, 431.35  33.76
and 2,212.17  141.65 mg/kg bw for males and of 109.57  5.92, 540.57  31.16 and
2,681.39  149.33 mg/kg bw for females from the low-, mid- and high-dose groups. The
Safety assessment of hydroxyanthracene derivatives
www.efsa.europa.eu/efsajournal 54 EFSA Journal 2018;16(1):5090
concentrations of aloin were 0.0009%, 0.0039%, and 0.0179%, and of aloenin 0.0022%, 0.0133%
and 0.0663% in the diet containing 0.16%, 0.8% and 4% of the whole leaf powder of Aloe,
respectively, corresponding to 0, 0.00078, 0.016, 0.395 mg aloin/kg bw per day for males and 0,
0.00098, 0.021, 0.479 mg aloin/kg bw per day for females. The content of aloin and aloenin was not
determined in the control diet. All animals survived to the termination but the authors reported that
several samples were lost (the type of the samples and the reason for the loss was not informed) and
therefore the number of animals evaluated for the various parameters ranged from 6 to 14. In
the high-dose group, diarrhoea was observed in males and loose stool in females through the
experimental period, body weights of females were statistically signiﬁcantly lower compared to the
controls and body weights of males were reported to show a tendency to decrease. The feed intake
was similar in all groups. From results of haematology analyses, only a statistically signiﬁcant increase
in leucocytes in the high-dose male group and statistically signiﬁcant decrease in haemoglobin in the
mid- and high-dose female groups as compared to the controls were considered treatment related by
the authors of the study. From results of clinical chemistry analyses, only treatment-related changes
compared to the controls were, according to the authors, a statistically signiﬁcant decrease in
inorganic phosphorus in the mid- and high-dose male groups and of inorganic phosphorus and calcium
in the high-dose female group. For males, no toxicologically signiﬁcant changes in absolute and
relative organ weights as compared to controls were recorded, as the only statistically signiﬁcant
change was the increase in the relative liver weight in the mid-dose group as compared to the control.
The Panel noted lack of a dose response and of histological changes in the liver. For females, no
toxicologically signiﬁcant absolute organ weight changes as compared to controls were recorded, as
the only statistically signiﬁcant change was the decrease in the absolute adrenal weight in the
high-dose group without a dose response or histological changes in adrenals. The changes in relative
organ weights of females as compared to controls were statistically signiﬁcant higher relative brain and
heart weights in the mid- and high-dose groups, and a statistically signiﬁcantly higher relative weight
of the kidneys in the high-dose group. According to the authors, these changes were of no
toxicological signiﬁcance as they were the results of lower body weights of these groups compared
with controls. The Panel agreed that the increases in the relative weights of these organs were
secondary to the decreased body weight. At necropsy, swelling of ileocaecal lymph nodes was
observed in 70% males and 77.8% females from the high-dose group as compared to none in the
controls. Microscopical ﬁndings considered by the authors as toxicologically signiﬁcant and with
incidences statistically signiﬁcantly higher than those in the controls were: (a) a severe dilatation of
lymph sinus in the swelled ileocaecal lymph nodes (60% for males and 77.8% in females vs 0% in the
controls), (b) yellow-brown pigmentation in ileocaecal lymph nodes (for males 90% vs 8.3%, and for
females 55.6% vs 0%), (c) sinus dilatation in mesenteric lymph nodes in the high-dose females (80%
vs 33.3%), (d) yellow-brown pigmentation in renal tubules in the high-dose group of either sex as
compared to the controls (for males 90% vs 8.3%, and for females 80.0% vs 28.6%). There was no
statistically signiﬁcant differences in the incidences of the tumours between the treated groups and the
controls of the same genders. No hyperplastic or neoplastic changes were found in the GI system of
the treated and controls animals. The authors concluded that the diarrhoea, lower body weight,
morphological changes in ileocaecal lymph nodes and yellowish pigmentation in renal tubules in both
sexes from the high-dose group might have been due to anthranoid in Aloe. Considering that changes
in some haematological and clinical chemistry parameters were recorded also in the mid-dose group of
males and females, the authors identiﬁed a no-observed-adverse-effect-level (NOAEL) of 0.16% in the
diet of the whole leaf powder of Aloe, equal to 87.70 and 109.7 mg whole leaf powder of aloe/kg bw
per day for males and females, respectively. The Panel concurred with the conclusions of the authors.
Three groups of Wistar Hanover rats (52–58/sex per group, 6 week of age at the start of the
study) received 0, 0.8% or 4% of whole leaf powder of Aloe (Aloe arborescens Miller var. natalensis
Berger, content of aloin 0.83% and of 1.91% of aloenin) in the diet for 2 years (Yokohira et al., 2009).
These dietary concentrations of the whole leaf powder of Aloe provided, according to the authors, the
test compound in mean daily doses of 374.5  152.7 and 2,073.9  731.9 mg/kg bw for males and in
462.9  138.8 and 2,509.6  701.7 mg/kg bw for females from the low- and the high-dose groups.
The concentrations of aloin were 0.0009% and 0.0179%, and of aloenin 0.0022% and 0.0663% in the
diet containing 0.8% and 4% of the whole leaf powder of Aloe, respectively, corresponding to 0,
0.0033, 0.37 mg aloin/kg bw per day for males and to 0, 0041, 0.449 mg/kg bw per day for females.
The content of aloin and aloenin was not determined in the control diet. The Panel noted that the
same dietary preparations were used in the 1-year chronic toxicity study (Matsuda et al., 2008) and
the 2 year carcinogenicity study (Yokohira et al., 2009) but that the dietary levels of aloin and aloenin
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reported present in the 0.8% carcinogenicity study diet is that given for the 0.16% chronic toxicity
study diet. The levels of aloin were also reported to be approximately 20 fold lower in the 0.8% diet
than the levels in the 4% diet in the carcinogenicity study, rather than the expected approximate 5
fold lower level. The Panel therefore considered that the dietary aloin and aloenin content in the 0.8%
group in the carcinogenicity study were incorrect and presumed the dietary data given in the chronic
toxicity study (Matsuda et al., 2008) was correct and applicable for both the chronic toxicity and
carcinogenicity studies. The survival was 67%, 77%, 79% for males and 59%, 67% and 77% for
females from 0, 0.8% and 4% groups. The difference in the survival rate was statistically signiﬁcant in
the high-dose females as compared to the control and to the low-dose groups. Diarrhoea was
observed in the high-dose males and loose stool in the high-dose females through the whole
experimental period. Body weights of males and females in the high-dose group were statistically
signiﬁcantly lower compared to the controls but the feed intake was similar in all groups. From
haematology parameters the only differences to controls were signiﬁcant increases in haemoglobin
(13.4  1.8 vs 11.7  3.5 control, p < 0.05) and platelet count (135  24.6 vs 114.3  24.8,
p < 0.05) of 4% group males. Clinical chemistry analyses revealed signiﬁcant decreases in aspartate
transaminase (AST), Na in the 4% male group and of Cl in the 0.8% and 4% male groups. Albumin/
globulin ratio was statistically signiﬁcantly increased in the 4% female group and Cl was signiﬁcantly
decreased in 0.8% female group. Statistically signiﬁcant differences to the controls in organ weights
were: increased relative liver weight of 4% males, increased absolute and relative spleen weights of
0.8% and 4% males (but without a dose response), and increased relative weight of uterus in 4%
females. Noteworthy microscopic non-neoplastic changes as compared to the controls were for
males statistically signiﬁcantly increased incidences of dilatation of sinus in mesenteric lymph nodes in
0.8% and 4% groups (14/39, 31/42 vs 5/38 in the control group, p < 0.05 and p < 0.01), of
thickening of colon epithelium in 0.8% and 4% groups (10/39, 34/42 vs 0/38, p < 0.01); of
yellow-brown pigmentation of renal tubules (18/39, 36/42 vs 5/38, p < 0.01). Noteworthy microscopic
non-neoplastic changes as compared to the controls were for females statistically signiﬁcantly
increased incidences of dilatation of sinus in mesenteric lymph nodes (38/45 vs 3/40, p < 0.01), and
thickening of colon epithelium (31/45 vs 0/40, p < 0.01) in the 4% group and of yellow-brown
pigmentation of renal tubules in 0.8% and 4% groups (33/42, 43/45 vs 18/40, p < 0.01). In addition
atypical hyperplasia in colon was recorded in the 4% male group (5/42 vs 0/38, p < 0.05) and in the
4% female group (3/45 vs 0/40, p > 0.05). Noteworthy microscopic neoplastic changes were
adenomas (3/42) and a carcinoma (1/42) in colon of males and adenomas in colon of females (3/45)
from 4% group, one adenocarcinoma in caecum (1/42) and one adenoma (1/42) in rectum in the 4%
male group compared to none in the control and 0.8% groups. There were no signiﬁcant differences
in the incidences of other tumours between the treated groups of males and females as compared to
controls. The authors concluded that the whole leave powder of Aloe ‘exerted equivocal carcinogenic
potential at 4% high dose level in the colon in the 2-year carcinogenicity study in rats. Aloe is not
carcinogenic at non-toxic dose levels and that carcinogenic potential at 4% high-dose on colon is
probably due to irritation of the intestinal tract by diarrhoea’. The Panel considered that the long-term
exposure of rats to whole leaf powder of Aloe at concentration of 4% (wt/wt) in the diet resulted in
development of adenomas and carcinomas in the large intestine. The Panel agreed with the authors
that irritation of the intestinal tract manifested clinically as diarrhoea could play a role in the aetiology
of the tumours observed in the large intestine.
Emodin
Feeding studies were conducted in two rodent species (mice and rats) within the US NTP on
emodin (NTP, 2001).
Mice
Groups of B6C3F1 mice (60/sex per group, 6 weeks old) received for 105 weeks dietary doses of
emodin which were for males 0, 160, 312, or 625 mg/kg diet and for females 0, 312, 625 or
1,250 mg/kg diet (equal to daily doses of 0, 15, 35, or 70 mg emodin/kg bw per day for males and 0,
30, 60, or 120 mg emodin/kg bw per day for females) (NTP, 2001). Clinical appearance, survival, feed
intake and body weights of treated and control males and females were similar during the study.
The noteworthy non-neoplastic changes were reported in kidneys. The statistically signiﬁcantly
increased incidences of renal tubule pigmentation were recorded after 12 and 24 months in all treated
male groups. The incidence of renal tubule pigmentation of females was statistically signiﬁcantly
increased in 625 and 1,250 mg emodin/kg diet groups after 12 months and in all treated groups after
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24 months. Severities increased in dose related manner. The incidences of nephropathy were
statistically signiﬁcantly increased only in females in 1,250 mg emodin/kg diet group after 12 months
and in all treated groups after 24 months. Severities of nephropathy appeared to increase with
increasing concentrations.
Neoplastic changes in kidneys were observed in males only. These were renal tubular adenomas
and adenocarcinomas. The incidences of these tumours were not statistically signiﬁcantly increased
compared to the controls but the incidence of adenomas or carcinomas combined in the mid-dose
male group exceeded the historical control range. As renal tubular neoplasms are rare in male mice,
the authors considered the presence of these tumours as suggestive of a possible association with
exposure to emodin. The Panel noted that renal tubular hyperplasia, adenomas, and carcinomas are
considered to represent a morphologic continuum of proliferative lesions. Therefore, in case of
treatment relationship of these tumours, one could expect increased incidence of renal tubule
hyperplasia in the emodin treated groups. However, the incidences of renal tubule hyperplasia were
not statistically signiﬁcantly increased in the treated groups. On the other hand, because the data on
incidence of adenomas or carcinomas combined in the mid-dose male group exceeded the historical
control range, the Panel considered that treatment dependency of these tumours could not be
excluded.
Other neoplastic changes were malignant lymphomas and alveolar/bronchiolar carcinomas in males.
The incidences of both tumours were decreased as compared to the control group. According to the
authors, the incidence of malignant lymphomas in the study was at the lower end of the historical
control range. As the incidences of alveolar epithelial hyperplasia in the lungs were not decreased in
the treated males and no decreases were observed in female mice, the decrease in the incidences of
alveolar/bronchiolar carcinoma in males was not considered by the authors to be treatment-related.
The Panel concurred with this view.
Rats
Groups of F344/N rats (65/sex per group, 6 weeks old) received for 105 weeks 0, 280, 830 or
2,500 mg emodin/kg diet (equal to daily doses of 0, 110, 320 or 1,000 mg emodin/kg bw per day for
males and 120, 370 or 1,100 mg emodin/kg bw per day for females) (NTP, 2001). Clinical appearance,
survival, feed intake and body weights of treated and control males and females were similar during
the study. The statistically signiﬁcantly increased incidences of renal tubular hyaline droplets (a
non-neoplastic kidney change which was also seen in a 14-week study) were recorded after 6, 12 and
24 months in males and females from all treatment groups and of renal tubular pigmentation after
2 years in all treatment groups of males. The noteworthy neoplastic changes were Zymbal gland
(sebaceous gland) carcinomas, squamous cell carcinomas of the nose, pituitary gland adenomas and
mononuclear cell leukaemia. The incidences of Zymbal gland carcinomas were in males 0/50; 1/50,
0/50, 1/50 and in females 0/50, 0/50; 0/50, 3/50 for dietary dose groups of 0, 280, 830 and 2,500 mg
emodin/kg diet, respectively. The incidences in males from the low and the high-dose groups were
within the historical controls. The incidence in the female high-dose group exceeded the historical
control values. The latter could, according to the Panel, indicate relation to treatment, as Zymbal gland
carcinoma is not a common type of tumour in rats.
Squamous cell carcinomas were recorded in the nasal cavity of males from 2,500 mg emodin/kg
diet group (0/50, 0/50, 0/50, 2/50). These tumours are rare in F344/N rats (the range in historical
controls is 0-2%). However, the absence of preneoplastic lesions or other treatment-related lesions in
the nasal cavity indicated, according to the authors, that the squamous cell carcinomas were unrelated
to treatment. The Panel concurred with these considerations.
Another neoplastic ﬁnding, increased incidence of pituitary gland adenoma (pars distalis) in females
in 830 and 2,500 mg emodin/kg diet groups (15/49, 21/50, 25/49, 25/49) was considered by the
authors of the study as not treatment related because (a) the incidences in the treated groups were
similar to the historical control incidence, (b) the incidence in concurrent control was lower than in the
historical controls, (c) there were no increases in incidence of hyperplasia in the pituitary gland of
females and (d) there was no evidence of an increase in the incidence of proliferative lesions in male
rats. The Panel concurred with the considerations of the authors.
The fourth type of neoplastic lesion was mononuclear cell leukaemia (MNCL) with incidence in the
males and females from 2,500 mg emodin/kg diet group signiﬁcantly less than in the controls and
lower than in historical control females and at the lower end of the historical control range for males.
The Panel noted that MNCL (a) is a unique and common ﬁnding in the Fischer rat strain used by the
US NTP program, (b) the incidence of MNCL in the F344 rats is around 50% for males and around
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30% for females, with large variation from study to study, (c) that exposure to some genotoxic
carcinogens did not lead to an increase in MNCL in F344 rats, while a number of substances, which are
believed to be non-carcinogens, caused increase and (d) based on this MNCL in the F344 rats has
been considered of limited relevance for humans (Caldwell, 1999).
Overall, the Panel noted that in carcinogenicity studies with emodin in the diet by NTP (2001) no
treatment-related non-neoplastic or neoplastic changes in the GI system were reported at doses up to
70 or 120 mg/kg bw per day for male and females mice, respectively, and at doses up to 1000 or
1100 mg/kg bw per day for male and female rats, respectively.
Sennosides
Rats
Four groups of Sprague–Dawley rats (50/sex per group) received 0, 5, 15 or 25 mg/kg bw per day
of puriﬁed senna extract (total content of sennosides 94.7% by ﬂuorimetry USP method, or 35.7% of
total sennosides and 5.1% of other anthranoids by a reversed-phase HPLC with UV detection) in
drinking water for 104 weeks (Lyden-Sokolowski et al., 1993). Slight to moderate loose stool (referred
by the authors’ laxative effect of the sennosides preparation) was observed through the clinical phase
of the study in the high-dose group and it was more pronounced in males compared to females. Loose
stool was also occasionally recorded in the mid-dose males. The survival of the controls and the
treated was similar (23/5, 22/50, 25/50, 23/50 and 26/50, 29/49, 31/50, 27/50 for males and females
from the control, low-, mid- and high-dose groups, respectively). Body weight gain and body weights
of the high-dose males were statistically signiﬁcantly lower than those of the controls. Body weight
and body weight gains of females from all treated group were comparable to those of the controls.
Water intake of mid- and high-dose females was about 15% less than in the controls. No difference in
water intake was reported for treated males compared to controls. No treatment-related changes
haematology, clinical chemistry and urinalysis parameters were observed. Kidney weights of females
from mid- and high-dose groups were statistically signiﬁcantly increased compared to the controls
(absolute: 11% and 16%, relative 15% and 23% higher in mid- and high-dose groups). In males the
relative kidney weight was 14% higher in the mid-dose group only compared to the control. A higher
incidence of reactive mesenteric lymph node hyperplasia without dose-response relationship was
reported for treated rats sacriﬁced before the scheduled termination but the incidence of this lesion
was similar in the control and high-dose group at the termination. Therefore, the authors considered
reactive mesenteric lymph node hyperplasia of no biological relevance. There was no increase in the
incidence of neoplastic lesions between the control and high-dose group. According to the authors the
results did not indicate any relationship between long-term exposure to puriﬁed senna extract and
development of tumours in kidney, adrenal, liver or GI system. The high dose which was associated
with moderate laxative effect in the rat was 20–25 times the recommended clinical dose according to
the authors. The Panel considered that the puriﬁed senna extract used in this study was not
carcinogenic to rats under condition of this bioassay. The Panel noted that incidence of mesenteric
lymph node hyperplasia and of neoplastic lesions was not presented separately for each sex.
Sprague–Dawley rats (60/sex per group, body weight of 145–218 g for males and 120–165 for
females at the start of the study) received by gavage 0, 25, 100 or 300 mg senna preparation/kg bw
for 104 weeks (Mitchell et al., 2006). The senna preparation consisted of powdered Tinnevelly
senna pods containing 1.829% of sennosides A–D, 1.596% of potential rhein, 0.111% of potential
aloe-emodin, 0.014% of total emodin and 0.004% of total chrysophanol (sum of potential
hydroxyanthraquinones 1.725%). The survival of all treated groups of females and the low-dose group
of males was comparable to controls while it was lower in the mid- and high-dose group males. The
differences to controls in several parameters were recorded solely in the high-dose group: (a) body
weights were decreased and for females attained statistical signiﬁcance on several occasions, (b)
water intake was increased in both sexes and attained statistical signiﬁcance on several occasions, (c)
serum levels of potassium and chloride were increased, (d) urinary levels of sodium, potassium and
chloride were decreased and the urine was darker, (e) the faeces were reported as ‘mucoid’. At
necropsy dark discolouration of kidneys was observed in some animals of all treated groups with the
highest incidence in the high-dose group. By microscopy, a treatment-related and dose-dependent
pigment deposition within cortical tubular epithelia along with diffuse swelling and basophilia were
reported in the kidneys. In some kidneys, vacuolisation of tubular cells and increased fat deposition
were reported. In the large intestine and caecum, a treatment-related diffuse mucosal epithelial
hyperplasia with incidence increasing in a dose-dependent manner was reported. No treatment-related
Safety assessment of hydroxyanthracene derivatives
www.efsa.europa.eu/efsajournal 58 EFSA Journal 2018;16(1):5090
tumours were observed in GI tract or other organs. The authors concluded that senna was not
carcinogenic at doses up to 300 mg/kg bw given for 2 years to SD rats. The Panel concurred that the
powdered senna pods was not carcinogenic under conditions of this bioassay.
Nine groups of male Wistar rats (body weight of 120–140 g at the start of the study) received the
following treatment in an initiation–promotion study: group 1 (N = 10) served as a vehicle control; group
2 (N = 20) received 15 mg azoxymethane (AOM)/kg bw; group 3 (N = 10) 10 mg/kg bw senna pod
extract from Cassia angustifolia containing about 50% sennoside B (SE) by gavage, group 4 (N = 10)
100 mg SE/kg bw; group 5 (N = 10) 15 mg AOM/kg bw and 10 mg SE/kg bw; group 6 (N = 10) 15 mg
AOM/kg bw and 100 mg SE/kg bw; group 7 (N = 10) 15 mg AOM/kg bw; group 8 (N = 10) 10 mg SE/kg
bw; group 9 (N = 10) 15 mg AOM/kg bw and 10 mg SE/kg bw (Mascolo et al., 1999). The Panel noted
that there is no explanation in the study on the why ‘group 20 has twice the number of animals compared
to the other groups. AOM was dissolved in saline and given intraperitoneally on day 1 and 5. SE was
dissolved in water and given by gavage 6 times per week. Groups 2–6 were terminated after 13 weeks,
and groups 1 and 7–9 after 28 weeks. According to the authors, the doses of SE were chosen to induce
laxation (10 mg/kg bw) or diarrhoea (100 mg/kg bw). No aberrant crypt foci (ACF) were observed in
control rats or those treated with a low dose of SE for 13 or 28 weeks or with a high dose SE for
13 weeks (groups 1, 3, 4 and 8). In rats treated solely with AOM, ACF in the colon were recorded both
after 13 weeks (group 2) and 28 weeks (group 7) of treatment. In these groups, a single adenoma and
carcinoma in the colon were recorded after 13 weeks (incidence 10.5%) and 1 adenoma and 12
adenocarcinomas (incidence 55.5%) were reported after 28 weeks. In rats treated with AOM and a low
dose of SE (group 5), the number of ACF and tumours were similar to those in group 2 (initiated with
AOM) after 13 weeks and not statistically signiﬁcantly increased after 28 weeks (group 9 compared to
group 7). In group 6 treated with AOM and a high dose of SE for 13 weeks, statistically signiﬁcant
increases compared to group 2 (initiated with AOM) were recorded in number of ACF which consisted of
4 or more crypt (43.8  11.7 vs 29.3  17.4 in group 2), number of crypt per ACF (4.2  0.8 vs
2.5  0.3 in group 2), incidence of tumours (90% vs 10% in group 2), number of tumours in colon/rat
(3.20  2.4 vs 0.11  0.3) and number of carcinomas (19 vs 1). According to the authors the results
indicated that SE did not cause ACF in the colon nor had a tumour promoting effect at a dose, which
caused laxation while at a dose which caused diarrhoea SE increased number of colonic tumours in rats.
The Panel agreed with the authors and noted that the diarrhoeagenic dose appeared to promote
development of tumours initiated by AOM.
Mice
Groups of male and female C3B6.129F1-Tr53tm1BrdN12 haploinsufﬁcient (p53+/) mice received in
basal diet 0, 100, 300, 1,000, 3,000 or 10000 mg senna/kg diet (equal to 0, 12, 36, 120, 365 and
1,260 mg/kg bw per day for males and 0, 14, 42, 140, 435, and 1,520 mg/kg bw per day for females)
for 40 weeks (Surh et al., 2013). The content of active components of the used senna was reported
as: 0.7% (wt/wt) sennoside A, 1.3% sennoside B, 0.06% sennidin A and 0.03% sennidin B. Body
weights, feed intake and clinical ﬁndings were recorded weekly. Survival of all treated groups was
similar to that of controls. Differences in body weight in dosed groups did not exceed 10% of the
weight in the control group throughout the study. The absolute and relative liver weights of males
from the highest dose group were statistically signiﬁcantly lower than in the control group. Microscopic
examination revealed epithelial hyperplasia in the large intestine: (a) in males from the highest dose
group the incidence of epithelial hyperplasia in caecum (22/25) and colon (25/25) was statistically
signiﬁcantly higher than in the control group (0/25 in both locations); (b) in females a statistically
signiﬁcantly higher incidence was reported in the colon of the group receiving 435 mg senna/kg bw
per day and in the caecum and colon of the group receiving 1,520 mg senna/kg bw per day, the
highest dose tested. Neoplastic ﬁndings included osteosarcomas in males (0/25, 0/25, 0/25, 3/25, 2/25
and 0/25 in groups exposed to 0, 12, 36, 120, 365 and 1,260 mg senna/kg bw per day, respectively),
and in females (2/25, 2/25, 1/25, 3/25, 0/25 and 2/25 in the groups exposed to 0, 14, 42, 140, 435
and 1,520 mg senna/kg bw per day, respectively), and hepatocellular adenomas in males (1/25, 0/25,
5/25, 0/25, 2/25 and 1/25 in groups exposed to 0, 12, 36, 120, 365 and 1260 mg senna/kg bw per
day, respectively). The incidence of osteosarcomas in males did not exceed the range in historical
controls (0–12%). In females exposed to 140 mg senna/kg bw per day the incidence of osteosarcoma
exceeded the historical control range of 0–12% but the difference to the concurrent control was not
statistically signiﬁcant. The incidences of hepatocellular adenoma exceeded the historical control range
(4–11%) only in the males exposed to 36 mg senna/kg bw per day (20%) and this incidence was not
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statistically signiﬁcantly higher than that in the control group (4%). The authors considered increased
incidences of osteosarcoma and hepatocellular adenoma as not treatment-related ﬁnding. The
Panel concurred with this conclusion.
Danthron
Mice
Two groups of C3H/HeN male mice (20/group, 2 months old) received either basal diet or diet
containing 0.2% chrysazin (1,8-dihydroxy-9, 10-anthracenedione=danthron), a synthetic anthraquinone
(N = 18) for 540 days (Mori et al., 1986). This dietary concentration was equivalent to 300 mg/
chrysazin/kg bw per day according to EFSA ‘Guidance on default values to be used in the absence of
measured data’ (EFSA Scientiﬁc Committee, 2012). Nineteen mice from the control group survived
until the scheduled termination. One control mouse died of pneumonia soon after the start of
experimental feeding (no exact information on the day of death). In the 0.2% chrysazin group, 16
mice survived to the scheduled termination, 3 mice died of pneumonia during the ﬁrst 100 days of the
clinical phase of the study and one mouse died on day 510. The Panel noted that this mouse has to be
subjected to the necropsy and the samples must have been taken for microscopic examination as the
effective number of the mice in this group was reported as 17. Terminal body weights of the mice
were similar in both groups (27.6 g  2.9 (SD) and 27.5 g  3.0 in the control and the treated
groups, respectively). The mean absolute liver weight of the treated mice was statistically signiﬁcantly
increased compared to that in the control group (1.7 g  0.1 (SD) and 2.1 g  0.5, p < 0.05). At
necropsy, the caecal wall in all mice from the 0.2% chrysazin group was thickened and multiple polyps
were visible. In the liver, single or multiple nodules were seen in 5/19 control mice and in 9/17 treated
mice. The nodules in the controls were smaller. Microscopic examination revealed that in the caeca
with polyps all layers of the caecal wall were frequently penetrated with cystic epithelium–lined glands.
Penetration of the Peyer’s patches with these cystic glands was also frequently seen. Fibrosis with
inﬁltration of inﬂammatory cells was associated with these changes. Goblet cells were increased in
number and excess mucin was present intracellularly and in the dilated lumen of the glands. Similar
changes were recorded in the upper 1/3 part of the colon. These changes were referred by the
authors of the study as adenomatous hyperplasia; the incidences were 17/17 in caecum and 5/17 in
the colon vs 0/19 in the control group. Microscopic examination of the livers revealed that 5/19 control
mice had adenomas but no carcinomas while 9/17 treated had adenomas and 4/19 had carcinomas.
According to the authors, the adenomatous hyperplasia in the large intestine indicated ‘a certain
carcinogenic potency of chrysazin in mice’ and the liver tumour ﬁndings indicated that chrysazin
‘enhanced the progression of spontaneously occurring hepatocarcinogenesis’. The Panel noted the
limitation in the study design (e.g. low number of animals/group, only one sex) and the limited
reporting (e.g. no data on housing and environmental conditions, no data on body weight changes,
feed intake and calculated intake of the test compound, or on incidence of non-neoplastic changes
other than adenomatous hyperplasia in caecum and colon in GI system or other organs/tissues). The
Panel considered that the presence of hyperplastic lesions in the large intestine and increased number
of liver adenomas (the most common hepatic neoplasm in laboratory mouse, Harada et al., 1999) and
carcinoma (a common spontaneous hepatic neoplasm in mice; Harada et al., 1999, Doull et al., 1983;
as cited by Mori et al., 1986) in the treated group indicated that chrysazin was carcinogenic to C3H/
HeN male mice under conditions of this limited bioassay.
Rats
Two groups of male ACI rats (2 months old) received either basal diet (N = 15) or this diet added
1% chrysazin (1,8-dihydroxy-9, 10-anthracenedione = danthron), a synthetic anthraquinone (N = 18)
for 16 months (Mori et al., 1985). This dietary concentration was equivalent to 520 mg/chrysazin per
kg bw per day according to EFSA ‘Guidance on default values to be used in the absence of measured
data’ (EFSA Scientiﬁc Committee, 2012). Fourteen rats from the control group and 12 from 1%
chrysazin group survived to the schedules termination. One rat in the control group died of pneumonia
before one year of the study. In the treated group, two rats manifesting diarrhoea and diagnosed with
anaemia died during the ﬁrst 3 months of the study and additional four were lost before the
12 months. According to the authors of the study, the feed intake and body weights of control and
treated rats were similar during the study. The non-neoplastic changes were recorded in the treated
group only and included focal hyperplasia of the glandular epithelium of the colon and caecum (which
was recorded both in the animals which had not or had intestinal tumours; exact incidence not
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reported) and focal necrosis, ﬁbrosis, cystic lesions and bile duct proliferation in the liver (exact
incidences not reported). The neoplastic changes were recorded in colon and caecum of 7 from 12
survivors in 1% chrysazin group. Three animals had single adenomas of the colon, four animals had
single adenocarcinomas of the colon and one of these animals had in addition to adenomas in the
caecum. No tumours were recorded in the control group. The authors ascribed the tumours in the
large intestine to the treatment of chrysazin (referred by them as ‘pure anthraquinone’’ because (a)
untreated ACI rats did not develop spontaneous intestinal tumours as previously reported (Maekawa
and Odashima, 1975, as cited by the authors of the study), (b) the rats in the present study in the
chrysazin group developed mucosal hyperplasia in the colon and the caecum, a preneoplastic lesion,
and (c) both tumours and mucosal hyperplasia in the colon and the caecum were not recorded in the
concurrent control group. The Panel concurred with the authors’ interpretation of the results but
noticed the limitation in the study design (e.g. low number of animals/group, only one sex, shorter
duration of the clinical phase as compared to the recommendation in the internationally recognised
guidelines for a carcinogenicity study) and the limited reporting (e.g. no data on housing conditions,
no data on body weight changes, feed intake and calculated intake of the test compound, no exact
information on time of death/prescheduled termination due to moribund condition, or on incidence of
non-neoplastic changes).
3.2.4. Human Data
Colon cancer and laxatives use
The Panel is aware that evaluations of epidemiological studies addressing the potential association
between CRC and the use of laxatives have been done previously by EMA, (2007a,b,c,d, 2008a,b). It is
not the purpose of the Panel to re-examine in this opinion all available information on this topic and
therefore only studies published after 2006, or some older studies not mentioned in the past
evaluations will be discussed in detail below. The interested reader is thus advice to consult EMA for
details on all studies taken into account.
The ﬁndings of three epidemiological studies on laxatives use and CRC that were not reviewed by
EMA (2007a,b,c,d, 2008a,b) (Dukas et al., 2000; Watanabe et al., 2004; Kojima et al., 2004) and
studies after 2006 are described below (Park et al., 2009; Zhang et al., 2013; Citronberg et al., 2014).
Park et al. (2009), within the EPIC-Norfolk prospective study (UK) conducted a nested case–control
study to investigate the association between CRC and bowel habit and laxative use. Among the 25,663
subjects enrolled in the study aged between 45 and 79 years, 299 CRC invasive cases were identiﬁed
after 12 years of follow-up. Data on health and lifestyle characteristics such as height, weight,
smoking, physical exercise and diet were collected at baseline while data on bowel movement and
laxative use were collected after three years from the ﬁrst health examination. In the study, 159 cases
and 771 controls were included. In this study, laxative use (odds ratio (OR): 0.92; 95% CI: 0.44–1.93)
was not associated with CRC, after controlling for waist to hip circumference, body mass index (BMI),
smoking, energy intake, alcohol intake, dietary ﬁbre and total meat intake. Having loose stools
compared to soft stools was associated with an increased risk (OR: 2.80; 95% CI: 1.41–5.56). The
limitation of the study was the low response rate of cases (53%), the low number of cases and
the high number of missing data on laxative frequency (91% among cases and 89% among controls).
The strength of the study was the good control for confounding factors.
Zhang et al. (2013) examined the association between bowel movement frequency, laxative use
and the risk of colorectal cancer in two prospective cohort studies in the US. Data on demographic,
lifestyle factors and medical history was collected from 88,173 women aged 30–55 years (The Nurses’
Health Study (NHS)) and from 23,722 men aged 40–75 years (Health Professionals Follow-up Study
(HPFS)). Participants were asked how often they use laxatives including softeners, bulking agents, and
suppositories. In the follow-up period (8 years for the NHS and 10 years for HPFS), 2,012 incident
colorectal cancer cases were identiﬁed. Weekly and daily use of laxative vs never use was associated
with an increased risk for colorectal cancer, although not statistical signiﬁcant, in men (HR: 1.41; 95%
CI: 0.96–2.06, p trend = 0.07) but not in women (HR: 0.98; 95% CI: 0.81–1.20, p trend = 0.79), after
controlling for age, history of CRC, history of endoscopy, aspirin use, BMI, physical activity, post-
menopausal hormone use, processed meat intake, alcohol consumption, calcium, folate, vitamin D and
total energy. No association was found for infrequent bowel movement. The strength of the study was
the large sample size and the high completeness of follow-up (> 90%). The limitations of the study
were as follow: the lack of control in the multivariable analysis for fruit and vegetable intake and
smoking; no subdivision of laxatives by type and the method of cases identiﬁcation (self-report).
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Citronberg et al. (2014), investigated the use of non-ﬁbre and ﬁbre containing laxative in relation to
risk of CRC in a prospective cohort study (N = 364,418) conducted in Washington state (Vitamins and
lifestyle study (VITAL). Baseline standardised questionnaires on socio-demographic and lifestyle
characteristics and medical history including history of constipation, bowel movement frequency and
the use of non-ﬁbre laxatives (e.g. Ex-Lax, Correctol) and ﬁbre laxatives (e.g. Metamucil, Citrucel)
were mailed to all participants between 2000 and 2002. Among these, 72,214 subjects, aged
50–76 years, with no CRC, ulcerative colitis or Crowns diseases and intestinal polyposis answered the
questionnaire and participated in the study. In 2008, 558 incidence cases of invasive CRC were
identiﬁed via linkage to state cancer registries. After controlling for age, sex, race, education, physical
activity, BMI, ﬁbre, calcium, fruit and vegetable intake, red and processed meat intake, alcohol
consumption, caloric intake, smoking, NSAID use, aspirin, family history of CRC, colonoscopy/
sigmoidoscopy screening history, polyp removal, hormonal replacement therapy use (for women),
bowel movement and constipation, an increased risk was found for 10-year use of non-ﬁbre laxative vs
none or less than once a year (1–4 times yearly, HR: 1.49; 95% CI: 1.04–2.14; 5 times or more yearly,
HR: 1.43; 95% CI: 0.82–2.48, p trend = 0.05) and CRC in both man and women. Regarding ﬁbre
laxative use over the past 10 years, a protective effect was found HR: 0.44; 95% CI: 0.21–0.95).
Constipation and bowel movement frequency were not associated with CRC risk. The strength of the
study was the good control for confounding factors and the subdivision of non-ﬁbre and ﬁbre laxatives
while the limitations of the study was the lack of description of the subjects lost from follow-up.
Dukas et al. (2000), within the Nurses’ Health Study, studied the association between bowel
movement frequency, laxative use and the risk of colorectal cancer among 84,577 women,
36–61 years of age and free of cancer. After 12 years of follow-up, 611 incident cases of colorectal
cancer were documented. The information on cancer incidence was obtained by asking participants to
report a diagnosis of cancer of the colon or rectum every two years. Participants were also asked for
the permission to obtain relevant hospital records and pathology reports. After controlling for age,
BMI, ﬁbre intake, physical activity, post-menopausal status and hormone use and bowel movement
frequency, no association was found between weekly to daily laxative use and colorectal cancer
(HR = 1.00; 95% CI = 0.72, 1.40). However, for distal colon cancer, monthly laxative use was
associated with an increased risk (HR = 1.67, 95% CI = 0.95, 2.94, p trend = 0.55), although not
statistically signiﬁcant. The strength of the study was the large sample size while the limitations of the
study were the method of cases identiﬁcation (self-report), the lack of control for important
confounding factors (e.g. smoking and fruit and vegetable intake) and no information on types of
laxatives.
Watanabe et al. (2004) conducted a cohort study to investigate the association between constipation
and laxative use and the risk of colorectal cancer in subjects of 40–64 years old living in 14 municipalities
in Miyagi Prefecture in rural northern Japan. Out of the 41,670 enrolled in the study, 20,044 were men
and 21,626 were women. Information on health, diet, alcohol consumption, smoking and physical
activity was collected in the study. After seven years of follow-up, 251 incident cases of colorectal cancer
were identiﬁed by record linkage with the Miyagi Prefectural Cancer Registry. After the exclusion of
colorectal cancer cases diagnosed in the ﬁrst 3 years of follow-up and after controlling for confoundings
(education, smoking, alcohol consumption, BMI, family history of colorectal cancer, pork intake, green
vegetables intake, orange intake, walking), an increased risk of colorectal cancer was found for subjects
using two times weekly or more laxatives (HR: 2.40; 95% CI: 1.11–5.18) in comparison to non-users.
The risk of colorectal cancer for laxative users vs non-users was 1.31 (95% CI: 0.88–1.95). In this study,
constipation was associated with an increased risk for colorectal cancer (HR: 1.35, 95% CI: 0.99–1.84).
The strength of this study was the high response rate (91.7%) and the good control for confounding
factors. The limitation of the study was the lack of data on types of laxatives.
Kojima et al. (2004) investigated the association between bowel movement frequency, laxatives use
and the risk of colorectal cancer in a large cohort of 25,731 men and 37,198 women, living in 24
communities in Japan, aged 40–79 years. A self-administrated questionnaire that covered demographic
characteristics and lifestyle factors that included diet, tobacco smoking, alcohol consumption and
physical activity, bowel movement frequency and laxative use, was completed by each participant.
After the follow-up (average 7.6 years), 649 cases of colorectal cancer were identiﬁed from population
cancer registries. After controlling for age, education, BMI, intake frequency of green leafy vegetables,
alcohol, smoking status, walking and family history of colorectal cancer, an increased risk, although not
statistically signiﬁcant, was found for laxative use and the risk of colorectal cancer in both men (HR:
1.28; 95% CI: 0.89–1.86) and women (HR: 1.20; 95% CI: 0.85–1.69). Women reporting bowel
movement every 6 days or less had an increased risk of developing colorectal (HR: 2.47, 95%
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CI: 1.01–6.01) and colon cancer (HR: 2.52, 95% CI: 0.93–6.82). The limitations of this study were the
criteria of deﬁning laxatives use (use of it only over the past year), the lack of data on frequency,
duration and type of laxatives. Moreover, they did not control for aspirin use and hormone replacement
therapy. The strength of the study was the large sample size and low number of subjects lost in the
follow-up period (3.3%).
3.2.4.1. Interactions
Chronic use or abuse of laxatives including hydroxyanthracene derivatives preparations may lead to
hypokalaemia due to increased loss of potassium. This hypokalaemia, may increase the activity of
cardiac glycosides and interfere with the action of antiarrythmic agents (Haverkamp et al. 2002).
Concomitant use with medicinal products inducing hypokalaemia (e.g. diuretics, corticosteroids and
liquorice root) may aggravate electrolyte imbalance (EMA, 2007a,b,c,d, 2008a,b, 2017a,b).
Senna may cause mild abdominal discomfort such as colic or cramps. Prolonged use or overdosage
can result in diarrhoea with excessive loss of water and electrolytes, particularly potassium; there is
also the possibility of developing an atonic non-functioning colon. Anthraquinone derivatives may
colour the urine yellowish-brown at acid pH, and red at alkaline pH. Reversible melanosis coli has been
reported after chronic use. Similar adverse effects are reported also for aloe, even though with a more
drastic and irritant action (Martindale, online).26
Theoretically, all laxatives, can accelerate intestinal transit, and may modulate the normal
absorption of intestinally absorbed drugs. However, drug absorption in the small intestine is less likely
to be affected than absorption in the colon since intestinal transit changes with anthranoid laxatives
occur mainly in the colon.
Forty healthy premenopausal volunteers were randomly allocated into one of three groups. The ﬁrst
group took senna (dose not stated) for two menstrual cycles then, after a washout period, took wheat
bran for two further menstrual cycles. The second group did the reverse. The third group took
loperamide (dose not stated) for two menstrual cycles. A 4-day dietary record was kept; whole-gut
transit time was measured; stools and blood were taken at the beginning and end of each
intervention. Senna and increased intestinal transit and serum oestrone sulfate and total- and non-
protein-bound oestrone concentrations fell with senna. No signiﬁcant change in serum oestrogens was
seen with loperamide. The authors concluded that speeding up intestinal transit can lower serum
oestrogen concentrations (Lewis et al., 1997).
As reported in EMA (2008a,b), certain aglycone hydroxyanthracenes have been described to be
metabolised by liver cytochromes P450 whereas a rhubarb extract was able to inhibit MDR1 function in
tumour cells. However, the Panel considered that data available concerning such putative
pharmacokinetic interactions are too weak to draw some conclusions.
3.2.4.2. Clinical studies in special populations
Use in children
In the open-label controlled trial conducted by Nolan et al. (1991), 169 children with encopresis
were randomly allocated to receive multimodal (MM) therapy, which includes laxatives plus behaviour
modiﬁcation (n = 83) or behaviour modiﬁcation (BM) only (n = 86). Treatment protocol in the MM
group consisted of using different laxatives throughout two phases. Laxatives used in the ﬁrst phase
included Microlax® (sodium citrate 90 mg, sodium lauryl sulfoacetate 9 mg, sorbic acid 5 mg, glycerol,
sorbitol, distilled water) and bisacodyl. In the maintenance phase, patients received Agarol® (liquid
parafﬁn, phenolphthalein, benzoic acid, sorbic acid), senna granules, and/or bisacodyl tablets. After
12 months of follow-up, 42 (51%) of the MM group vs 31 (36%) of the BM group (p = 0.079) had
achieved remission, while 52 (63%) vs 37 (43%) (p = 0.016) had achieved at least partial remission.
Laxative treatments safety or tolerability data were not evaluated and limited information concerning
senna were provided in the publication. Moreover, conclusions lack generalisability as they are
applicable to children with encopresis rather than constipated children in general.
In a randomised, single-blinded study conducted by Dahshan et al. (1999), the safety and the
efﬁcacy of three different bowel preparations (Group A: Magnesium citrate with X-Prep® and clear
liquid diet; Group B: Dulcolax® and Fleet® enema without dietary restriction. Group C: Golytely with
clear liquid diet) were assessed in children (aged between 3 and 20) undergoing colonoscopy. While
colon cleansing was superior in groups A and C compared to group B, tolerance and compliance were
26 https://www.medicinescomplete.com/mc/martindale/2009/
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signiﬁcantly better in groups A and B. Patients in group C reported adverse effects more frequently
compared to groups A and B. Although magnesium citrate and X-Prep® treatment combination was
efﬁcacious and well-tolerated, the efﬁcacy and tolerability of senna cannot be inferred since it was
given in combination with magnesium citrate. Several reports have indicated the occurrence of skin
irritations, which were bullous and comparable to skin irritations caused by scalds, with X-Prep® on
skin in children wearing napkins (Sitzmann et al., 1979).
In a cross-over study conducted by Perkin (1977), children with chronic constipation under 15 years
of age received lactulose (10–15 mL daily) or senna (10–20 mL daily). The latter was shown to be less
effective and it has been associated with higher frequency of side effects (no details were provided on
speciﬁc adverse events). This study has been reviewed by Gordon et al. (2013). According to the
authors, no severe or signiﬁcant adverse effects were reported in the two groups (lactulose vs senna).
Minor adverse events such as colic or diarrhoea, were reported in patients included in the senna group.
In an open-label randomised study, Sondheimer and Gervaise (1982) compared the efﬁcacy of
mineral oil (1.5–5 mL/kg per day) or standardised senna concentrate (Senokot, in tablet or syrup form
in doses sufﬁcient to induce at least one bowel movement daily, no further details available) in 37
children (aged 3–12 years) with chronic functional constipation. Mineral oil demonstrated more
beneﬁcial outcomes in terms of symptom control. Safety outcomes were not evaluated.
Berg et al. (1983) compared senna (one tablet of Senokot increased to two, if there was no
improvement, no further details available) to placebo and reported no signiﬁcant differences in the
number of soiling episodes per week. No safety outcomes were reported.
In a prospective, randomised, single blinded study, patients ages 6–21 years were assigned to a
2-day cleanout regimen of polyethylene glycol-based solution (PEG-P) at a dose of 1.5 g/kg bis in die
(BID - twice daily) for 2 days or to senna 15 mL daily (ages 6–12) or 30 mL daily (ages 12–21) for
2 days. No signiﬁcant difference in the serum electrolyte and creatine levels between the two
treatment groups has been reported. No signiﬁcant adverse events were recorded (Terry et al., 2013).
In the study conducted by Kierkus et al. (2013), 240 patients (ages 8–18) were randomly allocated to
one of the three groups and treated with three different methods for bowel preparation for paediatric
colonoscopy. In the ﬁrst group, patients received high-volume polyethylene glycol (PEG) (60 kg/day for
2 days), in the second low-volume PEG (30 kg/day) combined with bisacodyl (BPEG) (10–15 mg/day
for 2 days) and in the third group, patients received sennosides (2 mg/kg day for 2 days). Adverse
events, such as abdominal pain, nausea, vomiting, headache, dizziness and fatigue, were reported in
133 patients. There were no signiﬁcant differences in the incidence of the adverse events among the
treatment groups, except for nausea, which was statistically more frequent in the BPEG group (22/80)
compared to the PEG group (11/80) but not to the sennosides group (13/80). No serious adverse
event was recorded.
To assess the incidence of functional constipation, the factors involved and the efﬁcacy of the
treatment, a prospective study was performed on 62 children using a standard questionnaire in
addition to physical and anthropometric assessments. Treatments included demystiﬁcation, behavioural
changes and drugs (mineral oil and senna). Senna (20–30 mg/dose) combined with mineral oil
showed good results on 16 (26%) patients. Maintenance treatment with mineral oil (15–30 mL/day)
and senna at 5–15 mg/day had satisfactory results in 32% of the patients (1 month later), in 71%
(3–6 months later), and in 85% (6–12 months later). No safety outcomes were reported by the
authors (Martınez-Costa et al., 2005).
The aforementioned data do not provide sufﬁcient evidence to conclude the efﬁcacy and safety of
senna leaves when used for the treatment of constipated children
No clinical studies were available to assess the effects of cascara, frangula, aloe and rhubarb as
laxatives in children.
According to the ESCOP monograph, the use of laxatives in children under 10 years of age cannot
be recommended. According to the ‘Note for guidance on clinical investigation of medicinal products in
the paediatric population’ (CPMP/ICH/2711/99) of 27 July 2000, the age limit between ‘children’ and
‘adolescents’ is set to 12 years of age.
According to the updated EMA monographs on Aloe and Senna (EMA, 2017a,b), children younger
than 12 years should not use products containing hydroxyanthracene derivatives to treat constipation.
Use during pregnancy and lactation
The EMA Committee on herbal medicinal products has evaluated the use of a number of herbal
extracts for medicinal use (EMA, 2007a,c,d, 2008b).
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Limited data were available but it was reported that no teratogenic or fetotoxic effects were seen
in rats after oral treatment with aloe extract up to 1000 mg/kg bw or aloin A up to 200 mg/kg bw
(EMA, 2007a).
EMA (2007c) report a study in 95 pregnant women suffering constipation and administered
Laxariston® for an average of 61.4 days and a daily dose of 3.9 g (3 g contained 0.3 g frangula bark
(13.5 mg hydroxyanthracene derivatives), 0.3 g senna leaves (7.5 mg hydroxyanthracene derivatives),
0.15 g rhubarb root (6.75 mg hydroxyanthracene derivatives) and 0.015 g achillea extract. Four
patients (4.2%) were reported to suffer adverse reactions, but no further details were provided.
In summary, it is generally concluded for hydroxyanthracene derivate laxatives that reﬂex
stimulation might occur not only in the colon, but also uterine muscles, which might lead to the
development of hyperaemia in the pelvic region and to miscarriage as a result of neuromuscular
stimulation of uterine muscles. In addition, it was concluded by EMA that there was insufﬁcient data
on the excretion of hydroxyanthracene derivate metabolites in breast milk and use during lactation was
not recommended.
According to the updated EMA monographs on Aloe and Senna, the safety of hydroxyanthracene
derivatives has not been established during pregnancy and lactation. Due to the lack of sufﬁcient data
and because of concerns on genotoxic and cancerogenic potential of these substances, the use during
pregnancy and lactation is contraindicated (EMA, 2017a,b).
4. Discussion
The present opinion, following a request from the European Commission to EFSA, in accordance with
Article 29(1)(a) of Regulation (EC) No 178/2002 provides a scientiﬁc assessment of the hydroxyanthracene
derivatives in foods, including preparations such as food supplements and infusions.
The safety of hydroxyanthracene derivatives is limited only to those anthranoid compounds
extracted from the plants of the Rheum, Rhamnus, Senna and Aloe groups, which include (as also
detailed in Section 2.3 of this opinion) the glycosides such as sennosides (A + B), aloins (A + B),
cascarosides (A + B + C + D), frangulins (A + B), aloe-emodin and emodin glycosides and small
amounts of free aglycone anthrones, dianthrones and aglycone anthraquinones.
This procedure was triggered by Member States concerns during discussions on the possible
authorisation of health claim related to hydroxyanthracene derivatives and improvement of bowel
function previously substantiated in an EFSA scientiﬁc opinion (EFSA NDA Panel, 2013).
The EFSA NDA Panel considered as necessary to recommend certain restrictions when
hydroxyanthracene derivatives are used as herbal medicinal products for their laxative properties.
In particular, the NDA Panel noted that ‘stimulant laxatives should not be consumed continually for
periods longer than one to two weeks’ and ‘the use of stimulant laxatives for more than two weeks
requires medical supervision’ (EFSA NDA Panel, 2013). Furthermore, EFSA NDA Panel recommended in
the scientiﬁc opinion that the ‘long-term use of stimulant laxatives should be avoided owing to the
danger of electrolyte imbalance, impaired function of the intestine, and dependence on laxatives’, and
as a second line treatment option (e.g. ‘stimulant laxative should only be used if an effect on bowel
function cannot be achieved by a change of diet or the administration of bulk forming agents’) (EFSA
NDA Panel, 2013). The EFSA NDA Panel based the above-mentioned recommendations and restrictions
on the available evidence obtained mainly from monographs published by the WHO and by the HMPC
of EMA. In addition, the ANS Panel noted that aloe vera whole leaf extract has been classiﬁed by the
International Agency for Research on Cancer as a possible (Group 2B) human carcinogen (IARC,
2016).
The current risk assessment was performed to address questions on speciﬁc concerns on the
potential genotoxicity and carcinogenicity and not as an overall evaluation of hydroxyanthracene
derivatives used in food and food supplements.
Glycosidic hydroxyanthracene derivatives remain intact until they are hydrolysed in the GI tract to
their corresponding anthrones (aglycone anthrones). Regarding aglycone hydroxyanthracenes, as
demonstrated in animals, they may be absorbed intact, however only rhein is present in the systemic
circulation. In the GI tract, remaining hydroxyanthracenes may be reduced back to the corresponding
anthrones by the microbiota. After absorption, hydroxyanthracenes such as aloe-emodin are rapidly
and totally oxidised to rhein. In the gut epithelium and liver, absorbed aglycone hydroxyanthracenes
are conjugated into corresponding glucuronides and sulfates, which are excreted in bile or urine. The
Panel considered that animal models in general reﬂect the fate of hydroxyanthracenes in humans.
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The genotoxicity of hydroxyanthracene derivatives has been evaluated in numerous in vitro and
in vivo studies identiﬁed from the public literature. The available studies focused mainly on emodin,
aloe-emodin, rhein and sennosides and at lesser extent on aloe vera, senna and fructus sennae
extracts. A limited number of genotoxicity studies on chrysazin (danthron) and chrysophanol was also
available.
In the in vitro studies, among the extracts, only senna extracts proved to be mutagenic in bacteria,
in the TA 1537 and TA98 S. Typhimurium tester strain. Senna extract also induced DNA damage in
Bacillus subtilis and dose-related increases in chromosomal aberrations in CHO cells. Negative results
were reported for mutagenicity in bacteria for aloe vera gel and for both aloe vera WLE and aloe vera
charcoal-ﬁltered whole leaf extract (decolourised). The 1,8-dihydroxyanthraquinones emodin, aloe-
emodin and danthron were shown to induce moderate increases in the frequency of gene mutation
and dose-related increases in micronuclei by a clastogenic mechanism interacting via intercalation into
DNA with DNA topoisomerase II. The genotoxic and mutagenic potency were greater for danthron and
lower for emodin in mouse lymphoma cells. Aloe-emodin was also mutagenic in S. Typhimurium (all
frameshift mutant sites). While these results further support the intercalating capability of aloe-emodin
and consequent catalytic inhibition of DNA topoisomerase II, they also show the induction of
frameshift mutations which per se, is a mutagenic event not related to the inhibition of DNA
topoisomerase II. Emodin, the least potent compound among these three anthraquinones, was also
shown to induce DNA DSB through poisoning of Topo II-cleavable complex and by inhibiting ATP
hydrolysis of DNA topoisomerase II. Thus, a potential mechanism of inhibition of DNA topoisomerase
II through poisoning of the DNA–topoisomerase ‘cleavable complex’ cannot be excluded. In addition,
aloe-emodin-induced UDS in various mammalian cells. These results are also compatible with a
mechanism of inhibition of DNA topoisomerase II activities.
However, in addition to the induction of frameshift and base-pair substitution mutations and
clastogenic effects through inhibition of DNA topoisomerase II identiﬁed for individual anthranoids,
plant extracts containing hydroxyanthracene derivatives (glycosidic and aglycones) have been
demonstrated to contain also other mutagenic components with different mechanisms of action which
appear to play a role on their genotoxicity and carcinogenicity.
Thus, both aloe vera WLE and aloe vera WLD for which the content of hydroxyanthracene
derivatives was reduced by 99% compared to the WLE, induced statistically signiﬁcant and biologically
relevant increases in the MF in the mammalian cell TK+/- mutation assay. These results indicate that
other components in the mixtures, in addition to the hydroxyanthracene derivatives may contribute to
the induced mutagenicity in vitro.
Overall, the results of genotoxicity testing in vitro indicate that extracts of aloe vera and senna and
individual hydroxyanthracene derivatives, particularly aloe-emodin, interact with bacterial and
mammalian DNA under certain conditions in vitro. However, for risk assessment, in vivo studies are
necessary to conclude on potential genotoxic hazard. In this respect, there are several in vivo studies
available, which include the rodent bone marrow micronucleus assays, the mouse somatic mutation
assay in fetal melanoblasts (Mouse Spot Test), the rat bone marrow chromosome aberration assays
and the in vivo/in vitro UDS assay in rat liver. The results indicated that senna, fructus sennae extracts,
sennosides and the individual 1,8-dihydroxyanthraquinones tested were uniformly negative. However,
the Panel noted that, in all these studies, no evidence of toxicity in the target cells was observed,
indicating that target tissues may not have been adequately exposed to the test compounds. This
assumption is substantiated by results of an in vivo study in rat, showing a low absorption of [14C]
aloe-emodin and a rapid metabolism to rhein, an anthranoid with no signiﬁcant genotoxic activity in a
battery of in vitro and in vivo assays.
On the other hand, signiﬁcant increases in DNA fragmentation in the colon cells was demonstrated
mice treated with aloe-emodin by oral gavage at 500, 1,000 and 2,000 mg/kg bw on two occasions
24 h apart. Slight increases in DNA breakage compared to the concurrent vehicle control values were
also observed in the kidney. These increases were dose-related but reached statistical signiﬁcance only
at the high dose. On this basis, the limited absorption of aloe-emodin and its quick transformation to
rhein (a compound devoid of genotoxic capabilities) indicate that bone marrow may be considered as
an inadequate tissue to demonstrate possible in vivo genotoxicity of both emodin and aloe-emodin.
Overall, based on the available data, the Panel considered that the in vitro genotoxicity of aloe-
emodin was also reproduced in vivo, mainly in the colon, the target tissue for carcinogenicity of the
WLE of aloe vera with a content of aloe-emodin of 0.071 mg/g of whole leaf. In addition, the presence
of mutagenic components other than hydroxyanthracene derivatives cannot be excluded based on the
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results obtained by Guo (2014) indicating that decolourised aloe vera extracts (WLD) are genotoxic
in vitro through different mechanisms of action.
In subchronic studies with 0%, 1%, 2% and 3% aloe vera non-decolourised leaf extract in drinking
water by NTP (2013) GI transit time was decreased in male and female rats. Goblet cell hyperplasia in
caecum and large intestine and lymphoid cell hyperplasia of mesenteric lymph nodes were reported in
mice and rats from all exposed groups (doses for mice from 3,700 to 9,100 (males) or 9,700 (females)
mg/kg bw per day, and for rats from 1,100 to 3,800 mg/kg bw per days for males and 1,300 to
3,200 g/kg bw per day for females. Epithelial hyperplasia was reported in caecum and colon of mice
kept on diet providing daily doses of 625 mg senna/kg bw or higher for 29 days. In short-term studies
(15 or 16 days) with emodin in feed, diarrhoea was reported in some male mice receiving 1,200 mg/kg
bw per day, in some female mice receiving 530–5,000 mg/kg bw per day, and in all male and most
female rats administered with 17,000 or 50,000 mg emodin/kg diet (1,400 or 3,700 mg/kg bw for males
and 1,250 or 2,000 mg/kg bw for females) (NTP, 2001).
In 13-week studies (NTP, 2001), diarrhoea was reported in male mice kept administered 400
and 800 mg emodin/kg bw per day) and in female mice receiving 40–1,100 mg emodin/kg bw per
day). In male and female rats, diarrhoea was reported at various times in all emodin exposed
groups i.e. dose of 20–300 mg emodin/kg bw per day). In short-term and subchronic studies with
emodin. no treatment-related histological changes in the GI system were reported. Treatment-related
non-neoplastic changes were reported in kidneys (NTP, 2001).
In a 1-year chronic toxicity study in rats with a whole leave powder of Aloe (Aloe arborescens Miller
var. natalensis Berger) added to the diet at concentrations up to 2,212.17 mg extract/kg bw per day
for males and 2,681.39 mg extract/kg bw per day for females, no hyperplastic or neoplastic changes
in the GI system were seen. The low incidences of tumours found in other tissues were similar in the
control and the treated groups (Matsuda et al., 2008).
In a carcinogenicity study in rats with whole leaf powder of Aloe added to the diet at
concentrations of 0.8% or 4%, hyperplasia in the colon was recorded in some animals in the high-
dose group but not in the controls of the same gender (males: 5/42 vs 0/38, p < 0.05; females: 3/45
vs 0/40, p > 0.05). Furthermore, neoplastic changes were seen in the large intestine of some animals
solely in the high-dose group (adenomas (3/42) and a carcinoma (1/42) in colon of males and
adenomas in colon of females (3/45), one adenocarcinoma in caecum (1/42) and one adenoma (1/42)
in rectum in males compared to none in the control and 0.8% groups). As laboratory rats do not
develop spontaneous neoplasm in the large intestine the occurrence of hyperplasia in the colon and of
tumours in the caecum, colon and rectum in some of the rats from the high-dose group was
considered by the Panel as indication of a carcinogenic potential of the whole leaf powder of Aloe
when given in a dose associated with diarrhoea in this study.
In carcinogenicity study (104 weeks) in mice exposed to aloe vera non-decolourised WLE in
drinking water at concentrations from 1% to 3% (wt/wt) (from 2,940 to 11,760 mg/kg bw for males
and from 2,180 to 11,830 mg/kg bw per day for females), no treatment-related neoplastic changes
were reported. However, the incidence of goblet cell hyperplasia of large intestine was statistically
signiﬁcantly increased in all treated groups as compared to controls and the incidence of mesenteric
lymph node cellular inﬁltration was statistically signiﬁcantly increased in the high-dose males (NTP,
2013, Boudreau et al., 2013). In a carcinogenicity study (104 weeks), rats were exposed to the same
aloe vera non-decolourised WLE in drinking water at concentrations from 0.5% to 1.5% (wt/wt) (from
250 to 1136 mg/kg bw per day for males and from 330 to 1280 mg/kg bw per day for females). There
was a statistically signiﬁcant dose-trend increases in (a) incidence of mucosal hyperplasia of the
caecum and colon for males and females, (b) of mucosal hyperplasia in forestomach, glandular
stomach, ileum and rectum of females, and of glandular stomach, jejunum and rectum of males, (c) of
mesenteric lymph nodes hyperplasia for males, and (d) of cystic degeneration in mesenteric lymph
nodes hyperplasia for males and females. Moreover, statistically signiﬁcant dose-dependent increases
in the incidences of large intestine adenomas and carcinomas were reported for male and female rats.
The incidence of large intestine adenoma was statistically signiﬁcantly higher in 1% and 1.5% groups
of males and females and of carcinoma of males from 1% and 1.5% groups and of females from
1.5% group. The large intestine tumours were not seen in the control and 0.5% groups of male and
female rats. The Panel noted that laboratory rodents do not develop spontaneous neoplasms in the
large intestine. Therefore, the Panel considered the presence of hyperplastic changes in the large
intestine of mice and rats and of neoplastic changes in GI system of rats in the NTP study as indication
of carcinogenic effect of aloe vera non-decolourised WLE. The Panel noted that the authors of the NTP
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studies suggested that lack of the neoplastic changes in the large intestine of mice exposed to aloe
vera non-decolourised WLE could be explained by the fact that the intestinal bacteria in mice are less
efﬁcient than the intestinal bacteria of rats in converting aloin A and aloin B to aloe-emodin anthrone
and subsequently to aloe-emodin which bear genotoxic capabilities. In addition, mice have shorter
gastrointestinal tracts and faster gastrointestinal transit times than rats, which could contribute to the
lack of a tumour response in this species (Boudreau et al., 2013).
In carcinogenicity studies with emodin administered to mice or rats in the diet, no tumours of large
intestine were reported (doses amounting to 625 or 1,250 mg/kg bw per day for male and female
mice, and to 1,000 or 1,100 mg/kg bw for male and female rats) (NTP, 2001).
No treatment-related neoplasms were found in carcinogenicity study in rats exposed to puriﬁed
senna extract in drinking water providing doses up to 25 mg/kg bw per day. Also, in another
carcinogenicity study with senna preparation administered to rats by gavage in doses amounting to
300 mg/kg bw per day, no treatment-related tumours were found in GI tract or other organs but
diffuse mucosal epithelial hyperplasia in the large intestine with incidence increasing in dose-dependent
manner was reported. Furthermore, no treatment-related neoplasms were reported in p53+/- mice
kept on diet containing senna up to 10,000 mg/kg diet (equal to 1,260 and 1,560 mg/kg bw per day
for males and females, respectively) for 40 weeks. In an initiation–promotion study in rats, senna pod
extract administered by gavage for 13 or 28 weeks did not induce ACF, did not affect incidence of
tumours induced by AOM when given in a low dose (10 mg senna pod extract/kg bw per day), but the
high and diarrhoeagenic dose of senna pod extract (100 mg/kg bw per day) appeared to promote
development of tumours initiated by AOM in the colon (Mascolo et al., 1999). The Panel speculated
whether irritation of the intestinal tract by diarrhoea could play a role in promoting the development of
the tumours initiated by AOM. The Panel also noted that senna extracts contain sennosides A, B, C
and D, which are glycosidic di-anthrones converted to rhein by gut microbiota, one of the major
metabolites of hydroxyanthracene derivatives, practically devoid of any genotoxic activity.
In male mice, a dietary exposure to 0.2% chrysazin (a synthetic anthraquinone, also known as
danthron) for 540 days was associated with adenomatous hyperplasia in the caecum and colon and
higher incidence of liver adenomas and carcinomas than in the control group. In male rats, 1%
chrysazin in the diet was associated with focal hyperplasia of glandular epithelium of caecum and
colon and with occurrence of adenomas, adenocarcinomas in the colon and caecum. The
Panel considered that both studies indicated carcinogenic effect of chrysazin. The Panel noted the
limitations of both studies (small number of animals per group, use of one sex, one dose of the test
compound and limited reporting).
Overall, the Panel considered that the results of carcinogenicity studies indicated a carcinogenic
effect of a whole leaf powder of aloe when given to rats at dietary concentration of 4%, a level
associated with diarrhoea or loose stool, of aloe vera whole leaf extract in drinking water when given
to rats at concentration of 1% or higher, and of chrysazin given in the diet at concentrations of 0.2%
and 1% to mice and rats, respectively. Apart of tumours exposure to these test compounds caused
hyperplastic changes in the large intestine of rats and mice. Senna extract was not carcinogenic to rats
at doses up to 25 mg/kg bw per day in drinking water. Senna preparation was not carcinogenic to rats
at doses amounting to 300 mg/kg bw per day administered by gavage but the rats developed diffuse
mucosal epithelial hyperplasia in the large intestine and caecum with an incidence increasing in a dose-
dependent manner. Senna in the diet in doses amounting to 1,260 and 1,520 mg/kg bw per day was
not carcinogenic to p53+/- males and females, respectively, but induced epithelial hyperplasia in the
large intestine.
In previous evaluations (EMA, 2007a,b,c,d, 2008a,b), the relation between laxatives use and
colorectal cancer was reported and it was concluded that ‘The question of a possible carcinogenic risk
of long-term use of anthranoid-containing laxatives is still open and the results of the more recent
studies are inconsistent. Therefore the conditions determined in the pharmacovigilance actions for
anthranoid-containing laxatives have to be maintained’.
An increased risk for colorectal cancer was found in all ﬁve cohort studies reviewed but only the
study by Watanabe et al. (2004) (HR: 2.40; 95% CI: 1.11–5.18) and the study by Citronberg et al.
(2014) showed statistical signiﬁcance (1–4 times yearly vs none or less than once a year, HR: 1.49;
95% CI: 1.04–2.14; 5 times or more yearly vs none or less than once a year, HR: 1.43; 95% CI:
0.82–2.48, p trend = 0.05). Based on the studies reviewed by EMA and the results of more recent
large epidemiological studies, the Panel agreed with previous evaluations that the prolonged use of
laxatives is a possible risk factor for colorectal cancer. Nevertheless, better designed epidemiological
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studies (e.g. cohort studies with large sample size and proper control for confounding factors) that
investigate the relationship between anthranoids laxatives use and colorectal are needed.
The Panel noted that parts of plants containing hydroxyanthracene derivatives may be part of the
normal diet. However, no data on the concentrations of hydroxyanthracene derivatives present in the
parts of the plants consumed were made available to the Panel by interested parties following a call
for data.
Exposure to hydroxyanthracene derivatives from food supplements has been estimated from the
recommended daily doses of food supplements as provided by the interested parties following the
launch of a public ‘Call for data’ (see Section 2.6).
The Panel noted that exposure to aloe-emodin and emodin is not known due to lack of data
provided by the interested parties.
Maximum daily exposure to hydroxyanthracene derivatives is reported below:
• Exposure to sennoside B was estimated up to 0.35 mg/kg bw per day, corresponding to
24.83 mg/person per day for a 70-kg adult.
• Exposure to rhein was estimated up to 1.12 mg/kg bw per day, corresponding to
78.8 mg/person per day for a 70-kg adult.
• Exposure to glucofrangulin A was estimated up to 0.37 mg/kg bw per day, corresponding to
26 mg/person per day for a 70-kg adult.
• Exposure to barbaloin was estimated up to 0.34 mg/kg bw per day, corresponding to
24 mg/person per day for a 70-kg adult.
• Exposure to aloin A+B was estimated up to 0.72 mg/kg bw per day, corresponding to
51 mg/person per day for a 70-kg adult.
The Panel noted that the recommended daily doses provided by the interested parties are
extremely variable. In order to calculate the worst-case scenario the highest number in the range was
used for the calculation. The Panel further noted that the concentrations of single hydroxyanthracene
derivatives used in the food supplements vary also depending whether used alone or in combination
with other hydroxyanthracene derivatives.
Exposure in young children was not performed since the use of food supplements containing
hydroxyanthracene derivatives is not recommended in this population category.
The dose of hydroxyanthracene derivatives used in herbal medicinal products for the treatment of
constipation should not exceed 30 mg/day for a maximum period of 2 weeks, in adults’ only (excluding
pregnant and lactating women).
5. Conclusion
Epidemiological data suggest an increased risk for colorectal cancer associated with the general use
of laxatives, several of which contain hydroxyanthracene derivatives.
Based on the data currently available, the Panel concluded that the hydroxyanthracenes, emodin,
aloe-emodin and the structurally related substance danthron, have been shown to be genotoxic in vitro.
Aloe extracts have also been shown to be genotoxic in vitro and the Panel concluded this was most
likely due – at least in part – to hydroxyanthracene derivatives present in the extract. However, the
Panel further noted that Aloe extracts depleted of hydroxyanthracenes, contained an additional
genotoxic component(s).
Furthermore, aloe-emodin was shown to be genotoxic in mice, the whole leaf aloe extract was
carcinogenic to rats and there was evidence of carcinogenicity of the structural analogue danthron in
both rodent species. Given that aloe-emodin and emodin may be present in the extracts, the
Panel concluded that hydroxyanthracene derivatives should be regarded as genotoxic and carcinogenic
unless there are speciﬁc data to the contrary, such as for rhein, and that there is a safety concern for
extracts containing hydroxyanthracene derivatives although uncertainty persists.
The Panel was unable to provide advice on a daily intake of hydroxyanthracene derivatives that
does not give rise to concerns about harmful effects to health, for the general population, and as
appropriate, for vulnerable subgroups of the population.
Documentation provided to EFSA
1) FSE (Food Supplement Europe), July 2017. Response to EFSA request for information on the
use of hydroxyanthracene derivatives.
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2) Synadiet, June 2017. Response to EFSA request for information on the use of
hydroxyanthracene derivatives.
3) Aboca, June 2017. Response to EFSA request for information on the use of
hydroxyanthracene derivatives.
4) ORTIS Laboratoires, June 2017. Response to EFSA request for information on the use of
hydroxyanthracene derivatives.
5) Laboratoires Superdiet, June 2017. Response to EFSA request for information on the use of
hydroxyanthracene derivatives.
6) Laboratoires Juvasante’, June 2017. Response to EFSA request for information on the use of
hydroxyanthracene derivatives.
7) EHPM (European Federation of Associations of Health Food Products Manufacturers), June
2017. Response to EFSA request for information on the use of hydroxyanthracene derivatives.
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Abbreviations
ACF aberrant crypt foci
ADME absorption, distribution, metabolism and excretion
AG aluminium foil
ANS Panel Panel on Food Additives and Nutrient Sources Added to Food
AST aspartate transaminase
ATP adenosine triphosphate
AUC area under the curve
aw water activity
BfR German Federal Institute for Risk Assessment
BID bis in die (twice daily)
BM behaviour modiﬁcation
BMI body mass index
BOPP biaxially oriented polypropylene
BPEG bisacodyl polyethylene glycol
BSA bovine serum albumin
CAS Chemical Abstracts Service
CHL Chinese hamster lung
CHO Chinese hamster ovary
CI cumulative incidence
CPE cloud point extraction
CRC colorectal cancer
CZE capillary zone electrophoresis
DAD diode-array detection
DCF-DA 20,70-dichlorodihydroﬂuorescein diacetate
DGCCRF Direction Generale de la Concurrence, de la Consommation et de la Repression
des Fraudes
DHAQ 1,8-dihydroxy anthraquinone
DLLME dispersive liquid–liquid microextraction
DSB double-strand breaks
DT degradation time
DTU Technical University of Denmark
EFSA SC EFSA Scientiﬁc Commettee
EMA European Medicines Agency
FAD ﬂavin adenine dinucleotide
FDA Food and Drugs Administration
FMN ﬂavin mononucleotide
GATE gas-assisted three-liquid-phase extraction system
GC gas chromatography
GI gastrointestinal
GLP Good Laboratory Practice
GSH glutathione
HMPC Committee on Herbal Medicinal Products
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HPFS Health Professionals Follow-up Study
HPLC high-performance liquid chromatography
HPRT hypoxanthine-guanine phosphoribosyl transferase
HRE heat reﬂux extraction
HSA human serum albumin
HSCCC high-speed counter current technology
IARC International Agency for Research on Cancer
IL ionic liquid
ILATPS Ionic liquid- based aqueous two-phase systems
IL-UMAE ionic liquid-based ultrasonic/microwave-assisted extraction
IUPAC International Union of Pure and Applied Chemistry
JECFA Joint FAO/WHO Expert Committee on Food Additives
LC liquid chromatography
LOD limit of detection
LOQ limit of quantiﬁcation
LOH loss of heterozygosity
MAE microwave-assisted extraction
ME maceration extraction
MEC microemulsion electrokinetics chromatography
MF mutation frequencies
MM multimodal
MNCL mononuclear cell leukaemia
MS mass spectrometry
MSPE magnetic solid-phase extraction
MS/MS tandem mass spectrometry
NAD nicotinamide adenine dinucleotide
NCE normochromatic erythrocytes
NDA Panel Panel on Dietetic Products, Nutrition and Allergies
NHS Nurses’ Health Study
NOAEL no-observed-adverse-effect-level
NTP US National Toxicology Program
OR odds ratio
OTM Olive tail moment
OTC over-the-counter
PCE polychromatic erythrocytes
PDA photodiode array
PEG polyethylene glycol
PEG-P polyethylene glycol-based solution
PHWE pressurised hot water extraction
PLE pressurised liquid extraction
PP polypropylene
RBF round-bottom ﬂask
ROS reactive oxygen species
RP-HPLC reverse phase-high-performance liquid chromatography
RSM response surface methodology
SDME single drop microextraction
SDS-MEKC sodium dodecyl sulfate micellar electrokinetic chromatography
SE Soxhlet extraction
SFE super/subcritical ﬂuid extraction
SPE solid-phase extraction
SPME solid-phase microextraction
TLC thin-layer chromatography
UAE ultrasound-assisted extraction
UDP uridine 50-diphospho
UDS unscheduled DNA synthesis
UGT UDP-glucuronosyltransferase
Safety assessment of hydroxyanthracene derivatives
www.efsa.europa.eu/efsajournal 77 EFSA Journal 2018;16(1):5090
UHPLC-Q-TOF/MS ultra-high-performance liquid chromatography coupled with quadrupole
time-of-ﬂight tandem mass spectrometry
UNE ultrasonic nebulisation extraction
UPLC ultra-pressure liquid chromatography
UV ultraviolet
UV–Vis ultraviolet–visible
WHO World Health Organization
WLD decolourised whole leaf extract
WLE whole leaf extract
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Appendix A – Complete list of hydroxyanthracene derivatives(a)
Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
Parent compounds
Anthracene
 
Anthracene
120-12-7 C14H10 178.234
Anthraquinone
O
O
 
Anthracene-9,10-dione
84-65-1 C14H8O2 208.216
Emodin O
O
H3C
OH
OH
OH
 
1,3,8-trihydroxy-6-methylanthracene-9,10-dione
518-82-1 C15H10O5 270.24
Dihydroxyanthraquinones
Chrysophanol O
O
OH OH
H3C
1,8-dihydroxy-3-methylanthracene-9,10-dione
481-74-3 C15H10O4 254.241 Rhubarb
Physcion O
O
OH OH
H3C O
CH3
1,8-dihydroxy-3-methoxy-6-methylanthracene-9,10-dione
521-61-9 C16H12O5 284.267
Safety assessment of hydroxyanthracene derivatives
www.efsa.europa.eu/efsajournal 79 EFSA Journal 2018;16(1):5090
Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
Rhein
O
HO
O
O
OHOH
4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
478-43-3 C15H8O6 284.223
Rhein anthrone 480-09-1 C15H10O5 270.24
Aloe-emodin O
O
OH
OH OH
1,8-dihydroxy-3-(hydroxymethyl)anthracene-9,10-dione
481-72-1 C15H10O5 270.24 Aloe
Emodin anthrone 491-60-1 C15H12O4 256.257
7-Hydroxy aloe emodin O
O
OH
OH
HO
OH
1,2,8-trihydroxy-6-(hydroxymethyl)anthracene-9,10-dione
156547-97-6 C15H10O6 286.239
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Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
Nataloe-emodin O
O
OH
CH3
OH
HO
1,2,8-trihydroxy-6-methylanthracene-9,10-dione
478-46-6 C15H10O5 270.24
Nataloe-emodin 8-methyl
ether
O
O
OH
CH3
O
HO
CH3
1,2-dihydroxy-8-methoxy-6-methylanthracene-9,10-dione
125708-14-7 C16H14O5 286.282
Anthrone glycosides
Aloin A
(S)
O
O
(S)
(R)
(R)
(S)
(R)
OH
OH
OH
OH
OH OH
HO
H H
(10S)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]-10H-anthracen-9-one
1415-73-2 C21H22O9 418.398 Aloe
Aloin B
(R)
O
O
(S)
(R)
(R)
(S)
(R)
OH
OH
OH
OH
OH OH
HO
H H
(10R)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-
3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-10H-anthracen-9-one
28371-16-6 C21H22O9 418.398
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Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
5-Hydroxyaloin A
(R)
O
O
(S)
(R)
(R)
(S)
(R)
OH
OH
OH
OH
OH OH
HO
H H
OH
(10S)-1,5,8-trihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-
3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-10H-anthracen-9-one
138373-23-6 C21H22O10 434.39
5-Hydroxyaloin B
(S)
O
O
(S)
(R)
(R)
(S)
(R)
OH
OH
OH
OH
OH OH
HO
H H
OH
(10R)-1,5,8-trihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-
3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-10H-anthracen-9-one
138373-24-7 C21H22O10 434.39
Aloinoside A
(S)
OH O OH
(S)
O
(R)(R)
(R)
O
(R)
(R)
(R)
(R)
(S)
O
HO
OH
CH3
OH
OH
OH
H H
OH
HO
(10S)-1,8-dihydroxy-10-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]-3-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-
methyloxan-2-yl]oxymethyl]-10H-anthracen-9-one
56645-88-6 C27H32O13 564.54
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Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
Aloinoside B
(R)
OH O OH
(S)
O
(R)(R)
(R)
O
(R)
(R)
(R)
(R)
(S)
O
HO
OH
CH3
OH
OH
OH
H H
OH
HO
(10R)-1,8-dihydroxy-10-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]-3-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-
methyloxan-2-yl]oxymethyl]-10H-anthracen-9-one
11006-91-0 C27H32O13 564.54
Cascaroside A
(S)
O OHO
(S)
O
(R)
(S)
(R)
(R)
OH
H H
OH
OH
OH
OH
(S)
O
(R)
(S)
(S)
(R)
OH
HO
HO
HO
(10S)-1-hydroxy-3-(hydroxymethyl)-10-[(2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]-8-[(2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-10H-anthracen-9-one
53823-08-8 C27H32O14 580.539 Cascara
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Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
Cascaroside B
(R)
O OHO
(S)
O
(R)
(S)
(R)
(R)
OH
H H
OH
OH
OH
OH
(S)
O
(R)
(S)
(S)
(R)
OH
HO
HO
HO
(10R)-1-hydroxy-3-(hydroxymethyl)-10-[(2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]-8-[(2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-10H-anthracen-9-one
53861-34-0 C27H32O14 580.539
Cascaroside C
(S)
O OHO
(S)
O
(R)
(S)
(R)
(R)
CH3
H H
OH
OH
OH
OH
(S)
O
(R)
(S)
(S)
(R)
OH
HO
HO
HO
(10S)-1-hydroxy-3-methyl-10-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]oxy-10H-anthracen-9-one
53823-09-9 C27H32O13 564.54
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Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
Cascaroside D
(R)
O OHO
(S)
O
(R)
(S)
(R)
(R)
CH3
H H
OH
OH
OH
OH
(S)
O
(R)
(S)
(S)
(R)
OH
HO
HO
HO
(10R)-1-hydroxy-3-methyl-10-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]oxy-10H-anthracen-9-one
53861-35-1 C27H32O13 564.54
Cascaroside E
(R)
O OHO
(S)
O
(R)
(S)
(R)
(R)
CH3
H H
OH
OH
OH
OH
(S)
O
(R)
(S)
(S)
(R)
OH
HO
HO
HO
HO
(10R)-1,6-dihydroxy-3-methyl-10-[(2S,3R,4R,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]-8-[(2S,3R,4R,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-10H-anthracen-9-one
164178-32-9 C27H32O14 580.539
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Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
Cascaroside F
(S)
O OHO
(S)
O
(R)
(S)
(R)
(R)
CH3
H H
OH
OH
OH
OH
(S)
O
(R)
(S)
(S)
(R)
OH
HO
HO
HO
HO
(10S)-1,6-dihydroxy-3-methyl-10-[(2S,3R,4R,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]-8-[(2S,3R,4R,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-10H-anthracen-9-one
164322-83-2 C27H32O14 580.539
Glucofrangulin A
O OOH
O
OH3C
(S)
O
(S)
(R)
(R)
(R)
(S)
O
(R)
(S)
(S)
(R)
OH
OH
HO OH
H3C OH
OH
OH
1-hydroxy-3-methyl-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]oxy-6-[(2S,3R,4R,5R,6S)-3,4,5-
trihydroxy-6-methyloxan-2-yl]oxyanthracene-9,10-dione
21133-53-9 C27H30O14 578.523 Frangula
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Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
Glucofrangulin B
O OOH
O
OH3C
(S)
O
(R)
(S)
(S)
(R)
OH
HO OH
OH
(R)
O
(R)
OH
OH
OH
6-[(3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-3-yl]oxy-1-
hydroxy-3-methyl-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]oxyanthracene-9,10-dione
14062-59-0 C26H28O14 564.493
Dianthrones
Palmidin C O OHOH
OHH3C
CH3
OH O OH
10-(4,5-dihydroxy-2-methyl-10-oxo-9H-anthracen-9-yl)-1,3,8-
trihydroxy-6-methyl-10H-anthracen-9-one
17177-86-5 C30H22O7 494.499
Safety assessment of hydroxyanthracene derivatives
www.efsa.europa.eu/efsajournal 87 EFSA Journal 2018;16(1):5090
Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
Dianthrone glycosides (sennosides)
Sennoside A
(R)
O
(S)
OH O
O
HO
O
OH
(R)
(R)
(S)
(S)
(S)
O
O OHO
(R)
O
(S)
(S)
(S)
(R)
OH
OH
OHHO
HO
OH
OH
OH
H H
(9R)-9-[(9R)-2-carboxy-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-
3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-
yl]-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid
81-27-6 C42H38O20 862.746 Cassia
Sennoside A1
(Sennoside G)
(Sennoside A&B)
OOH O
O
HO
O
OH
(R)
(R)
(S)
(S)
(S)
O
O OHO
(R)
O
(S)
(S)
(S)
(R)
OH
OH
OHHO
HO
OH
OH
OH
H H
9-[2-carboxy-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-yl]-4-
hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid
66575-30-2 C42H38O20 862.746
Safety assessment of hydroxyanthracene derivatives
www.efsa.europa.eu/efsajournal 88 EFSA Journal 2018;16(1):5090
Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
Sennoside B
(R)
O
(S)
OH O
O
HO
O
OH
(R)
(R)
(S)
(S)
(S)
O
O OHO
(R)
O
(S)
(S)
(S)
(R)
OH
OH
OHHO
HO
OH
OH
OH
H H
(9S)-9-[(9R)-2-carboxy-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-
3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracen-9-
yl]-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid
128-57-4 C42H38O20 862.746
Sennoside C
(R)
O
(R)
OH O
HO
O
OH
(R)
(R)
(S)
(S)
(S)
O
O OHO
(R)
O
(S)
(S)
(S)
(R)
OH
OH
OHHO
HO
OH
OH
OH
H H
(9R)-4-hydroxy-9-[(9R)-4-hydroxy-2-(hydroxymethyl)-10-oxo-5-
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]
oxy-9H-anthracen-9-yl]-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-
carboxylic acid
37271-16-2 C42H40O19 848.763
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Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
Sennoside D
(R)
O
(S)
OH O
HO
O
OH
(R)
(R)
(S)
(S)
(S)
O
O OHO
(R)
O
(S)
(S)
(S)
(R)
OH
OH
OHHO
HO
OH
OH
OH
H H
(9R)-4-hydroxy-9-[(9S)-4-hydroxy-2-(hydroxymethyl)-10-oxo-5-
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]
oxy-9H-anthracen-9-yl]-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-
trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-
carboxylic acid
37271-17-3 C42H40O19 848.763
Sennoside E
OOH O
HO
O
OH
(R)
O
(S)
(S)
(S)
(R)
O OHO
(R)
O
(S)
(S)
(S)
(R)
OH
OH
OHO
HO
OH
OH
H H
HO
O
O
O
OH
9-[2-carboxy-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-
3-oxalooxyoxan-2-yl]oxy-4-hydroxy-10-oxo-9H-anthracen-9-yl]-4-
hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid
11137-63-6 C44H38O23 934.765
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Name
Structural formula
IUPAC Name
CAS Registry
Number
Chemical
formula
Molecular
weight
Botanical
Source
Sennoside F
(S)
O
(R)
OH O
HO
O
OH
(R)
O
(S)
(S)
(S)
(R)
O OHO
(S)
O
(R)
(S)
(S)
(R)
OH
OH
OHHO
OH
OH
H H
HO
O
O
O
O
HO
(9S)-9-[(9R)-2-carboxy-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-
3,4,5-trihydroxy-6-(oxalooxymethyl)oxan-2-yl]oxy-9H-anthracen-9-
yl]-4-hydroxy-10-oxo-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)oxan-2-yl]oxy-9H-anthracene-2-carboxylic acid
1037532-47-0 C44H38O23 934.765
IUPAC: International Union of Pure and Applied Chemistry; CAS: Chemical Abstracts Service.
(a): Chemical structures from SciFinder, available at: https://www.cas.org/products/scifinder.
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Appendix B – Identity and nature of source materials
The plant synonyms included in the Appendix B refers to the ‘The Plant List’ website (http://www.theplantlist.org); in this opinion, tables list only
synonyms having high or medium conﬁdence levels (see below). When the number of synonyms is very large, only high conﬁdence level is considered.
Conﬁdence Levels:
For each name record, The Plant List offers an indication of the conﬁdence that the Status of the name record is correct: Our conﬁdence assessments
are based primarily on the nature and taxonomic integrity of the source data.
High Conﬁdence level
is applied to the Status of name records derived from taxonomic datasets which treat the whole of the taxonomic group in question on a global basis
and have been peer reviewed (e.g. ILDIS, WCSP, see collaborators).
Medium Conﬁdence level
is applied to the Status of name records derived from:
• Either national or regional databases via a rules-based automated process, reﬂecting the challenges inherent in resolving taxonomic differences
between different name data sets for the same species for different geographic areas. Regional datasets used as sources for The Plant List are
primarily those stored within Tropicos (see collaborators for details).
• Or taxonomic data sets which treat the whole of the taxonomic group in question on a global basis but which have not yet undergone peer review
(e.g. GCC and WCSP (in review) see Collaborators).
Aloe spp. Family Xanthorrhoeaceae
Species Synonym(a) Common name
Parts
used
EU Ph. EMA
The
Plant
List
USDA Mansf.
EFSA
Comp.
BELFRIT Other
Aloe africana
Mill
Aloe angustifolia Haw.
Aloe bolusii Baker
Aloe pseudoafricana Salm-Dyck
Pachidendron africanum (Mill.) Haw
Pachidendron angustifolium (Haw.)
Haw.
African aloe Leaf,
leaf gel
– X X spp X World Health
Organization,
1999
Japan Ph
US Ph
Safety assessment of hydroxyanthracene derivatives
www.efsa.europa.eu/efsajournal 92 EFSA Journal 2018;16(1):5090
Species Synonym(a) Common name
Parts
used
EU Ph. EMA
The
Plant
List
USDA Mansf.
EFSA
Comp.
BELFRIT Other
Aloe
arborescens Mill
A. arborea Medik.
A. frutescens Salm-Dyck
A. fruticosa Lam.
A. fulgens Tod.
A. natalensis J.M. Wood & M.S.
Evans
A. perfoliatum Meyen
A. principis (Haw) Stearn
A. salm-dyckiana Schult. & Schult.f
A. sigmoidea Baker.
Catevala arborescens (Mill.) Medik.
Pachidendron principis Haw
Candelabra aloe
Octopus plant
Torch plant
Leaf,
leaf gel
X X X spp X
Aloe ferox Mill A. galpinii Baker
A. horrida Haw
A. muricata Haw.
A. pseudoferox Salm-Dyck
A. subferox Spreng
A. supralaevis Haw.
Pachidendron ferox (Mill.) Haw.
Pachidendron pseudoferox (Salm-
Dyck) Haw
Pachidendron supralaeve (Haw.)
Haw
Cape aloe
Uganda aloe
Leaf,
leaf gel
8.0 (2014)
8.3 (2015)
X X X X spp X Germany
WHO Mon. 1999
Japan Ph
US Ph
Aloe perryi
Baker
– Perry’s aloe
Socotra aloe
West indian aloe
Zanzibar aloe
Leaf,
leaf gel
X X X spp X
Aloe plicatilis
(L.) Mill
A. lingua Thunb.
A. tripetala Medik.
Kumara disticha Medik
Rhipidodendum distichum (Medik.)
Willd.
Rhipidodendrum plicatile (L.) Haw.
Leaf,
leaf gel
X spp X
Safety assessment of hydroxyanthracene derivatives
www.efsa.europa.eu/efsajournal 93 EFSA Journal 2018;16(1):5090
Species Synonym(a) Common name
Parts
used
EU Ph. EMA
The
Plant
List
USDA Mansf.
EFSA
Comp.
BELFRIT Other
Aloe vera (L.)
Burm. f
A. barbadensis Mill
A. chinensis Steud. ex Baker
A. elongata Murray
A. ﬂava Pers.
A. indica Royle
A. lanzae Tod.
A. rubescens DC
A. vulgaris Lam
Barbados aloe
Curacao aloe
Indian aloe
Mediterranean aloe
Leaf,
leaf gel
8.3 (2015) X X X X spp X Germany
WHO Mon. 1999
Japan Ph
US Ph
(a): Only resolved names and with conﬁdence level 3. spp = Aloe spp (cited as a group); Ph = Pharmacopoeia; EU Ph = European Pharmacopoeia; EMA = European Medicines Agency; The plant
List = The Plant List (2013). Version 1.1. Published on the Internet; http://www.theplantlist.org/; USDA = United States Department of Agriculture, Natural Resources Conservation Service
Available at: https://plants.usda.gov/java/; Mansf. = Mansfeld’s World Database of Agricultural and Horticultural Crops. Available at: http://mansfeld.ipk-gatersleben.de/apex/f?p=185:3::::::#;
EFSA Comp. = Compendium of botanicals reported to contain naturally occurring substances of possible concern for human health when used in food and food supplements (2012). Available
at https://www.efsa.europa.eu/it/efsajournal/pub/2663; BELFRIT = Harmonised list of Plants allowed in Food supplements by Belgium, France and Italy; WHO Mon. = WHO Monographs on
selected medicinal plants (http://apps.who.int/medicinedocs/en/)
Genus Cassia and Senna – Family Leguminosae
Species Synonym(a) Common name
Parts
used
EU Ph. EMA
The
Plant
List
USDA Mansf.
EFSA
Comp.
BELFRIT Other
Cassia ﬁstula L. Bactyrilobium ﬁstula Willd.
Cassia bonplandiana DC
Cassia excelsa Kunth
Cassia ﬁstuloides Collad.
Cassia rhombifolia Roxb.
Cathartocarpus excelsius G.Don.
Cathartocarpus ﬁstula Pers.
Cathartocarpus ﬁstuloides
(Collad.) G.Don.
Cathartocarpus rhombifolius
G.Don
Golden shower
Indian laburnum
Purging cassia
Fruit X X X spp X
Cassia italica
(Mill.) F.W.
Andrew
Senna italica (Mill.) F.W.Andrew Port Royal senna
Mecca senna
Senegal senna
Tripoli senna
Whole
plant
X as
Senna
Italica
X spp X
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Species Synonym(a) Common name
Parts
used
EU Ph. EMA
The
Plant
List
USDA Mansf.
EFSA
Comp.
BELFRIT Other
Cassia
mimosoides L.
var Nomame
(Siebold)
Makino
Chamaecrista nomame (Sieber) H.
Ohashi
Cassia nomame Leaf,
pod
Italian List
Senna
alexandrina
Mill.
Cassia acutifolia Delile
Cassia alexandrina (Garsault)
Thell.
Cassia angustifolia M. Vahl.
Cassia senna L.
Senna acutifolia (Delile) Batka
Senna alexandrina Garsault
Senna angustifolia (Vahl) Batka
Alexandrian senna Leaf,
pod
8.3 (2015) X X X X spp X China Ph
US Ph
Senna
obtusifolia (L.)
H.S. Irwin &
Barneby
Cassia humilis Collad.
Cassia obtusifolia L.
Cassia toroides Roxb.
Cassia toroides Raf.
Diallobus falcatus Raf.
Diallobus uniﬂorus Raf.
Senna toroides Roxb.
Java-bean
Charamazca
Whole
plant
X X X spp X
Senna
occidentalis (L.)
Link
Cassia caroliniana Walter
Cassia ciliata Raf.
Cassia falcata L.
Cassia foetida Pers.
Cassia macradenia Collad.
Cassia obliquifolia Schrank.
Cassia occidentalis L.
Cassia occidentalis (L.) Rose
Cassia planisiliqua L.
Ditramexa occidentalis Britton &
Rose
Ditremexa occidentalis (L.) Britton
& Wilson
Septicweed
Coffee senna
Negro coffee
Bark,
leaf
X X X spp X
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Species Synonym(a) Common name
Parts
used
EU Ph. EMA
The
Plant
List
USDA Mansf.
EFSA
Comp.
BELFRIT Other
Senna tora (L.)
Roxb.
Cassia borneensis Miq
Cassia gallinaria Collad.
Cassia numilis Collad.
Cassia tora L.
Emelista tora Britton & Rose
Sickle senna
Foetid cassia
Wild senna
Leaf,
seed
X X X spp X
Genus Frangula Mill. and Rhamnus L.- Family Rhamnaceae
Species Synonym(a) Common name
Parts
used
EU Ph. EMA
The
Plant
List
USDA Mansf
EFSA
Comp.
BELFRIT Other
Frangula alnus
Mill.
Frangula atlantica Grubov
Frangula frangula H. Karst.
Frangula nigra Samp.
Frangula pentapetala Gilib.
Frangula vulgaris Hill
Girtanneria frangula Neck.
Rhamnus frangula L.
Glossy buckthorn
Alder buckthorn
Frangula
Persian bark
Bark 8.0 (2014) X X X X spp X WHO Mon.
2004
Frangula
purshiana
Cooper
Cardiolepis obtusa Raf.
Frangula anonifolia (Greene)
Grubov
Rhamnus annonifolia Greene
Rhamnus purshiana DC.
Cascara buckthorn
Pursh’s buckthorn
Bearberry
Sacred bark
Bark 8.0 (2014) X X X X spp X WHO Mon.
2004
US Ph
Rhamnus alpina
L.
Frangula latifolia Mill. – Bark,
fruit
– – X – – spp X –
Rhamnus
cathartica L.
Cervispina cathartica (L.)
Moench
Common buckthorn Whole
plant
– – X X X spp X –
(a): Only resolved names and with conﬁdence level 3. spp. = Cassia spp. (cited as a group); Ph = Pharmacopoeia; EU Ph = European Pharmacopoeia; EMA = European Medicines Agency; The
plant List = The Plant List (2013). Version 1.1. Published on the Internet; http://www.theplantlist.org/; USDA = United States Department of Agriculture, Natural Resources Conservation
Service Available at: https://plants.usda.gov/java/. Mansf. = Mansfeld’s World Database of Agricultural and Horticultural Crops. Available at: http://mansfeld.ipk-gatersleben.de/apex/f?p=185:
3::::::#; EFSA Comp. = Compendium of botanicals reported to contain naturally occurring substances of possible concern for human health when used in food and food supplements (2012).
Available at: https://www.efsa.europa.eu/it/efsajournal/pub/2663; BELFRIT = Harmonized list of Plants allowed in Food supplements by Belgium, France and Italy. WHO Mon. = WHO
Monographs on selected medicinal plants (http://apps.who.int/medicinedocs/en/).
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Genus Rheum L. – Family Polygonaceae
Species Synonym Common name
Parts
used
EU Ph. EMA
The
Plant
List
USDA Mansf.
EFSA
Comp.
BELFRIT Other
Rheum australe
D. Don
R. emodii Wall ex Meisn. – Leaf,
rhizome
X X spp X India Ph
Rheum
ofﬁcinale Baill.
– Chinese rhubarb
Medicinal rhubarb
Root,
rhizome
8.0 (2014) X X X X spp X WHO Mon.
1999
Japan Ph
Rheum
palmatum L.
R. potaninii Losinsk
R. qinlingense Y.K.Yang,
DK Zhang & JK Wu
Chinese rhubarb Root,
rhizome
8.0 (2014) X X X X spp X WHO Mon.
1999
Japan Ph
Rheum
rhabarbarum L.
R. franzenbachii M€unter
R. undulatum L.
Garden rhubarb Rhizome,
stalk
X X spp X
Rheum
rhaponticum L.
– – Leaf,
rhizome
8.0 (2014) X spp X
Rheum x
hybridum
Murray
– – Leaf,
rhizome
spp X
EU Ph = European Pharmacopoeia; EMA = European Medicines Agency; The plant List = The Plant List (2013). Version 1.1. Published on the Internet; http://www.theplantlist.org/; USDA = United
States Department of Agriculture, Natural Resources Conservation Service Available at: https://plants.usda.gov/java/; Mansf. = Mansfeld’s World Database of Agricultural and Horticultural Crops.
Available at: http://mansfeld.ipk-gatersleben.de/apex/f?p=185:3::::::#; EFSA Comp. = Compendium of botaniclas reported to contain naturally occurring substances of possible concern for human
health when used in food and food supplements (2012). Available at https://www.efsa.europa.eu/it/efsajournal/pub/2663; BELFRIT = Harmonized list of Plants allowed in Food supplements by
Belgium, France and Italy; WHO Mon. = WHO Monographs on selected medicinal plants (http://apps.who.int/medicinedocs/en/).
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